

A physiological approach to hepatic drug clearance

Clinical Pharmacology and Therapeutics

18, 377-390

DOI: [10.1002/cpt1975184377](https://doi.org/10.1002/cpt1975184377)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Drug Disposition and Liver Disease. Drug Metabolism Reviews, 1975, 4, 139-175.	1.5	113
2	Bioavailability of Drugs. Clinical Pharmacokinetics, 1976, 1, 36-51.	1.6	71
3	Altered Hepatic Blood Flow and Drug Disposition ¹ . Clinical Pharmacokinetics, 1976, 1, 135-155.	1.6	202
4	Propranolol Disposition in Chronic Liver Disease. Clinical Pharmacokinetics, 1976, 1, 264-279.	1.6	94
5	Pharmacokinetics in Patients with Cardiac Failure. Clinical Pharmacokinetics, 1976, 1, 389-405.	1.6	121
6	Perfusion-limited effects of plasma drug binding on hepatic drug extraction. Life Sciences, 1976, 19, 125-130.	2.0	60
7	Effects of liver disease on drug disposition in man. Biochemical Pharmacology, 1976, 25, 2675-2681.	2.0	92
8	Disposition of propranolol isomers in mice. European Journal of Pharmacology, 1976, 40, 93-100.	1.7	33
9	Abnormal Regulation of Plasma Pyridoxal 5'-Phosphate in Patients with Liver Disease. Gastroenterology, 1976, 71, 1043-1049.	0.6	73
10	Normal Disposition of Oxazepam in Acute Viral Hepatitis and Cirrhosis. Annals of Internal Medicine, 1976, 84, 420.	2.0	222
11	Influence of liver disease on the elimination of drugs. European Journal of Drug Metabolism and Pharmacokinetics, 1976, 1, 129-140.	0.6	20
12	The pharmacokinetics of chlormethiazole following intravenous administration in the aged. European Journal of Clinical Pharmacology, 1976, 10, 407-415.	0.8	54
13	Comparison of single dose kinetics of imipramine, nortriptyline and antipyrine in man. Psychopharmacology, 1976, 50, 21-27.	1.5	37
14	A method of computing drug distribution in plasma using stepwise association constants: Clofibrate acid as an illustrative example. Computer Programs in Biomedicine, 1976, 6, 142-148.	0.8	41
15	Interaction of Quinidine with Anticonvulsant Drugs. New England Journal of Medicine, 1976, 294, 699-702.	13.9	128
16	Theophylline Disposition in Patients with Hepatic Cirrhosis. New England Journal of Medicine, 1977, 296, 1495-1497.	13.9	211
17	Drug Metabolism under Pathological and Abnormal Physiological States in Animals and Man. Xenobiotica, 1977, 7, 25-92.	0.5	224
18	Species Differences in Metabolism of Tiaramide Hydrochloride, a New Anti-inflammatory Agent. Xenobiotica, 1977, 7, 505-516.	0.5	16

#	ARTICLE	IF	CITATIONS
19	Drug Disposition in Liver Disease. New England Journal of Medicine, 1977, 296, 1527-1528.	13.9	13
20	Antidepressant evaluation and the pharmacological actions of FG4963 in depressive patients. European Journal of Pharmacology, 1977, 42, 31-37.	1.7	72
21	Studies of the effect of thyroid dysfunction on the elimination of beta-adrenoreceptor blocking drugs.. British Journal of Clinical Pharmacology, 1977, 4, 79-82.	1.1	24
22	Lignocaine kinetics in cardiac patients and aged subjects.. British Journal of Clinical Pharmacology, 1977, 4, 439-448.	1.1	158
23	Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings]. British Journal of Clinical Pharmacology, 1977, 4, 630P.	1.1	12
24	Protein Binding of Coumarin Anticoagulants in Disease States. Clinical Pharmacokinetics, 1977, 2, 110-126.	1.6	21
25	Effect of 60 Co g Radiation on Hexobarbital-Induced Sleeping Times in Rats. Radiation Research, 1977, 69, 594.	0.7	0
26	Protein Binding and Kinetics of Drugs in Liver Diseases. Clinical Pharmacokinetics, 1977, 2, 32-44.	1.6	269
27	Influence of phenobarbital on factors responsible for hepatic clearance of indocyanine green in the rat: Relative contributions of induction and altered liver blood flow. Biochemical Pharmacology, 1977, 26, 1247-1250.	2.0	33
28	Pharmacokinetics in renal disease. American Journal of Medicine, 1977, 62, 461-465.	0.6	81
29	The biotransformation of drugs in renal failure. American Journal of Medicine, 1977, 62, 482-485.	0.6	129
30	Kinetics of intravenous administered l-phenylalanine in patients with cirrhosis of the liver. Clinica Chimica Acta, 1977, 78, 453-463.	0.5	16
31	The role of drug interactions in interindividual variability of drug metabolism in man. Naunyn-Schmiedeberg's Archives of Pharmacology, 1977, 297, S35-S36.	1.4	1
32	Hepatic clearance of drugs. I. Theoretical considerations of a well-stirred model and a parallel tube model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. Journal of Pharmacokinetics and Pharmacodynamics, 1977, 5, 625-653.	0.6	673
33	Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects. Journal of Pharmacokinetics and Pharmacodynamics, 1977, 5, 481-494.	0.6	166
34	Interaction of clofibrate with warfarin. I. Effect of clofibrate on the disposition of the optical enantiomorphs of warfarin. Journal of Pharmacokinetics and Pharmacodynamics, 1977, 5, 495-505.	0.6	14
35	Hepatic clearance of local anesthetics in man. Journal of Pharmacokinetics and Pharmacodynamics, 1977, 5, 111-122.	0.6	39
36	GI Drug Absorption in Rats Exposed to Cobalt-60 $\hat{3}$ -Radiation I: Extent of Absorption. Journal of Pharmaceutical Sciences, 1977, 66, 361-365.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Tissue Binding of Drugs. <i>Journal of Pharmaceutical Sciences</i> , 1977, 66, 1211-1212.	1.6	30
38	Comparative Pharmacokinetics of Coumarin Anticoagulants XXXI: Effect of Plasma Protein Binding on Distribution Kinetics of Dicumarol in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1977, 66, 1741-1743.	1.6	14
39	Disposition and placental transfer of etidocaine in pregnancy. <i>European Journal of Clinical Pharmacology</i> , 1977, 12, 359-365.	0.8	24
40	Histological changes in the liver and indices of drug metabolism in alcoholics. <i>European Journal of Clinical Pharmacology</i> , 1977, 11, 295-303.	0.8	80
41	Plasma level of chlormethiazole and two metabolites after oral administration to young and aged human subjects. <i>European Journal of Clinical Pharmacology</i> , 1977, 12, 137-145.	0.8	60
42	The disposition kinetics of diazepam in pregnant women at parturition. <i>European Journal of Clinical Pharmacology</i> , 1978, 13, 275-284.	0.8	30
43	Pharmacokinetics and metabolism of the anilide local anaesthetics in neonates. 11 etidocaine. <i>European Journal of Clinical Pharmacology</i> , 1978, 13, 365-371.	0.8	22
44	Apparent volumes of distribution and drug binding to plasma proteins and tissues. <i>European Journal of Clinical Pharmacology</i> , 1978, 13, 373-378.	0.8	109
45	Influence of bed rest on the pharmacokinetics of phenazone. <i>European Journal of Clinical Pharmacology</i> , 1978, 13, 379-383.	0.8	10
46	Pharmacokinetics of a single oral dose of hydroflumethiazide in health and in cardiac failure. <i>European Journal of Clinical Pharmacology</i> , 1978, 14, 29-37.	0.8	17
47	Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. <i>British Journal of Cancer</i> , 1978, 38, 709-718.	2.9	21
48	Effect of route of administration and distribution on drug action. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1978, 6, 559-585.	0.6	68
49	Relationship between in vivo and in vitro drug metabolism in man. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1978, 3, 39-45.	0.6	33
50	The effect of urethane and pentobarbital anaesthesia and hepatic portal vein catheterization on liver blood flow in the rat. <i>Experientia</i> , 1978, 34, 1061-1062.	1.2	17
52	The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates. <i>European Journal of Clinical Pharmacology</i> , 1978, 14, 203-212.	0.8	35
53	Pharmacokinetics of Iodoxamic Acid in Rhesus Monkey: Biliary Excretion, Plasma Protein Binding, and Enterohepatic Circulation. <i>Journal of Pharmaceutical Sciences</i> , 1978, 67, 930-934.	1.6	8
54	Increased Plasma Protein Binding of Propranolol and Chlorpromazine Mediated by Disease-Induced Elevations of Plasma α_1 -Acid Glycoprotein. <i>New England Journal of Medicine</i> , 1978, 299, 1435-1439.	13.9	325
55	Effects of Renal Disease upon Drug Disposition. <i>Drug Metabolism Reviews</i> , 1978, 8, 293-302.	1.5	27

#	ARTICLE	IF	CITATIONS
56	Diseases and Drug Protein Binding. <i>Clinical Pharmacokinetics</i> , 1978, 3, 144-154.	1.6	127
57	Individual Differences in the Disposition of Drugs Metabolised in the Body. <i>Clinical Pharmacokinetics</i> , 1978, 3, 155-175.	1.6	40
58	Drug Metabolism and Pharmacokinetics in Malnutrition. <i>Clinical Pharmacokinetics</i> , 1978, 3, 216-240.	1.6	93
59	Pulmonary Disease and Drug Kinetics. <i>Clinical Pharmacokinetics</i> , 1978, 3, 257-266.	1.6	45
60	Clinical Pharmacokinetics of Theophylline. <i>Clinical Pharmacokinetics</i> , 1978, 3, 267-293.	1.6	438
61	The Influence of Cirrhosis on Steady-State Blood Concentrations of Unbound Propranolol after Oral Administration ¹ . <i>Clinical Pharmacokinetics</i> , 1978, 3, 478-487.	1.6	82
62	Direct measurement of propranolol bioavailability during accumulation to steady-state. <i>British Journal of Clinical Pharmacology</i> , 1978, 6, 345-350.	1.1	121
63	Disposition of sodium valproate in epileptic patients. <i>British Journal of Clinical Pharmacology</i> , 1978, 5, 495-499.	1.1	102
64	Clinical consequences of microsomal enzyme-induction by antiepileptic drugs. <i>Pharmacology & Therapeutics</i> , 1978, 2, 285-314.	0.2	3
65	Differentiated effects of liver cirrhosis on the albumin binding sites for diazepam, salicylic acid and warfarin. <i>Biochemical Pharmacology</i> , 1978, 27, 2729-2735.	2.0	40
66	Influence of phenobarbital on the distribution and elimination of desmethyylimipramine in the rat. <i>Biochemical Pharmacology</i> , 1978, 27, 1521-1526.	2.0	9
67	Reduced drug elimination in congestive heart failure. <i>American Journal of Medicine</i> , 1978, 65, 271-276.	0.6	48
68	Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. <i>American Heart Journal</i> , 1978, 96, 627-635.	1.2	46
69	Pharmacokinetics of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , 1978, 41, 986-995.	0.7	48
70	Impairment of antipyrine clearance in humans by propranolol. <i>Circulation</i> , 1978, 57, 1161-1164.	1.6	78
71	The effects of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man. <i>Acta Psychiatrica Scandinavica</i> , 1978, 58, 56-74.	2.2	43
72	The Disposition and Effects of Sedatives and Analgesics in Liver Disease. <i>Annual Review of Medicine</i> , 1978, 29, 205-218.	5.0	23
73	Drug metabolism in hepatosplenic schistosomiasis in the Sudan: a study with antipyrine. <i>Gut</i> , 1978, 19, 808-811.	6.1	14

#	ARTICLE	IF	CITATIONS
74	Hepatic Elimination of Renin in Man. <i>Clinical Science</i> , 1978, 55, 377-382.	1.8	4
75	Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole.. <i>BMJ: British Medical Journal</i> , 1978, 2, 861-863.	2.4	36
76	Dihydroergotamine: Pharmacokinetics and Usefulness in Spinal Anaesthesia. <i>Acta Anaesthesiologica Scandinavica</i> , 1978, 22, 215-220.	0.7	13
77	The pharmacokinetic profile of oxazepam. <i>Acta Psychiatrica Scandinavica</i> , 1978, 58, 47-55.	2.2	12
79	Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (Librium). <i>Gastroenterology</i> , 1978, 75, 479-485.	0.6	171
80	Mechanism for reduced drug clearance in patients with cirrhosis. <i>Gastroenterology</i> , 1978, 74, 566-571.	0.6	132
81	Enhanced Bioavailability and Decreased Clearance of Analgesics in Patients with Cirrhosis. <i>Gastroenterology</i> , 1979, 77, 96-102.	0.6	137
82	Comparison of In Vivo and In Vitro Drug Metabolism in Experimental Hepatic Injury in the Rat. <i>Gastroenterology</i> , 1979, 76, 697-703.	0.6	11
83	Hepatic Circulation and Drug Disposition in Cirrhosis. <i>Gastroenterology</i> , 1979, 77, 184-186.	0.6	19
84	Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat. <i>Gastroenterology</i> , 1979, 76, 1358-1362.	0.6	126
85	The Application of Clearance Concepts to Propranolol Disposition in Man. <i>Drug Metabolism Reviews</i> , 1979, 10, 107-123.	1.5	6
86	Predicting Steady State Serum Concentrations of Drugs. <i>Annual Review of Pharmacology and Toxicology</i> , 1979, 19, 347-356.	4.2	20
87	Presystemic Drug Elimination. <i>Annual Review of Pharmacology and Toxicology</i> , 1979, 19, 447-468.	4.2	75
88	Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.. <i>Gut</i> , 1979, 20, 596-601.	6.1	36
89	Effect of Salicylic Acid on Pharmacokinetics of Free and Plasma Protein-Bound Bilirubin in Experimental Unconjugated Hyperbilirubinemia. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 1-6.	1.6	32
90	Pharmacokinetics and Bioavailability of Intravenous, Intramuscular, and Oral Lorazepam in Humans. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 57-63.	1.6	180
91	Pharmacokinetic and Clinical Implications of Quinidine Protein Binding. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 466-470.	1.6	61
92	Effect of Serum Protein Binding on Sulfisoxazole Distribution, Metabolism, and Excretion in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 742-746.	1.6	25

#	ARTICLE	IF	CITATIONS
93	Clearance Constants in Physiologically Based Pharmacokinetic Models. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 1066-1067.	1.6	2
94	Effect of Altered Plasma Protein Binding on Apparent Volume of Distribution. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 1203-1205.	1.6	230
95	Plasma Binding of Benzodiazepines in Humans. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 1320-1322.	1.6	42
96	Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on indocyanine green blood clearance in rhesus monkeys. <i>Toxicology</i> , 1979, 14, 263-272.	2.0	9
97	Human pharmacokinetics of nitrazepam: Effect of age and diseases. <i>European Journal of Clinical Pharmacology</i> , 1979, 15, 163-170.	0.8	65
98	Pharmacokinetics of quinidine related to plasma protein binding in man. <i>European Journal of Clinical Pharmacology</i> , 1979, 15, 187-192.	0.8	27
99	Distribution and elimination of hydroflumethiazide in man. <i>European Journal of Clinical Pharmacology</i> , 1979, 16, 125-131.	0.8	4
100	Binding of imipramine to plasma protein and to brain tissue: Relationship to CSF tricyclic levels in man. <i>Psychopharmacology</i> , 1979, 63, 187-192.	1.5	20
101	Effect of plasma protein and tissue binding on the time course of drug concentration in plasma. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1979, 7, 195-206.	0.6	58
102	Disposition of synthetic glucocorticoids I. Pharmacokinetics of dexamethasone in healthy adults. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1979, 7, 249-264.	0.6	91
103	Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1979, 7, 643-663.	0.6	19
104	The effect of age on cardiac output and its distribution in the rat. <i>Experientia</i> , 1979, 35, 78-79.	1.2	28
106	Protein binding of diazepam and digitoxin in uremic and normal serum. <i>Biochemical Pharmacology</i> , 1979, 28, 1037-1042.	2.0	37
107	Phenobarbitone effects on hepatic microsomal enzymes and liver blood flow in the guinea pig. <i>Biochemical Pharmacology</i> , 1979, 28, 2856-2857.	2.0	11
108	Characteristics and differences in the hepatic mixed function oxidase of different species. , 1979, 6, 41-98.		95
109	The effect of ageing on the hepatic clearance of propranolol.. <i>British Journal of Clinical Pharmacology</i> , 1979, 7, 49-54.	1.1	233
110	Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs.. <i>British Journal of Clinical Pharmacology</i> , 1979, 7, 201-206.	1.1	77
111	Methods of the assessment of the effect of drugs on liver blood flow in man.. <i>British Journal of Clinical Pharmacology</i> , 1979, 7, 223-229.	1.1	21

#	ARTICLE	IF	CITATIONS
112	Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.. British Journal of Clinical Pharmacology, 1979, 8, 209-217.	1.1	95
113	Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia.. British Journal of Clinical Pharmacology, 1979, 8, 219-227.	1.1	64
114	Modification of phenytoin clearance by valproic acid in normal subjects.. British Journal of Clinical Pharmacology, 1979, 8, 553-556.	1.1	16
115	Impairment of drug metabolism in polycystic nonâ€parasitic liver disease.. British Journal of Clinical Pharmacology, 1979, 8, 331-335.	1.1	17
116	Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients.. British Journal of Clinical Pharmacology, 1979, 8, 21-31.	1.1	48
117	Clinical Pharmacokinetics of Oral Anticoagulants. Clinical Pharmacokinetics, 1979, 4, 1-15.	1.6	112
118	Drug Pharmacokinetics in the Postoperative Period. Clinical Pharmacokinetics, 1979, 4, 16-22.	1.6	27
119	Clinical Pharmacokinetics of Propranolol. Clinical Pharmacokinetics, 1979, 4, 73-90.	1.6	163
120	A Re-evaluation of Intersubject Variation in Enzyme Induction in Man1. Clinical Pharmacokinetics, 1979, 4, 104-110.	1.6	11
121	Role of the Lung in Total Body Clearance of Circulating Drugs. Clinical Pharmacokinetics, 1979, 4, 355-367.	1.6	53
122	Drug Kinetics and Hepatic Blood Flow. Clinical Pharmacokinetics, 1979, 4, 433-448.	1.6	78
123	Drug Prescribing in Hepatobiliary Disease. Drugs, 1979, 17, 198-212.	4.9	20
124	Effect of 4-N-acetyl-sulfisoxazole on the disposition of sulfisoxazole in the rat. International Journal of Pharmaceutics, 1979, 3, 311-318.	2.6	7
125	Effects of phenobarbitone on hepatic microsomal enzyme activity and liver blood flow in spontaneously hypertensive rats. Life Sciences, 1979, 24, 535-540.	2.0	5
126	Differences in the protein binding of several drugs and bilirubin in serum and heparinized plasma of rats. Life Sciences, 1979, 25, 471-477.	2.0	11
129	Disposition Kinetics of Oral Quinidine When Administered Concurrently with Propranolol. Journal of Clinical Pharmacology, 1979, 19, 378-383.	1.0	3
130	Fentanyl Pharmacokinetics in Awake Volunteers. Journal of Clinical Pharmacology, 1980, 20, 652-658.	1.0	39
131	Chapter 29. Altered Drug Disposition in Disease States. Annual Reports in Medicinal Chemistry, 1980, 15, 277-287.	0.5	11

#	ARTICLE	IF	CITATIONS
132	The role of the liver in theophylline elimination. <i>Lung</i> , 1980, 158, 101-109.	1.4	1
133	Simultaneous determination of d- and l-propranolol in human plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1980, 221, 109-117.	1.7	96
134	Prenatal and neonatal drug metabolism in man. <i>European Journal of Clinical Pharmacology</i> , 1980, 18, 9-15.	0.8	55
135	Nortriptyline therapy in elderly patients: Dosage prediction after single dose pharmacokinetic study. <i>European Journal of Clinical Pharmacology</i> , 1980, 18, 147-150.	0.8	26
136	Effect of posture and sleep on pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 1980, 18, 175-183.	0.8	29
137	Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium $\frac{1}{2}$) in man. <i>European Journal of Clinical Pharmacology</i> , 1980, 18, 275-278.	0.8	31
138	Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver. <i>European Journal of Clinical Pharmacology</i> , 1980, 17, 275-284.	0.8	44
139	The use of marker drugs to measure organ function: A theoretical interpretation. <i>European Journal of Clinical Pharmacology</i> , 1980, 18, 511-516.	0.8	4
140	Comparative Pharmacokinetics of Coumarin Anticoagulants XLV: Pharmacokinetic and Pharmacodynamic Studies of Acute Interaction between Warfarin and Phenylbutazone in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1980, 69, 14-20.	1.6	12
141	Lidocaine Pharmacokinetics in Pregnant and Nonpregnant Sheep. <i>Journal of Pharmaceutical Sciences</i> , 1980, 69, 32-37.	1.6	22
142	Biological Disposition of Sodium Dichloroacetate in Animals and Humans after Intravenous Administration. <i>Journal of Pharmaceutical Sciences</i> , 1980, 69, 419-421.	1.6	49
143	Hepatic Extraction of Endogenous Inhibitors of Plasma Protein Binding. <i>Journal of Pharmaceutical Sciences</i> , 1980, 69, 480-481.	1.6	7
144	Effect of Plasma Protein Binding on Renal Clearance of Drugs. <i>Journal of Pharmaceutical Sciences</i> , 1980, 69, 482-483.	1.6	69
145	Effect of heparin on bilirubin clearance in rats: Pharmacokinetic consequences of extensive hepatic extraction of plasma protein binding inhibitors. <i>Journal of Pharmaceutical Sciences</i> , 1980, 69, 1228-1230.	1.6	3
146	Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects. <i>Biopharmaceutics and Drug Disposition</i> , 1980, 1, 149-156.	1.1	39
147	Dose-dependent disposition of oral propranolol in normal subjects. <i>Biopharmaceutics and Drug Disposition</i> , 1980, 1, 159-166.	1.1	19
148	Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1980, 8, 53-68.	0.6	7
149	Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1980, 8, 165-176.	0.6	318

#	ARTICLE	IF	CITATIONS
150	Effect of serum protein binding on pharmacokinetics and anticoagulant activity of phenprocoumon in rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1980, 8, 177-191.	0.6	17
151	Impaired elimination of caffeine in cirrhosis. <i>Digestive Diseases and Sciences</i> , 1980, 25, 193-197.	1.1	76
152	Hyperglobulinemia in alcoholic cirrhosis. <i>Digestive Diseases and Sciences</i> , 1980, 25, 489-493.	1.1	24
153	Determination of the kinetic constants for metabolism of inhaled toxicants in vivo using gas uptake measurements. <i>Toxicology and Applied Pharmacology</i> , 1980, 54, 100-116.	1.3	119
154	Pharmacokinetics of fenclofenac following single and multiple doses. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1980, 5, 217-223.	0.6	14
155	A METHOD OF DETERMINING INTRINSIC HEPATIC CLEARANCE FROM THE FIRST-PASS EFFECT. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1980, 7, 339-343.	0.9	13
156	Cimetidine Impairs Elimination of Chlordiazepoxide (Librium) in Man. <i>Annals of Internal Medicine</i> , 1980, 93, 266.	2.0	169
157	Altered drug metabolism and elevated serum bile acids in liver disease: A unified pharmacokinetic explanation. <i>Gastroenterology</i> , 1980, 78, 177-179.	0.6	40
158	Cimetidine spares the glucuronidation of lorazepam and oxazepam. <i>Gastroenterology</i> , 1980, 79, 912-916.	0.6	146
159	Spironolactone and enzyme induction in patients with alcoholic cirrhosis. <i>Gastroenterology</i> , 1980, 78, 996-1000.	0.6	28
160	Specific Antibodies and Fab Fragments to Alter the Pharmacokinetics and Reverse the Pharmacologic/Toxicologic Effects of Drugs. <i>Drug Metabolism Reviews</i> , 1980, 11, 223-262.	1.5	42
161	Reduction in Lidocaine Clearance during Continuous Infusion and by Coadministration of Propranolol. <i>New England Journal of Medicine</i> , 1980, 303, 373-377.	13.9	160
162	Elevated plasma free drug concentrations of propranolol and diazepam during cardiac catheterization.. <i>Circulation</i> , 1980, 62, 1119-1122.	1.6	14
163	Drug Pharmacokinetics in Cardiac and Hepatic Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 1980, 20, 389-413.	4.2	45
164	Effect of Cimetidine and other antihistaminics on the elimination of aminopyrine, phenacetin and caffeine. <i>Life Sciences</i> , 1980, 26, 1261-1268.	2.0	85
165	Minireview: Part II: Biochemical considerations of morbid obesity. <i>Life Sciences</i> , 1980, 26, 2215-2221.	2.0	4
166	Hepatic clearances of drugs and metabolites. <i>Trends in Pharmacological Sciences</i> , 1980, 1, 247-251.	4.0	10
167	Hepatic transport of indocyanine green in rats chronically intoxicated with carbon tetrachloride. <i>Biochemical Pharmacology</i> , 1980, 29, 1291-1297.	2.0	17

#	ARTICLE	IF	CITATIONS
168	Prediction of mescaline clearance by rabbit lung and liver from enzyme kinetic data. <i>Biochemical Pharmacology</i> , 1980, 29, 253-255.	2.0	13
169	PHENOBARBITONE INTERACTION WITH ORAL CONTRACEPTIVE STEROIDS IN THE RABBIT AND RAT. <i>British Journal of Pharmacology</i> , 1980, 69, 441-452.	2.7	30
171	Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man.. <i>British Journal of Clinical Pharmacology</i> , 1980, 10, 41-49.	1.1	52
172	Propranolol disposition in renal failure.. <i>British Journal of Clinical Pharmacology</i> , 1980, 10, 561-566.	1.1	51
173	Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.. <i>British Journal of Clinical Pharmacology</i> , 1980, 9, 399-405.	1.1	12
174	Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy.. <i>British Journal of Clinical Pharmacology</i> , 1980, 10, 281-285.	1.1	12
175	A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs.. <i>British Journal of Clinical Pharmacology</i> , 1980, 10, 491-497.	1.1	18
176	Effect of heparin administration on plasma binding of benzodiazepines.. <i>British Journal of Clinical Pharmacology</i> , 1980, 9, 171-175.	1.1	56
177	Antiarrhythmic agents and their use in therapy. , 1980, 9, 75-106.		14
178	Disease-induced Changes in the Plasma Binding of Basic Drugs. <i>Clinical Pharmacokinetics</i> , 1980, 5, 246-262.	1.6	332
179	Influence of Age and Smoking on Drug Kinetics in Man Studies Using Model Compounds. <i>Clinical Pharmacokinetics</i> , 1980, 5, 309-319.	1.6	71
180	Drug Kinetics in Childbirth. <i>Clinical Pharmacokinetics</i> , 1980, 5, 340-364.	1.6	37
181	Clinical significance of plasma binding of basic drugs. <i>Trends in Pharmacological Sciences</i> , 1981, 2, 283-284.	4.0	18
182	Saturable Metabolism and its Relationship to Toxicity. <i>CRC Critical Reviews in Toxicology</i> , 1981, 9, 105-150.	4.9	81
183	Clinical Implications of Enzyme Induction and Enzyme Inhibition. <i>Clinical Pharmacokinetics</i> , 1981, 6, 1-24.	1.6	152
184	Altered Plasma Protein Binding of Drugs in Thyroid Disease. <i>Clinical Pharmacokinetics</i> , 1981, 6, 298-305.	1.6	23
185	Drug Metabolites in Renal Failure. <i>Clinical Pharmacokinetics</i> , 1981, 6, 329-345.	1.6	61
186	Disposition of Antipyrine and Phenytoin Correlated with Age and Liver Volume in Man. <i>Clinical Pharmacokinetics</i> , 1981, 6, 389-396.	1.6	99

#	ARTICLE	IF	CITATIONS
187	Quantitative structure-pharmacokinetic relationships and drug design. , 1981, 15, 131-182.		121
188	Concepts basic to pharmacokinetics. , 1981, 12, 109-131.		104
189	History of pharmacokinetics. , 1981, 12, 537-562.		131
190	Preservation of glucuronidation in carbon tetrachloride-induced acute liver injury in the rat. Biochemical Pharmacology, 1981, 30, 993-999.	2.0	27
192	Decreased in vivo acetylation of sulfisoxazole in the rabbit in the presence of 4-N-acetylsulfisoxazole. International Journal of Pharmaceutics, 1981, 7, 179-188.	2.6	6
193	Normal Metabolism of Morphine in a Cirrhosis. Gastroenterology, 1981, 81, 1006-1011.	0.6	150
194	Liver Physiology and Disease Acute Cholestasis in Patients with Toxic-Shock Syndrome. Gastroenterology, 1981, 81, 928-931.	0.6	33
195	Metabolic Clearance and Production Rates of $3\text{-}^{125}\text{I}$ - $5\text{-}^{125}\text{I}$ -Diiodothyronine in Hyperthyroidism and Hypothyroidism in Man: Comparison of Infusions Using Radiolabeled Versus Unlabeled Iodothyronine*. Journal of Clinical Endocrinology and Metabolism, 1981, 52, 722-730.	1.8	10
196	Characteristics of bovine parathyroid hormone extraction by dog liver in vivo. American Journal of Physiology - Endocrinology and Metabolism, 1981, 241, E208-E214.	1.8	9
197	Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease. Gastroenterology, 1981, 80, 112-118.	0.6	29
198	Mechanisms for reduced hepatic clearance and elevated plasma levels of bile acids in cirrhosis. Gastroenterology, 1981, 80, 1438-1444.	0.6	51
199	In vivo drug metabolism and liver lobule heterogeneity in the rat. Gastroenterology, 1981, 81, 563-569.	0.6	14
200	Phenytoin-Valproic Acid Interaction in Rhesus Monkey. Epilepsia, 1981, 22, 19-25.	2.6	17
201	Nonlinear first-pass metabolism of propranolol in the rat.. Journal of Pharmacobio-dynamics, 1981, 4, 131-141.	0.5	10
202	Influence of cimetidine on pharmacokinetics of propranolol.. BMJ: British Medical Journal, 1981, 282, 1917-1919.	2.4	82
203	Propranolol and sotalol metabolism after a drinking party. Clinical Pharmacology and Therapeutics, 1981, 29, 705-710.	2.3	30
204	Factors Influencing Procainamide Total Body Clearance in the Immediate Postmyocardial Infarction Period. Journal of Clinical Pharmacology, 1981, 21, 20-25.	1.0	11
205	First-Pass Effect: Nonlinear Concept Comprising an Explicit Solution of Integrated Michaelis-Menten Equation. Journal of Pharmaceutical Sciences, 1981, 70, 195-198.	1.6	3

#	ARTICLE	IF	CITATIONS
206	Effect of Sulfadimethoxine on Thiopental Distribution and Elimination in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1981, 70, 323-326.	1.6	20
207	Importance of Radiochemical Purity of Radiolabeled Drugs Used for Determining Plasma Protein Binding of Drugs. <i>Journal of Pharmaceutical Sciences</i> , 1981, 70, 1372-1373.	1.6	19
208	Variability of plasma hydralazine concentrations in male hypertensive patients. <i>Arthritis and Rheumatism</i> , 1981, 24, 987-992.	6.7	16
209	Plasma propranolol concentrations in rats with adjuvant-induced arthritis. <i>Biopharmaceutics and Drug Disposition</i> , 1981, 2, 291-297.	1.1	19
210	Effect of short-term ethanol administration on lorazepam clearance. <i>Hepatology</i> , 1981, 1, 47-53.	3.6	36
211	Hepatic and extrahepatic glucuronidation of lorazepam in the dog. <i>Hepatology</i> , 1981, 1, 329-335.	3.6	17
212	Protein binding of drugs in plasma, interstitial fluid and tissues: Effect on pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 1981, 21, 77-81.	0.8	27
213	Cimetidine impairs the elimination of chlormethiazole. <i>European Journal of Clinical Pharmacology</i> , 1981, 21, 83-85.	0.8	24
214	Pharmacokinetic concepts ? Drug binding, apparent volume of distribution and clearance. <i>European Journal of Clinical Pharmacology</i> , 1981, 20, 299-305.	0.8	88
215	Disposition of intravenous diazepam in young men and women. <i>European Journal of Clinical Pharmacology</i> , 1981, 20, 207-213.	0.8	24
216	Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients. <i>European Journal of Clinical Pharmacology</i> , 1981, 19, 197-203.	0.8	13
217	Pharmacokinetics of intravenous and oral tolmesoxide. <i>European Journal of Clinical Pharmacology</i> , 1981, 19, 119-125.	0.8	10
218	Effects of growth hormone on antipyrine kinetics in children. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 127-132.	2.3	23
219	Prazosin kinetics in hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 439-446.	2.3	30
220	High-performance liquid chromatographic determination of acetaminophen in plasma: single-dose pharmacokinetic studies. <i>Biomedical Applications</i> , 1981, 226, 224-230.	1.7	91
221	A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: Analysis at steady state*1. <i>Toxicology and Applied Pharmacology</i> , 1981, 60, 509-526.	1.3	138
222	The comparison of in vivo plasma radioactivity clearance and ¹⁴ CO ₂ breath elimination of model drugs in the rat: A study in regional hepatocyte function. <i>Toxicology and Applied Pharmacology</i> , 1981, 61, 177-184.	1.3	7
223	Oral absorption and presystemic first-pass effect of chlorpheniramine in rabbits. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1981, 9, 725-738.	0.6	12

#	ARTICLE	IF	CITATIONS
224	Experimental hepatobiliary injury. Digestive Diseases and Sciences, 1981, 26, 50-59.	1.1	0
225	Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. Journal of Pharmacokinetics and Pharmacodynamics, 1981, 9, 245-260.	0.6	40
226	Influence of plasma protein binding kinetics on hepatic clearance assessed from a "tubule" model and a "well-stirred" model. Journal of Pharmacokinetics and Pharmacodynamics, 1981, 9, 15-26.	0.6	37
227	A standard approach to compiling clinical pharmacokinetic data. Journal of Pharmacokinetics and Pharmacodynamics, 1981, 9, 59-127.	0.6	30
228	Reduction of Liver Blood Flow and Propranolol Metabolism by Cimetidine. New England Journal of Medicine, 1981, 304, 692-695.	13.9	420
229	Quinidine-Rifampin Interaction. New England Journal of Medicine, 1981, 304, 1466-1469.	13.9	77
230	Drug Disposition in Old Age. New England Journal of Medicine, 1982, 306, 1081-1088.	13.9	605
231	Major Drug Interactions: Effect of Liver Disease, Alcohol, and Malnutrition. Annual Review of Medicine, 1982, 33, 113-149.	5.0	82
232	FENTANYL PHARMACOKINETICS IN ANAESTHETIZED PATIENTS WITH CIRRHOSIS. British Journal of Anaesthesia, 1982, 54, 1267-1270.	1.5	129
233	Pharmacokinetics of Drugs during Various Detoxification Procedures for Overdose and Environmental Exposure. Drug Metabolism Reviews, 1982, 13, 715-743.	1.5	6
234	Effect of Hypotension on Liver Blood Flow and Lidocaine Disposition. New England Journal of Medicine, 1982, 307, 866-869.	13.9	55
235	Physiological and Pharmacokinetic Factors Affecting Performance of Sustained Release Dosage Forms. Drug Development and Industrial Pharmacy, 1982, 8, 1-25.	0.9	15
236	Antibiotics and Hepatic Disease. Medical Clinics of North America, 1982, 66, 257-266.	1.1	7
237	Benzodiazepines in the Elderly. Medical Clinics of North America, 1982, 66, 1017-1035.	1.1	44
238	Lidocaine Clinical Pharmacokinetics. Drug Intelligence & Clinical Pharmacy, 1982, 16, 291-294.	0.4	11
239	An Evaluation of the Effects of Smoking on Codeine Pharmacokinetics and Bioavailability in Normal Human Volunteers. Drug Intelligence & Clinical Pharmacy, 1982, 16, 849-854.	0.4	9
240	Disposition of Zomepirac Sodium in Man. Journal of Clinical Pharmacology, 1982, 22, 470-476.	1.0	19
241	Racial Background and Lidocaine Pharmacokinetics. Journal of Clinical Pharmacology, 1982, 22, 391-394.	1.0	9

#	ARTICLE	IF	CITATIONS
242	Increased Toxicity and Reduced Clearance of Lidocaine by Cimetidine. <i>Annals of Internal Medicine</i> , 1982, 96, 592.	2.0	155
243	Cimetidine as an Inhibitor of Drug Metabolism: Therapeutic Implications and Review of the Literature. <i>Drug Intelligence & Clinical Pharmacy</i> , 1982, 16, 380-386.	0.4	41
244	Direct Measurement of Hepatic Extraction of Chenodeoxycholic Acid and Ursodeoxycholic Acid in Man. <i>Clinical Science</i> , 1982, 63, 197-203.	1.8	24
245	Correlation of drug conjugative metabolism rates between in vivo and in vitro: Glucuronidation and sulfation of p-nitrophenol as a model compound in rat.. <i>Journal of Pharmacobio-dynamics</i> , 1982, 5, 811-817.	0.5	41
246	Effect of simultaneous administration of drugs on absorption and excretion. XIII. Effect of salicylic acid on the absorption, distribution and elimination of carbutamide in rabbits.. <i>Chemical and Pharmaceutical Bulletin</i> , 1982, 30, 2169-2173.	0.6	4
247	Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs. <i>Cancer Treatment Reviews</i> , 1982, 9, 85-124.	3.4	32
248	A comprehensive computer simulation of drug metabolism and pharmacokinetics. <i>Computers and Education</i> , 1982, 6, 243-252.	5.1	19
249	Prediction of intestinal first-pass effect of phenacetin in the rat from enzyme kinetic data " correlation with in vivo data using mucosal blood flow. <i>Biochemical Pharmacology</i> , 1982, 31, 2545-2548.	2.0	36
250	Hepatic extraction of bile acids in rats. <i>Biochemical Pharmacology</i> , 1982, 31, 205-209.	2.0	24
251	Hepatic drug transport in the rat. <i>Biochemical Pharmacology</i> , 1982, 31, 1553-1565.	2.0	55
252	Differential effects of chronic ethanol feeding on cytochrome P-448- and P-450-mediated drug metabolism in the rat. <i>Biochemical Pharmacology</i> , 1982, 31, 695-699.	2.0	11
253	An antibiotic interaction with ethinylloestradiol in the rat and rabbit. <i>The Journal of Steroid Biochemistry</i> , 1982, 16, 407-413.	1.3	34
254	Dosage regimen design. , 1982, 17, 143-163.		11
257	Verapamil bioavailability and dosage in liver disease.. <i>British Journal of Clinical Pharmacology</i> , 1982, 13, 240-241.	1.1	3
258	Effect of rifampicin on metoprolol and antipyrine kinetics.. <i>British Journal of Clinical Pharmacology</i> , 1982, 13, 387-391.	1.1	58
259	On the role of alpha 1 acid glycoprotein in lignocaine accumulation following myocardial infarction.. <i>British Journal of Clinical Pharmacology</i> , 1982, 13, 411-415.	1.1	40
260	Enhanced metabolism of mexiletine after phenytoin administration.. <i>British Journal of Clinical Pharmacology</i> , 1982, 14, 219-223.	1.1	50
261	Plasma levels of (+) and (S)-propranolol and 4-hydroxypropranolol after administration of racemic (+/S)-propranolol in man.. <i>British Journal of Clinical Pharmacology</i> , 1982, 14, 79-82.	1.1	70

#	ARTICLE	IF	CITATIONS
262	Metoprolol pharmacokinetics and the oral contraceptive pill.. British Journal of Clinical Pharmacology, 1982, 14, 120-122.	1.1	44
263	Assessment of the drug metabolism capacity of the liver.. British Journal of Clinical Pharmacology, 1982, 14, 631-651.	1.1	103
264	PROPRANOLOL INCREASES ARTERIAL AMMONIA IN LIVER CIRRHOSIS. Lancet, The, 1982, 320, 951-952.	6.3	35
265	Drug Interactions with Cimetidine. Clinical Pharmacokinetics, 1982, 7, 23-41.	1.6	243
266	Clinical Pharmacokinetics of Hydralazine. Clinical Pharmacokinetics, 1982, 7, 185-205.	1.6	60
267	β ₂ -Blocker Plasma Concentrations and Inflammatory Disease. Clinical Pharmacokinetics, 1982, 7, 281-284.	1.6	20
268	Inhibition of microsomal drug metabolism by histamine H ₂ -receptor antagonists studied in vivo and in vitro in rodents. Gastroenterology, 1982, 82, 89-96.	0.6	135
269	Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics, 1982, 10, 201-227.	0.6	570
270	Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing. Journal of Pharmacokinetics and Pharmacodynamics, 1982, 10, 157-172.	0.6	14
271	Comparative pharmacokinetics of benzodiazepines in dog and man. Journal of Pharmacokinetics and Pharmacodynamics, 1982, 10, 411-426.	0.6	72
272	Variable first-pass elimination of propranolol following single and multiple oral doses in hypertensive patients. European Journal of Drug Metabolism and Pharmacokinetics, 1982, 7, 183-189.	0.6	6
273	Glucuronidation of Morphine in Human Liver and Interaction with Oxazepam. Acta Anaesthesiologica Scandinavica, 1982, 26, 47-51.	0.7	26
274	THE PHYSIOLOGICAL SIGNIFICANCE OF TOTAL BODY CLEARANCE IN PHARMACOKINETIC STUDIES. Journal of Clinical Pharmacy and Therapeutics, 1982, 7, 25-30.	0.7	11
275	Albumin Does Not Mediate the Removal of Taurocholate by the Rat Liver. Journal of Pharmaceutical Sciences, 1982, 71, 373-374.	1.6	23
276	Dose-Dependent Pharmacokinetics of the Antihypertensive 2,3,4,4a-Tetrahydro-1H-pyrazino[1,2a]quinoxalin-5-(6H)-one in Dogs and Rats. Journal of Pharmaceutical Sciences, 1982, 71, 414-417.	1.6	2
277	Determination of Tissue to Blood Partition Coefficients in Physiologically-Based Pharmacokinetic Studies. Journal of Pharmaceutical Sciences, 1982, 71, 454-456.	1.6	31
278	Disposition of Quinidine in the Rabbit. Journal of Pharmaceutical Sciences, 1982, 71, 812-815.	1.6	22
279	Protein Binding of Caffeine in Young and Elderly Males. Journal of Pharmaceutical Sciences, 1982, 71, 1415-1418.	1.6	49

#	ARTICLE	IF	CITATIONS
280	Pharmacokinetic studies of sulfapyridine acetylation in the rabbit. <i>Biopharmaceutics and Drug Disposition</i> , 1982, 3, 185-189.	1.1	0
281	Dose-dependent pharmacokinetics of furosemide in the rat. <i>Biopharmaceutics and Drug Disposition</i> , 1982, 3, 345-359.	1.1	40
282	Pharmakokinetic properties of noscapine. <i>European Journal of Clinical Pharmacology</i> , 1982, 22, 535-539.	0.8	92
283	Kinetics and metabolism of (+)-, (?)- and ($t_{1/2}$)-bufuralol. <i>European Journal of Clinical Pharmacology</i> , 1982, 23, 529-533.	0.8	35
284	Diazepam plasma binding in the perinatal period: Influence of nonesterified fatty acids. <i>European Journal of Clinical Pharmacology</i> , 1982, 22, 153-160.	0.8	19
285	Comparative disposition of pethidine and norpethidine in old and young patients. <i>European Journal of Clinical Pharmacology</i> , 1982, 22, 175-179.	0.8	39
286	Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. <i>European Journal of Clinical Pharmacology</i> , 1982, 22, 441-445.	0.8	67
287	Effect of rifampicin treatment on the kinetics of mexiletine. <i>European Journal of Clinical Pharmacology</i> , 1982, 23, 261-266.	0.8	74
288	Pharmacokinetics and bioavailability of indapamide ? A new antihypertensive drug. <i>European Journal of Clinical Pharmacology</i> , 1982, 22, 295-299.	0.8	20
289	Furosemide disposition in cirrhosis. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 719-725.	2.3	45
290	General kinetic and dynamic principles and their application to continuous infusion anaesthesia. <i>Anaesthesia</i> , 1983, 38, 10-25.	1.8	21
291	Systemic spillâ€over of bile acids. <i>European Journal of Clinical Investigation</i> , 1983, 13, 433-437.	1.7	28
292	The pharmacokinetics of furazlocillin in healthy humans. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1983, 11, 5-30.	0.6	7
293	Comparative pharmacokinetics of caffeine in young and elderly men. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1983, 11, 109-126.	0.6	121
294	A physiological pharmacokinetic model for morphine disposition in the pregnant rat. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1983, 11, 147-163.	0.6	52
295	Protein binding and hepatic clearance: Studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1983, 11, 225-243.	0.6	45
296	An understanding of the role of enzyme localization of the liver on metabolite kinetics: A computer simulation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1983, 11, 451-468.	0.6	26
297	Bioaccessibility of ethmosin taken internally. <i>Pharmaceutical Chemistry Journal</i> , 1983, 17, 532-536.	0.3	0

#	ARTICLE	IF	CITATIONS
298	Ethanol interaction with drug acetylation in vivo and in vitro. <i>Pharmacology Biochemistry and Behavior</i> , 1983, 18, 295-300.	1.3	8
299	The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. <i>Klinische Wochenschrift</i> , 1983, 61, 851-858.	0.6	28
300	Amitriptyline and ethanol: Pharmacokinetic and pharmacodynamic interaction. <i>European Journal of Clinical Pharmacology</i> , 1983, 25, 325-331.	0.8	67
301	Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding I. Theoretical considerations. <i>European Journal of Clinical Pharmacology</i> , 1983, 25, 399-405.	0.8	43
302	Displacement of lidocaine from serum? 1-acid glycoprotein binding sites by basic drugs. <i>European Journal of Clinical Pharmacology</i> , 1983, 25, 413-417.	0.8	39
303	The effect of ethanol administration on the disposition and elimination of chlormethiazole. <i>European Journal of Clinical Pharmacology</i> , 1983, 24, 383-385.	0.8	5
304	The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. <i>European Journal of Clinical Pharmacology</i> , 1983, 24, 387-390.	0.8	19
305	Increased oral clearance of metoprolol in pregnancy. <i>European Journal of Clinical Pharmacology</i> , 1983, 24, 217-220.	0.8	69
306	Pharmacokinetics of theophylline in Ethiopian children of differing nutritional status. <i>European Journal of Clinical Pharmacology</i> , 1983, 24, 89-92.	0.8	8
307	Toxicokinetics of methyl parathion and parathion in the dog after intravenous and oral administration. <i>Archives of Toxicology</i> , 1983, 54, 71-82.	1.9	44
308	Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. <i>Psychopharmacology</i> , 1983, 80, 275-278.	1.5	75
309	Subcutaneous infusion of cytosine arabinoside. <i>Cancer Chemotherapy and Pharmacology</i> , 1983, 10, 112-114.	1.1	12
310	Pharmacokinetics of betamethasone in healthy adults after intravenous administration. <i>European Journal of Clinical Pharmacology</i> , 1983, 25, 643-650.	0.8	43
311	The binding of ibuprofen to plasma proteins. <i>European Journal of Clinical Pharmacology</i> , 1983, 25, 815-818.	0.8	36
312	Effect of ethanol intake on disopyramide elimination by healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 1983, 25, 103-105.	0.8	5
313	Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration. <i>Biopharmaceutics and Drug Disposition</i> , 1983, 4, 103-112.	1.1	9
314	Pharmacokinetic Relationships Between Cinromide and Its Metabolites in the Rhesus Monkey I: 3-Bromocinnamamide, an Active Metabolite. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 493-496.	1.6	4
315	Dose-Dependent Elimination of Propranolol and its Major Metabolites in Humans. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 725-732.	1.6	43

#	ARTICLE	IF	CITATIONS
316	Fraction Unbound in Interstitial Fluid. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 834-836.	1.6	21
317	Steady-State Determination of the Contribution of Lung Metabolism to the Total Body Clearance of Drugs: Application to Carbamazepine. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 860-862.	1.6	10
318	Albumin Binding and Hepatic Uptake: The Importance of Model Selection. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 1232-1233.	1.6	21
319	In Vivo Evaluation of the Michaelis-Menten Constant For a Medium Extraction Ratio Drug: Application to Cinromide in the Rhesus Monkey. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 1352-1354.	1.6	1
320	Drug Metabolism in the Elderly: Confounding of Age, Smoking, and Ethanol Effects. <i>Drug Metabolism Reviews</i> , 1983, 14, 225-250.	1.5	25
321	Clinical Pharmacokinetics of α -Adrenoceptor Blocking Drugs in Thyroid Disease. <i>Clinical Pharmacokinetics</i> , 1983, 8, 1-16.	1.6	22
322	Pharmacokinetic Drug Interactions with Propranolol. <i>Clinical Pharmacokinetics</i> , 1983, 8, 253-262.	1.6	43
323	Effect of Oxprenolol on the Pharmacokinetics and Pharmacodynamics of Hydralazine. <i>Drugs</i> , 1983, 25, 136-140.	4.9	2
324	Impaired Binding of Drugs and Endogenous Ligands in Renal Diseases. <i>American Journal of Kidney Diseases</i> , 1983, 2, 578-601.	2.1	84
325	Variability in the human drug response. <i>Thrombosis Research</i> , 1983, 29, 3-15.	0.8	22
326	Drug metabolism and pharmacokinetics in malnutrition. <i>Trends in Pharmacological Sciences</i> , 1983, 4, 295-299.	4.0	20
327	Binding of phenothiazine neuroleptics to plasma proteins. <i>Biochemical Pharmacology</i> , 1983, 32, 2565-2570.	2.0	54
328	Drug distribution and renal excretion in the elderly. <i>Journal of Chronic Diseases</i> , 1983, 36, 91-102.	1.3	21
329	Influence of acetaminophen-induced hepatic necrosis on the pharmacokinetics of levonorgestrel. <i>Contraception</i> , 1983, 28, 149-157.	0.8	4
330	Plasma and Tissue Binding Considerations in Drug Disposition. <i>Drug Metabolism Reviews</i> , 1983, 14, 427-465.	1.5	88
331	Effect of inhibitors of prostaglandin synthesis on hepatic drug clearance.. <i>British Journal of Clinical Pharmacology</i> , 1983, 15, 109-111.	1.1	9
332	Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity.. <i>British Journal of Clinical Pharmacology</i> , 1983, 15, 303-309.	1.1	84
333	Genetically determined oxidation capacity and the disposition of debrisoquine.. <i>British Journal of Clinical Pharmacology</i> , 1983, 15, 443-450.	1.1	56

#	ARTICLE	IF	CITATIONS
334	Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly.. British Journal of Clinical Pharmacology, 1983, 16, 371-376.	1.1	54
335	The effect of cimetidine on tolbutamide kinetics.. British Journal of Clinical Pharmacology, 1983, 16, 438-440.	1.1	22
336	Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone.. British Journal of Clinical Pharmacology, 1983, 16, 441-444.	1.1	24
337	Influence of sex and oral contraceptive steroids on paracetamol metabolism.. British Journal of Clinical Pharmacology, 1983, 16, 503-509.	1.1	168
338	Induction of propranolol metabolism by rifampicin.. British Journal of Clinical Pharmacology, 1983, 16, 565-569.	1.1	46
339	Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations.. British Journal of Clinical Pharmacology, 1983, 16, 669-675.	1.1	101
340	Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation.. British Journal of Clinical Pharmacology, 1983, 16, 743-746.	1.1	38
341	Serum alpha 1-glycoprotein and the binding of drugs in obesity.. British Journal of Clinical Pharmacology, 1983, 16, 751-754.	1.1	68
342	Kinetics of oral trifluoperazine disposition in man.. British Journal of Clinical Pharmacology, 1983, 15, 380-382.	1.1	24
344	Physiological pharmacokinetic model for pentazocine. I. Tissue distribution and elimination in the rat. International Journal of Pharmaceutics, 1983, 15, 321-333.	2.6	34
345	Placental drug transfer: Effects of gestational age and species. , 1983, 23, 253-266.		67
346	Drug Administration in Hepatic Disease. New England Journal of Medicine, 1983, 309, 1616-1622.	13.9	97
347	Use of the Isolated Perfused Kidney as a Tool in Drug Disposition Studies. Drug Metabolism Reviews, 1983, 14, 931-960.	1.5	53
348	Effects of acute microwave irradiation on phenobarbital sleep and disposition to brain in mice. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1983, 11, 261-274.	1.1	9
349	Procainamide Disposition in Obesity. Drug Intelligence & Clinical Pharmacy, 1983, 17, 516-522.	0.4	35
350	The Effects of Cimetidine on Theophylline Pharmacokinetics at Steady State. Chest, 1983, 83, 221-224.	0.4	36
351	Pharmacologic Basis for Developing Rational Drug Regimens for Elderly Patients. Medical Clinics of North America, 1983, 67, 315-331.	1.1	35
352	General and Regional Haemodynamic Effects of Intravenous Ergotamine in Man. Clinical Science, 1983, 65, 599-604.	1.8	22

#	ARTICLE	IF	CITATIONS
353	Developmental change in clearance of glucuronide of p-phenylbenzoic acid from in vitro kinetic parameters and its correlation with clearance from in vivo in fetus of rat.. Journal of Pharmacobio-dynamics, 1983, 6, 565-570.	0.5	4
354	A note on saturable and inhibitory kinetics of p-aminohippurate renal transport in rabbits.. Journal of Pharmacobio-dynamics, 1983, 6, 161-169.	0.5	5
355	Relationship between trimethadione metabolism and hepatic drug-oxidizing enzyme activities in different animal species.. Journal of Pharmacobio-dynamics, 1983, 6, 481-486.	0.5	6
356	Clinical pharmacokinetics of intraarterial cisplatin in humans.. Journal of Clinical Oncology, 1983, 1, 755-762.	0.8	52
357	Drug Interactions & Reactions Update: Early Reports on Drug Interactions. Drug Intelligence & Clinical Pharmacy, 1983, 17, 105-109.	0.4	1
358	The Cimetidine-Lidocaine Interaction. Annals of Internal Medicine, 1983, 98, 174.	2.0	69
360	Frequently Cited References in Contemporary Pharmacokinetics. Drug Metabolism Reviews, 1984, 15, 1385-1402.	1.5	1
361	Benzodiazepine drug-drug interactions commonly occurring in clinical practice. Current Medical Research and Opinion, 1984, 8, 80-93.	0.9	18
362	Cimetidine on apparent liver blood flow. Gut, 1984, 25, 802-802.	6.1	1
363	Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. European Journal of Drug Metabolism and Pharmacokinetics, 1984, 9, 177-183.	0.6	82
364	Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. European Journal of Drug Metabolism and Pharmacokinetics, 1984, 9, 275-282.	0.6	58
365	In vivo plasma protein binding interaction between valproic acid and naproxen. European Journal of Drug Metabolism and Pharmacokinetics, 1984, 9, 359-363.	0.6	11
366	The role of hepatic biotransformation in mediating the acute toxicity of the phosphorothionate insecticide chlorpyrifos. Toxicology and Applied Pharmacology, 1984, 73, 60-68.	1.3	75
367	Interspecies Pharmacokinetic Scaling and the Evolutionary-Comparative Paradigm. Drug Metabolism Reviews, 1984, 15, 1071-1121.	1.5	263
368	Protein binding and hepatic clearance: Discrimination between models of hepatic clearance with diazepam, a drug of high intrinsic clearance, in the isolated perfused rat liver preparation. Journal of Pharmacokinetics and Pharmacodynamics, 1984, 12, 129-147.	0.6	49
369	Pharmacokinetics of l-propranolol during repetitive dosing in normal and uranyl nitrate-induced renal failure rats. Journal of Pharmacokinetics and Pharmacodynamics, 1984, 12, 479-493.	0.6	15
370	Prediction of the disposition of β -lactam antibiotics in humans from pharmacokinetic parameters in animals. Journal of Pharmacokinetics and Pharmacodynamics, 1984, 12, 241-261.	0.6	111
371	Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and ^{14}C -disopyramide. Journal of Pharmacokinetics and Pharmacodynamics, 1984, 12, 289-313.	0.6	27

#	ARTICLE	IF	CITATIONS
372	Effects of chlorpromazine on the disposition and beta-adrenergic blocking activity of propranolol in the dog. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1984, 12, 333-349.	0.6	4
373	Hepatic elimination of drugs with concentration-dependent serum protein binding. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1984, 12, 67-81.	0.6	14
374	The Influence of Vasoactive Agents on Metabolic Activity of the Liver in Cirrhosis: A Study of the Effects of Posterior Pituitary Extract, Vasopressin, and Somatostatin. <i>Hepatology</i> , 1984, 4, 59-62.	3.6	53
375	Bioluminescence Assays for Bile Acids in the Detection and Follow-Up of Experimental Liver Injury. <i>Hepatology</i> , 1984, 4, 639-643.	3.6	9
376	Correspondence. Liver Blood Flow Using Clearance Techniques. <i>Hepatology</i> , 1984, 4, 746-748.	3.6	0
377	A bioequivalency study of two trifluoperazine tablet formulations using ria and GCâ€“MS. <i>Biopharmaceutics and Drug Disposition</i> , 1984, 5, 25-32.	1.1	5
378	Effect of water deprivation on antipyrine disposition kinetics in rats. <i>Biopharmaceutics and Drug Disposition</i> , 1984, 5, 195-198.	1.1	5
379	Effects of penicillins on binding of phenytoin to plasma proteins in vitro and in vivo. <i>Biopharmaceutics and Drug Disposition</i> , 1984, 5, 219-227.	1.1	15
380	Relative Bioavailability of a Commercial Trifluoperazine Tablet Formulation using a Radioimmunoassay Technique. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 261-263.	1.6	10
381	Pharmacokinetics of the Antirheumatic Proquazone in Healthy Humans. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 332-340.	1.6	4
382	Pharmacokinetics of Diazepam and Nordiazepam in the Cat. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 348-351.	1.6	23
383	Hepatic Tissue Binding and the Oral First-Pass Effect. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 422-425.	1.6	9
384	Use of Hexadeuterated Valproic Acid and Gas Chromatography-Mass Spectrometry to Determine the Pharmacokinetics of Valproic Acid. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 489-494.	1.6	14
385	In Vitro and In Vivo Assessment of Hepatic and Extrahepatic Metabolism of Diazepam in the Rat. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 826-828.	1.6	28
386	Kinetics of Partitioning and Binding of Digoxin and Its Analogues in the Subcompartments of Blood. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 1042-1053.	1.6	28
387	Pharmacokinetic Implications of Stereoselective Changes in Plasmaâ€“Protein Binding: Warfarin/Sulfinpyrazone. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 1671-1673.	1.6	29
388	Pharmacokinetics and absolute bioavailability of diltiazem in humans. <i>Klinische Wochenschrift</i> , 1984, 62, 303-306.	0.6	51
389	Effect of age and sex on the plasma binding of acidic and basic drugs. <i>European Journal of Clinical Pharmacology</i> , 1984, 27, 91-97.	0.8	114

#	ARTICLE	IF	CITATIONS
390	Influence of age on serum protein binding of propranolol. <i>European Journal of Clinical Pharmacology</i> , 1984, 26, 251-254.	0.8	28
391	Ethanol-induced inhibition of hepatic uptake of propranolol in perfused rat liver and in man. <i>European Journal of Clinical Pharmacology</i> , 1984, 27, 209-215.	0.8	2
392	Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. <i>European Journal of Clinical Pharmacology</i> , 1984, 26, 47-53.	0.8	51
393	Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. <i>European Journal of Clinical Pharmacology</i> , 1984, 26, 363-369.	0.8	34
394	Aminoglutethimide and warfarin. <i>Cancer Chemotherapy and Pharmacology</i> , 1984, 12, 10-2.	1.1	25
395	Plasma concentrations of unbound phenytoin in the management of epilepsy.. <i>British Journal of Clinical Pharmacology</i> , 1984, 17, 539-546.	1.1	57
396	The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose.. <i>British Journal of Clinical Pharmacology</i> , 1984, 17, 553-557.	1.1	20
397	Pharmacokinetics of valproic acid in the elderly.. <i>British Journal of Clinical Pharmacology</i> , 1984, 17, 665-669.	1.1	87
398	Diazepam/beta-adrenoceptor antagonist interactions.. <i>British Journal of Clinical Pharmacology</i> , 1984, 17, 69S-76S.	1.1	20
399	Enzyme induction and beta-adrenergic receptor blocking drugs.. <i>British Journal of Clinical Pharmacology</i> , 1984, 17, 77S-84S.	1.1	17
400	Beta-adrenoceptor blocker pharmacokinetics and the oral contraceptive pill.. <i>British Journal of Clinical Pharmacology</i> , 1984, 17, 87S-89S.	1.1	22
401	The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics.. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 393-400.	1.1	24
402	The influence of cimetidine on the pharmacokinetics of 5-fluorouracil.. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 421-430.	1.1	52
403	Failure of "therapeutic" doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine.. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 853-860.	1.1	28
404	Cimetidine alters pethidine disposition in man.. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 907-914.	1.1	26
405	Oxazepam pharmacokinetics in thyroid disease.. <i>British Journal of Clinical Pharmacology</i> , 1984, 17, 49-53.	1.1	24
406	Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels.. <i>British Journal of Clinical Pharmacology</i> , 1984, 17, 92-98.	1.1	32
407	Pharmacodynamic correlates of modified absorption: studies with lormetazepam.. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 31-35.	1.1	14

#	ARTICLE	IF	CITATIONS
408	Rates of pharmacokinetic literature obsolescence. <i>International Journal of Pharmaceutics</i> , 1984, 21, 135-141.	2.6	4
409	Effect of pregnancy or renal dysfunction on differences in plasma protein binding of phenytoin in peripheral blood and blood exiting the liver of rats. <i>International Journal of Pharmaceutics</i> , 1984, 18, 217-221.	2.6	1
410	Altered Plasma Protein-Binding of Prednisolone in Patients With the Nephrotic Syndrome. <i>American Journal of Kidney Diseases</i> , 1984, 3, 339-348.	2.1	33
411	Effect of lipid solubility on hepatic first-pass metabolism of barbiturates in rabbits. <i>International Journal of Pharmaceutics</i> , 1984, 20, 73-85.	2.6	10
412	Hepatic extraction of adriamycin in patients with hepatocellular carcinoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1984, 20, 761-764.	0.9	15
413	Protein Binding and Drug Clearance. <i>Clinical Pharmacokinetics</i> , 1984, 9, 10-17.	1.6	110
414	Pharmacokinetic Consequences of Drug Displacement from Blood and Tissue Proteins. <i>Clinical Pharmacokinetics</i> , 1984, 9, 32-41.	1.6	62
415	The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam. <i>Clinical Pharmacokinetics</i> , 1984, 9, 177-183.	1.6	84
416	Time-Dependence in Benzodiazepine Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1984, 9, 203-210.	1.6	11
417	Pharmacokinetic and Pharmacodynamic Considerations in Drug Therapy of Cardiac Emergencies. <i>Clinical Pharmacokinetics</i> , 1984, 9, 273-308.	1.6	36
418	Interactions and Non-Interactions with Ranitidine. <i>Clinical Pharmacokinetics</i> , 1984, 9, 493-510.	1.6	78
419	Pharmacology of Combined α_1 -Blockade I. <i>Drugs</i> , 1984, 28, 16-34.	4.9	27
420	Physiologic Pharmacokinetic Models: Relevance, Experience, and Future Trends. <i>Drug Metabolism Reviews</i> , 1984, 15, 55-74.	1.5	39
421	First-Pass Elimination. <i>Clinical Pharmacokinetics</i> , 1984, 9, 1-25.	1.6	342
422	Hepatic extraction of chenodeoxycholic acid in dogs chronically intoxicated with dimethylnitrosamine. <i>Biochemical Pharmacology</i> , 1984, 33, 3219-3224.	2.0	4
423	Influence of red blood cells, serum albumin, and serum lipoproteins on the clearance of benzo[a]pyrene by isolated livers of 3-methylcholanthrene-treated rats. <i>Biochemical Pharmacology</i> , 1984, 33, 3433-3438.	2.0	4
424	An investigation of the effects of phenobarbitone on the pharmacokinetics of norethindrone in the rat using liver perfusion and everted gut sacs. <i>Biochemical Pharmacology</i> , 1984, 33, 1595-1600.	2.0	0
425	Cimetidine-induced decrease in lidocaine metabolism. <i>American Heart Journal</i> , 1984, 108, 413-415.	1.2	18

#	ARTICLE	IF	CITATIONS
426	Lidocaine disposition in obesity. American Journal of Cardiology, 1984, 53, 1183-1186.	0.7	73
427	The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone. Archives of Gerontology and Geriatrics, 1984, 3, 147-159.	1.4	18
429	Pharmacokinetic study of exogenously administered γ -endorphin using a rapid radioreceptor assay in rats. Life Sciences, 1984, 35, 1051-1059.	2.0	9
430	Interspecies Comparison of In Vivo Caffeine Pharmacokinetics in Man, Monkey, Rabbit, Rat and Mouse. Drug Metabolism Reviews, 1984, 15, 1355-1383.	1.5	154
431	Oxaprozin Dose Proportionality. Journal of Clinical Pharmacology, 1984, 24, 515-522.	1.0	10
432	Zomepirac \AA Aspirin Interactions in Man. Journal of Clinical Pharmacology, 1984, 24, 371-380.	1.0	7
433	Increased availability of propranolol in rats with uranyl nitrate-induced acute renal failure.. Journal of Pharmacobio-dynamics, 1984, 7, 536-544.	0.5	32
434	Influence of acute renal failure on pharmacokinetics of phenolsulfonphthalein in rats: A comparative study in vivo and in the simultaneous perfusion system of liver and kidney.. Journal of Pharmacobio-dynamics, 1985, 8, 377-384.	0.5	15
435	The effect of albumin on the uptake of bromosulfophthalein by isolated rat hepatocytes.. Journal of Pharmacobio-dynamics, 1985, 8, 90-94.	0.5	16
436	Taurolithocholate increases heme catabolism and alters the clearance of antipyrine in the rat. Gastroenterology, 1985, 88, 397-402.	0.6	7
437	Kinetics of Diazepam, Midazolam, and Lorazepam in Cigarette Smokers. Chest, 1985, 87, 223-226.	0.4	46
438	Verapamil-Rifampin Interaction. Drug Intelligence & Clinical Pharmacy, 1985, 19, 559-560.	0.4	19
439	Hepatic Drug Clearance following Traumatic Injury. Drug Intelligence & Clinical Pharmacy, 1985, 19, 799-806.	0.4	13
440	Changes in Pharmacokinetics of Valproic Acid in Guinea Pigs from Birth to Maturity. Epilepsia, 1985, 26, 243-251.	2.6	10
441	Special considerations in drug therapy for elderly dental patients. Special Care in Dentistry, 1985, 5, 24-26.	0.4	6
442	The Excretion of Rosaramicin in Breast Milk. Journal of Clinical Pharmacology, 1985, 25, 89-94.	1.0	12
443	Pharmacokinetic evidence for blood flow depression in dose dependent disposition of 4-aminoantipyrine in rabbits.. Journal of Pharmacobio-dynamics, 1985, 8, 365-376.	0.5	1
444	Characterization of the benzodiazepine binding site (diazepam site) on human serum albumin.. Chemical and Pharmaceutical Bulletin, 1985, 33, 5002-5012.	0.6	18

#	ARTICLE	IF	CITATIONS
445	The effect of cimetidine on the pharmacokinetics, pharmacodynamics and alpha1-adrenoceptor responsiveness of trimazosin in man. <i>European Journal of Clinical Pharmacology</i> , 1985, 29, 301-306.	0.8	5
446	Protein binding and disposition of lignocaine in the elderly. <i>European Journal of Clinical Pharmacology</i> , 1985, 29, 323-329.	0.8	47
447	Linear pharmacokinetics of intravenous ergotamine tartrate. <i>European Journal of Clinical Pharmacology</i> , 1985, 29, 61-66.	0.8	6
448	Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. <i>European Journal of Clinical Pharmacology</i> , 1985, 29, 477-481.	0.8	59
449	Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment. <i>European Journal of Clinical Pharmacology</i> , 1985, 28, 97-103.	0.8	19
450	Variability of fentanyl pharmacokinetics in man.. <i>Anaesthesia</i> , 1985, 40, 837-843.	1.8	38
451	Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1985, 13, 477-492.	0.6	82
452	Influence of food on the intravenous and oral dose kinetics of propranolol in the dog. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1985, 13, 229-241.	0.6	9
453	Binding and disposition of sulfisoxazole in alcoholic cirrhosis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1985, 13, 1-12.	0.6	4
454	A nonlinear physiologic pharmacokinetic model: I. Steady-state. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1985, 13, 73-92.	0.6	21
455	Effect of age on the disposition and tissue clearances of fluorinated pyrimidines in rats. <i>Pharmaceutical Research</i> , 1985, 02, 279-284.	1.7	6
456	Pharmacokinetic studies of theophylline in horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 1985, 8, 76-81.	0.6	19
457	Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: A single dose study. <i>Biopharmaceutics and Drug Disposition</i> , 1985, 6, 131-137.	1.1	16
458	A carrier-protein receptor is not a prerequisite for avid hepatic elimination of highly bound compounds: A study of propranolol elimination by the isolated perfused rat liver. <i>Hepatology</i> , 1985, 5, 590-593.	3.6	25
459	Modeling of substrate elimination by the liver: Has the albumin receptor model superseded the well-stirred model?. <i>Hepatology</i> , 1985, 5, 1231-1235.	3.6	19
460	Theoretical Limits of Changes in Plasma Protein Binding on Renal Drug Clearance. <i>Journal of Pharmaceutical Sciences</i> , 1985, 74, 108-109.	1.6	4
461	Variation in Hepatic Extraction Ratio with Unbound Drug Fraction: Discrimination Between Models of Hepatic Drug Elimination. <i>Journal of Pharmaceutical Sciences</i> , 1985, 74, 205-207.	1.6	19
462	Effect of Vitamin K3 on the First-Pass Elimination of Propranolol in the Rat. <i>Journal of Pharmaceutical Sciences</i> , 1985, 74, 578-581.	1.6	2

#	ARTICLE	IF	CITATIONS
463	Diurnal Variation of $\hat{I}\pm 1$ -Acid Glycoprotein Concentration in Normal Volunteers. Journal of Pharmaceutical Sciences, 1985, 74, 777-779.	1.6	38
464	Development of quantitative structure-pharmacokinetic relationships.. Environmental Health Perspectives, 1985, 61, 295-306.	2.8	51
465	Pharmacokinetics of natural and synthetic glucocorticoids. , 1985, , 235-281.		15
466	Central Nervous System Toxicity Associated with Concurrent Use of Triazolam and Cimetidine. Drug Intelligence & Clinical Pharmacy, 1985, 19, 666-668.	0.4	10
467	AGE AND NATURE OF OPERATION INFLUENCE THE PHARMACOKINETICS OF MIDAZOLAM. British Journal of Anaesthesia, 1985, 57, 866-871.	1.5	74
468	A SHEEP PREPARATION FOR STUDYING INTERACTIONS BETWEEN BLOOD FLOW AND DRUG DISPOSITION.. British Journal of Anaesthesia, 1985, 57, 1239-1247.	1.5	17
469	Limitation of theophylline elimination by reduced oxygen availability in mouse hepatocytes and rat isolated livers. Canadian Journal of Physiology and Pharmacology, 1985, 63, 903-907.	0.7	11
470	Fasting serum bile acid level in cirrhosis. Journal of Hepatology, 1985, 1, 609-617.	1.8	15
471	Effect of Severe Alcoholic Liver Disease on the Disposition of Methadone in Maintenance Patients. Alcoholism: Clinical and Experimental Research, 1985, 9, 349-354.	1.4	48
472	Comparison of Drug Dosing Methods. Clinical Pharmacokinetics, 1985, 10, 1-37.	1.6	66
473	Pharmacokinetic Interactions of the Macrolide Antibiotics. Clinical Pharmacokinetics, 1985, 10, 63-79.	1.6	136
474	Effects of Ethanol on Drug and Metabolite Pharmacokinetics. Clinical Pharmacokinetics, 1985, 10, 228-247.	1.6	73
475	Importance of Drug Enantiomers in Clinical Pharmacology. Drugs, 1985, 30, 333-354.	4.9	258
476	Effects of ranitidine on the disposition of metoprolol.. British Journal of Clinical Pharmacology, 1985, 19, 219-224.	1.1	24
477	Verapamil dispositionâ€œeffects of sulphinpyrazone and cimetidine.. British Journal of Clinical Pharmacology, 1985, 19, 385-391.	1.1	28
478	Verapamil pharmacokinetics and apparent hepatic and renal blood flow.. British Journal of Clinical Pharmacology, 1985, 20, 101-106.	1.1	45
479	The influence of diflunisal on the pharmacokinetics of oxazepam.. British Journal of Clinical Pharmacology, 1985, 20, 225-234.	1.1	14
480	The influence of age and smoking on the elimination of disopyramide.. British Journal of Clinical Pharmacology, 1985, 20, 453-458.	1.1	31

#	ARTICLE	IF	CITATIONS
481	Lack of effect of nizatidine on hepatic drug metabolism in man.. British Journal of Clinical Pharmacology, 1985, 20, 710-713.	1.1	33
482	Effects of pregnancy on seizure threshold and the disposition and efficacy of antiepileptic drugs in the mouse. Life Sciences, 1985, 36, 663-669.	2.0	12
483	Physiologic pharmacokinetic models and interanimal species scaling. , 1985, 29, 49-68.		60
484	Drug interactions with cimetidine: An update. , 1985, 27, 353-370.		56
485	Physiologically based pharmacokinetics of valproic acid in rabbits. International Journal of Pharmaceutics, 1985, 27, 45-60.	2.6	19
486	Intrinsic hepatic clearance and child-turcotte classification for assessment of liver function in cirrhosis. Journal of Hepatology, 1985, 1, 253-259.	1.8	44
487	Cardiovascular and pharmacokinetic consequences of combined administration of verapamil and propranolol in dogs. American Journal of Cardiology, 1985, 56, 147-156.	0.7	14
488	Lack of effect of several barbiturates on liver blood flow. Biochemical Pharmacology, 1985, 34, 3776-3778.	2.0	2
489	Reduced hepatic uptake of propranolol in rats with acute renal failure. Biochemical Pharmacology, 1985, 34, 2679-2683.	2.0	17
490	Biliary excretion of FITC metabolites after administration of FITC labeled asialo orosomucoid as a measure of lysosomal proteolysis. Biochemical Pharmacology, 1985, 34, 1399-1405.	2.0	17
491	Free drug measurements: methodology and clinical significance. Clinica Chimica Acta, 1985, 151, 193-216.	0.5	213
492	Induction of cytochromes P-450 in pancreatic disease: Consequence, coincidence or cause?. Clinica Chimica Acta, 1985, 153, 73-84.	0.5	27
493	Age-related changes in drug handling in man. American Journal of Cardiology, 1986, 57, C59-C62.	0.7	10
494	Age-dependent propranolol clearance in perfused rat liver. Biochemical Pharmacology, 1986, 35, 1149-1152.	2.0	13
495	Pharmacokinetics and antiarrhythmic activity of ajmaline in rats subjected to coronary artery occlusion. British Journal of Pharmacology, 1986, 88, 71-77.	2.7	9
496	Binding to serum Î± ₁ -acid glycoprotein and effect of Î±-adrenoceptor antagonists in rats with inflammation. British Journal of Pharmacology, 1986, 88, 697-705.	2.7	23
497	Effects of cimetidine and ranitidine on the pharmacokinetics of quinine.. British Journal of Clinical Pharmacology, 1986, 22, 346-350.	1.1	19
498	Paracetamol metabolism in pregnancy.. British Journal of Clinical Pharmacology, 1986, 22, 359-362.	1.1	71

#	ARTICLE	IF	CITATIONS
499	The plasma protein binding of basic drugs.. British Journal of Clinical Pharmacology, 1986, 22, 499-506.	1.1	161
500	Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.. British Journal of Clinical Pharmacology, 1986, 22, 541-550.	1.1	64
501	Prolonged midazolam elimination half-life.. British Journal of Clinical Pharmacology, 1986, 21, 425-429.	1.1	84
502	Effect of nadolol on liver haemodynamics and function in patients with cirrhosis.. British Journal of Clinical Pharmacology, 1986, 21, 713-719.	1.1	26
503	Metabolism and clearance of T-2 mycotoxin in perfused rat livers*1, *2. Fundamental and Applied Toxicology, 1986, 7, 424-433.	1.9	21
504	Drug Disposition in Obese Humans. Clinical Pharmacokinetics, 1986, 11, 199-213.	1.6	171
505	Microwave Facilitation of Methylatropine Antagonism of Central Cholinomimetic Drug Effects. Radiation Research, 1986, 105, 328.	0.7	20
506	SYMPATHETIC TONE MODULATES PORTAL VENOUS PRESSURE IN ALCOHOLIC CIRRHOSIS. Lancet, The, 1986, 328, 939-943.	6.3	85
507	Pharmacokinetic parameters obtained with racemates. Trends in Pharmacological Sciences, 1986, 7, 155-158.	4.0	70
508	The pathophysiology of severe falciparum malaria. Parasitology Today, 1986, 2, 271-282.	3.1	65
509	Effect of disease states on theophylline elimination. Journal of Allergy and Clinical Immunology, 1986, 78, 727-735.	1.5	22
510	Introduction to Pharmacokinetics. Journal of Pharmacy Technology, 1986, 2, 67-73.	0.5	0
511	Effect of portacaval shunt on drug disposition in patients with cirrhosis. Gastroenterology, 1986, 91, 163-167.	0.6	18
512	Pharmacokinetic study of 4-methylumbelliferone in rats: Influence of dose on its first-pass hepatic elimination.. Journal of Pharmacobio-dynamics, 1986, 9, 117-124.	0.5	12
513	Characterization of the interaction of albumin with isolated rat liver cells to reveal the mechanism of albumin-mediated hepatic transport.. Journal of Pharmacobio-dynamics, 1986, 9, 244-248.	0.5	9
514	Prediction of serum concentration time course of quinidine in human using a physiologically based pharmacokinetic model developed from the rat.. Journal of Pharmacobio-dynamics, 1986, 9, 132-138.	0.5	1
515	The Effect of Ethanol Intake on Propoxyphene Absorption and Biotransformation in Dogs. Alcoholism: Clinical and Experimental Research, 1986, 10, 393-396.	1.4	1
516	The Hepatic and Renal Mechanisms of Drug Interactions with Cimetidine. Drug Intelligence & Clinical Pharmacy, 1986, 20, 342-348.	0.4	22

#	ARTICLE	IF	CITATIONS
517	Pharmacology and Therapeutic Use of Low-dose Dopamine. <i>Pharmacotherapy</i> , 1986, 6, 304-310.	1.2	42
519	Effect of Mechanical Ventilation on Hepatic Drug Pharmacokinetics. <i>Chest</i> , 1986, 90, 837-841.	0.4	35
520	Benzodiazepine hypnotic metabolism: drug interactions and clinical implications. <i>Acta Psychiatrica Scandinavica</i> , 1986, 74, 32-38.	2.2	10
521	Dose-proportionality, bioavailability, and steady-state kinetics of astemizole in man. <i>Drug Development Research</i> , 1986, 8, 71-78.	1.4	37
522	Effect of propranolol on hepatic and systemic hemodynamics in dogs with chronic bile duct ligation. <i>Hepatology</i> , 1986, 6, 92-97.	3.6	29
523	Hemodynamic studies in long- and short-term portal hypertensive rats: The relation to systemic glucagon levels. <i>Hepatology</i> , 1986, 6, 414-418.	3.6	65
524	Pharmacokinetics of Ketoconazole Administered Intravenously to Dogs and Orally as Tablet and Solution to Humans and Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1986, 75, 443-447.	1.6	46
525	Pharmacokinetics of Dothiepin in Humans: A Single Dose Dose-Proportionality Study. <i>Journal of Pharmaceutical Sciences</i> , 1986, 75, 582-585.	1.6	17
526	Effect of the Immunomodulator Tilorone on Antipyrine Disposition in the Rat. <i>Journal of Pharmaceutical Sciences</i> , 1986, 75, 946-948.	1.6	13
527	Potential pulmonary uptake and clearance of morphine in postoperative patients. <i>European Journal of Clinical Pharmacology</i> , 1986, 30, 567-574.	0.8	16
528	Profound reduction in morphine clearance and liver blood flow in shock. <i>Intensive Care Medicine</i> , 1986, 12, 366-369.	3.9	47
529	Cirrhosis of the liver markedly impairs the elimination of mexiletine. <i>European Journal of Clinical Pharmacology</i> , 1986, 30, 83-88.	0.8	25
530	Effect of cirrhosis and renal failure on the kinetics of clotiazepam. <i>European Journal of Clinical Pharmacology</i> , 1986, 30, 89-92.	0.8	8
531	Influence of physical exercise on the pharmacokinetics of propranolol. <i>European Journal of Clinical Pharmacology</i> , 1986, 31, 375-377.	0.8	28
532	Thiopentone levels during cardiopulmonary bypass.. <i>Anaesthesia</i> , 1986, 41, 4-10.	1.8	23
533	Antipyrine clearance and metabolite formation: the influence of liver volume and smoking. <i>European Journal of Clinical Investigation</i> , 1986, 16, 321-327.	1.7	16
534	In vivo interaction of the enantiomers of disopyramide in human subjects. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1986, 14, 335-356.	0.6	64
535	A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1986, 14, 227-260.	0.6	227

#	ARTICLE	IF	CITATIONS
536	A dispersion model of hepatic elimination: 2. Steady-state considerations-influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1986, 14, 261-288.	0.6	85
537	Pharmacokinetics and dynamics of penbutolol in humans: Evidence for pathway-specific stereoselective clearance. <i>Klinische Wochenschrift</i> , 1986, 64, 636-641.	0.6	17
538	Intra-arterial administration of hexobarbital enantiomers to the rat: disposition and estimation of apparent extraction ratio. <i>Pharmaceutisch Weekblad</i> , 1986, 8, 139-144.	0.7	11
539	Stereoselective pharmacokinetics of perhexiline. <i>Xenobiotica</i> , 1986, 16, 491-502.	0.5	36
540	Microwave Facilitation of Methylalntrexone Antagonism of Morphine-Induced Analgesia in Mice. <i>Journal of Bioelectricity</i> , 1986, 5, 35-46.	0.7	10
541	Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis.. <i>Gut</i> , 1986, 27, 190-195.	6.1	127
542	Norepinephrine removal and release in the forearm of healthy subjects.. <i>Hypertension</i> , 1986, 8, 801-809.	1.3	46
543	Effects of liver blood flow on hepatic uptake kinetics of galactose in anesthetized cats: parallel tube model. <i>Canadian Journal of Physiology and Pharmacology</i> , 1987, 65, 1193-1199.	0.7	11
544	PLASMA CONCENTRATIONS OF UNBOUND VALPROATE AND THE MANAGEMENT OF EPILEPSY. <i>Australian and New Zealand Journal of Medicine</i> , 1987, 17, 574-579.	0.5	15
545	Oral Enoximone Pharmacokinetics in Patients with Congestive Heart Failure. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 654-660.	1.0	9
546	Lack of Effect of Withdrawal from Cigarette Smoking on Theophylline Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 221-225.	1.0	5
547	Pharmacokinetic study of 4-methylumbelliferone in mice.. <i>Journal of Pharmacobio-dynamics</i> , 1987, 10, 195-200.	0.5	4
548	Age-dependent change in warfarin distribution volume in rats. Effect of change in extracellular water volume.. <i>Journal of Pharmacobio-dynamics</i> , 1987, 10, 330-335.	0.5	3
549	Binding of drugs to sera of patients with renal disease and liver disease.. <i>Chemical and Pharmaceutical Bulletin</i> , 1987, 35, 308-314.	0.6	1
550	Principles of Drug Disposition in the Horse. <i>Veterinary Clinics of North America Equine Practice</i> , 1987, 3, 221-250.	0.3	4
551	The Effect of Acute Withdrawal from Cigarette Smoking on Indocyanine Green and Antipyrine Clearance. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 226-232.	1.0	3
552	Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. <i>Neuropharmacology</i> , 1987, 26, 831-836.	2.0	35
553	Method for chronic portal vein infusion in unrestrained rats. <i>Journal of Pharmacological Methods</i> , 1987, 17, 67-74.	0.7	15

#	ARTICLE	IF	CITATIONS
554	Effect of inhalation anesthetics on antipyrine pharmacokinetics of mice. <i>Biochemical Pharmacology</i> , 1987, 36, 1023-1027.	2.0	5
555	Alcohol and drug interactions. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 271-278.	1.4	0
556	Food increases the bioavailability of propafenone.. <i>British Journal of Clinical Pharmacology</i> , 1987, 23, 735-741.	1.1	39
557	The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics.. <i>British Journal of Clinical Pharmacology</i> , 1987, 23, 743-751.	1.1	21
558	Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.. <i>British Journal of Clinical Pharmacology</i> , 1987, 23, 753-757.	1.1	48
559	A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.. <i>British Journal of Clinical Pharmacology</i> , 1987, 24, 527-535.	1.1	20
561	Oral mexiletine-theophylline interaction. <i>International Journal of Cardiology</i> , 1987, 17, 227-228.	0.8	23
562	Metabolism of caffeine to 6-amino-5-[N-methylformyl-amino]-1, 3-dimethyluracil in the isolated, perfused liver from control or phenobarbital-, β^2 -naphthoflavone- and 3-methylcholanthrene-pretreated rats. <i>Toxicology Letters</i> , 1987, 38, 55-66.	0.4	1
563	Clinical Pharmacokinetics of Nicotine. <i>Clinical Pharmacokinetics</i> , 1987, 12, 30-40.	1.6	97
564	The Pharmacokinetics of Antiarrhythmic Agents in Pregnancy and Lactation. <i>Clinical Pharmacokinetics</i> , 1987, 12, 253-291.	1.6	82
565	Protein Binding as a Primary Determinant of the Clinical Pharmacokinetic Properties of Non-Steroidal Anti-Inflammatory Drugs. <i>Clinical Pharmacokinetics</i> , 1987, 12, 402-432.	1.6	186
566	The Pharmacokinetics of Lignocaine and β^2 -Adrenoceptor Antagonists in Patients with Acute Myocardial Infarction. <i>Clinical Pharmacokinetics</i> , 1987, 13, 293-316.	1.6	40
567	Alterations in the Metabolism of Oestrogens During Treatment with Aminoglutethimide in Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 1987, 13, 393-406.	1.6	51
568	Pharmacokinetics in the aged. , 1987, , 184-203.		6
569	The Role of Pharmacokinetics in Anaesthesia: Application to Intravenous Infusions. <i>Anaesthesia and Intensive Care</i> , 1987, 15, 7-14.	0.2	6
570	Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 1987, 32, 619-623.	0.8	9
571	Bioavailability of disopyramide in normal volunteers using unbound concentration. <i>European Journal of Clinical Pharmacology</i> , 1987, 32, 625-629.	0.8	7
572	Pharmacokinetics and pharmacodynamics in critically ill patients. <i>World Journal of Surgery</i> , 1987, 11, 210-217.	0.8	28

#	ARTICLE	IF	CITATIONS
573	Changed pharmacokinetics under the influence of age. Pharmaceutisch Weekblad Scientific Edition, 1987, 9, 50-55.	0.9	3
574	The influence of binding to albumin and $\hat{1}\pm 1$ -acid glycoprotein on the clearance of drugs by the liver. Pharmaceutisch Weekblad, 1987, 9, 65-74.	0.7	11
575	Pharmacokinetics in liver disease. Pharmaceutisch Weekblad Scientific Edition, 1987, 9, 79-84.	0.9	8
576	Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. European Journal of Clinical Pharmacology, 1987, 32, 153-158.	0.8	10
577	Acute effects of short-term subcutaneous terbutaline on theophylline disposition. European Journal of Clinical Pharmacology, 1987, 32, 191-193.	0.8	7
578	Inter- and intra-subject variability of nitrendipine and the effects of food. European Journal of Clinical Pharmacology, 1987, 32, 357-360.	0.8	14
579	Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver. Cancer Chemotherapy and Pharmacology, 1987, 19, 240-5.	1.1	43
580	Effects of josamycin on carbamazepine kinetics. European Journal of Clinical Pharmacology, 1987, 32, 321-323.	0.8	26
581	The influence of antituberculosis drugs on the plasma level of verapamil. European Journal of Clinical Pharmacology, 1987, 32, 107-109.	0.8	13
582	Factors responsible for interindividual differences in the dose requirement of phenprocoumon. European Journal of Clinical Pharmacology, 1987, 33, 49-54.	0.8	13
583	Haemodynamic effects of combined oral nifedipine and sublingual nitroglycerin in patients with chronic stable angina. European Journal of Clinical Pharmacology, 1987, 33, 349-354.	0.8	0
584	Influence of smoking and gender on the disposition kinetics of metoprolol. European Journal of Clinical Pharmacology, 1987, 33, 355-361.	0.8	13
585	Gallopamil binding to human serum proteins. European Journal of Clinical Pharmacology, 1987, 33, 375-380.	0.8	6
586	Etintidine-theophylline interaction study in humans. Biopharmaceutics and Drug Disposition, 1987, 8, 561-569.	1.1	8
587	Microwave facilitation of domperidone antagonism of apomorphine-induced stereotypic climbing in mice. Bioelectromagnetics, 1987, 8, 45-55.	0.9	18
588	Kinetics of ajmaline disposition and pharmacologic response in beagle dogs. Journal of Pharmacokinetics and Pharmacodynamics, 1987, 15, 39-55.	0.6	8
589	Etintidine-propranolol interaction study in humans. Journal of Pharmacokinetics and Pharmacodynamics, 1987, 15, 557-568.	0.6	6
590	Drug disposition in patients with HBsAg-positive chronic liver disease. Digestive Diseases and Sciences, 1987, 32, 710-714.	1.1	22

#	ARTICLE	IF	CITATIONS
591	Temperature dependence of di-2-ethylhexyl phthalate (DEHP) pharmacokinetics in rainbow trout*1. Toxicology and Applied Pharmacology, 1987, 88, 305-312.	1.3	35
592	Ticlopidine-theophylline interaction. Clinical Pharmacology and Therapeutics, 1987, 41, 358-362.	2.3	45
593	A comparison of the early pharmacokinetics of midazolam in pregnant and nonpregnant women. Anaesthesia, 1987, 42, 1057-1062.	1.8	33
594	Pharmacodynamics and Pharmacokinetics of Ethanol, Diazepam and Pentobarbital in Young and Aged Rats. Basic and Clinical Pharmacology and Toxicology, 1987, 61, 308-312.	0.0	19
595	Acid glycoprotein and serum binding of drugs in healthy and diseased dogs. Journal of Veterinary Pharmacology and Therapeutics, 1987, 10, 43-48.	0.6	26
596	Pharmacokinetics of antipyrine, acetaminophen and lidocaine in fed and fasted horses. Journal of Veterinary Pharmacology and Therapeutics, 1987, 10, 73-82.	0.6	60
597	Altered pharmacology in burned patients. Bailliere's Clinical Anaesthesiology, 1987, 1, 649-661.	0.2	1
598	Differential Effect of Pentobarbital and Chloralose in Anesthetic Doses on the Serum Protein Binding of Lidocaine in the Dog. Journal of Pharmaceutical Sciences, 1988, 77, 466-467.	1.6	1
599	Effect of amiodarone on the disposition of procainamide in the rat. Journal of Pharmaceutical Sciences, 1988, 77, 662-665.	1.6	9
600	Pharmacokinetics of a Valpromide Isomer, Valnoctamide, in Dogs. Journal of Pharmaceutical Sciences, 1988, 77, 831-834.	1.6	20
601	Effect of Altered Albumin Concentrations on Elimination of Unbound Prazosin In Vivo in the Rat and in the Isolated Perfused Rat Liver. Journal of Pharmaceutical Sciences, 1988, 77, 948-951.	1.6	7
602	Dose-dependent pharmacokinetics of probenecid in the rat. Biopharmaceutics and Drug Disposition, 1988, 9, 59-70.	1.1	21
603	Severe cholestasis leads to vitamin D depletion without perturbing its C-25 hydroxylation in the dog. Hepatology, 1988, 8, 1577-1585.	3.6	17
604	Long-term effect of nadolol on quantitative liver function tests in patients with cirrhosis. European Journal of Clinical Pharmacology, 1988, 34, 501-504.	0.8	9
605	Comparison of paracetamol metabolism in young adult and elderly males. European Journal of Clinical Pharmacology, 1988, 35, 157-160.	0.8	68
606	Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. European Journal of Clinical Pharmacology, 1988, 34, 653-656.	0.8	12
607	Single- and multiple-dose pharmacokinetics of terodiline in geriatric patients. European Journal of Clinical Pharmacology, 1988, 34, 291-297.	0.8	17
608	Nisoldipine: Kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. European Journal of Clinical Pharmacology, 1988, 34, 387-394.	0.8	30

#	ARTICLE	IF	CITATIONS
609	Influence of continuous ambulatory peritoneal dialysis on serum α_1 -acid glycoprotein concentration and drug binding. <i>European Journal of Clinical Pharmacology</i> , 1988, 35, 339-343.	0.8	8
610	Bioavailability and pharmacokinetics of oxazepam. <i>European Journal of Clinical Pharmacology</i> , 1988, 35, 385-389.	0.8	44
611	Estimating reduced availability due to first pass elimination from relative total clearance and renal clearance. <i>European Journal of Clinical Pharmacology</i> , 1988, 35, 397-400.	0.8	2
612	Dose-dependent metabolism and hepatic distribution of phenprocoumon in rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1988, 16, 1-12.	0.6	2
613	Prediction of hepatic first-pass metabolism and plasma levels following intravenous and oral administration of barbiturates in the rabbit based on quantitative structure-Pharmacokinetic relationships. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1988, 16, 279-301.	0.6	26
614	Effect of plasma protein binding on drug disposition in muscle tissue: Application of statistical moment analysis and network theory to in situ local single-pass perfusion system. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1988, 16, 129-149.	0.6	11
615	Kinetic analysis of albumin-mediated uptake of warfarin by perfused rat liver. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1988, 16, 165-181.	0.6	48
616	Influence of obesity on sulfonamide disposition in Zucker rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1988, 13, 273-283.	0.6	4
617	The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1988, 13, 123-127.	0.6	5
618	Sex differences in sulfobromophthalein-glutathione transport by perfused rat liver. <i>Biochemical Pharmacology</i> , 1988, 37, 3119-3126.	2.0	19
619	Stereoselective delivery and actions of beta receptor antagonists. <i>Biochemical Pharmacology</i> , 1988, 37, 115-124.	2.0	141
620	Disposition of hexobarbital: 15 years of an intriguing model substrate. <i>Drug Metabolism Reviews</i> , 1988, 19, 109-164.	1.5	16
621	Pharmacokinetics of Calcium Antagonists Under Development. <i>Clinical Pharmacokinetics</i> , 1988, 15, 1-14.	1.6	67
623	Principles of Drug Biodisposition in the Neonate. <i>Clinical Pharmacokinetics</i> , 1988, 14, 189-216.	1.6	182
624	Ranitidine Versus Cimetidine. <i>Clinical Pharmacokinetics</i> , 1988, 15, 44-56.	1.6	65
625	Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast Cancer. <i>Drugs</i> , 1988, 35, 685-710.	4.9	96
626	α -Adrenoceptor Blockade and Exercise. <i>Sports Medicine</i> , 1988, 5, 209-225.	3.1	78
627	Alteration in the disposition and metabolism of S(-)-propranolol in rats with active respiratory viral infection. <i>Life Sciences</i> , 1988, 42, 1245-1252.	2.0	2

#	ARTICLE	IF	CITATIONS
628	Drug metabolism in the elderly. , 1988, 36, 131-149.		52
629	Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.. British Journal of Clinical Pharmacology, 1988, 25, 297-305.	1.1	116
630	Regional chemotherapy of liver metastases from colorectal carcinoma: hepatic artery or portal vein infusion?. Cancer Treatment Reviews, 1988, 15, 243-256.	3.4	9
631	Splanchnic and hepatic renin metabolism in alcoholic cirrhosis. Journal of Hepatology, 1988, 7, 93-97.	1.8	1
632	Principles of Drug Biodisposition in the Neonate. Clinical Pharmacokinetics, 1988, 14, 261-286.	1.6	114
633	COMPARISON OF THE EFFECTS OF ISOFLURANE OR FENTANYL-NITROUS OXIDE ANAESTHESIA ON PROPRANOLOL DISPOSITION IN DOGS. British Journal of Anaesthesia, 1988, 60, 791-796.	1.5	17
634	PHARMACOKINETICS OF MIDAZOLAM IN ANAESTHETIZED CIRRHOTIC PATIENTS. British Journal of Anaesthesia, 1988, 60, 762-767.	1.5	72
635	Carbaryl Metabolism is Inhibited by Cimetidine in the Isolated Perfused Rat Liver and in Man. Journal of Toxicology: Clinical Toxicology, 1988, 26, 269-281.	1.5	2
636	Steady-State Extrarenal Sorbitol Clearance as a Measure of Hepatic Plasma Flow. Gastroenterology, 1988, 95, 749-759.	0.6	100
637	Protein Binding of Psychotropic Drugs: Equilibrium Dialysis and Lipophilicity Correlations. , 1988, , 1-32.		1
638	Near-total Reduction in Verapamil Bioavailability by Rifampin. Chest, 1988, 94, 954-959.	0.4	46
639	Alteration of Pentoxifylline Pharmacokinetics by Cimetidine. Journal of Clinical Pharmacology, 1988, 28, 649-654.	1.0	12
640	Effect of H2 receptor blockers, roxatidine, and cimetidine on drug metabolizing ability and blood flow of the liver.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1988, 19, 301-302.	0.1	0
641	Pharmacokinetics of Midazolam Following Intravenous and Oral Administration in Patients with Chronic Liver Disease and in Healthy Subjects. Journal of Clinical Pharmacology, 1989, 29, 272-277.	1.0	116
642	NEUROBEHAVIOURAL EFFECTS OF PROPOFOL ON THE NEONATE FOLLOWING ELECTIVE CAESAREAN SECTION. British Journal of Anaesthesia, 1989, 62, 649-654.	1.5	79
643	Pharmacokinetic Interaction Between Indoramin and Ethanol. Human Toxicology, 1989, 8, 237-241.	0.9	6
644	Calcium Channel Blockers as Inhibitors of Drug Metabolism. Chest, 1989, 96, 393-399.	0.4	19
645	Intra and interindividual variability in the kinetics of a poorly and highly metabolising solvent.. Occupational and Environmental Medicine, 1989, 46, 831-845.	1.3	6

#	ARTICLE	IF	CITATIONS
646	Presystemic branchial metabolism limits di-2-ethylhexyl phthalate accumulation in fish. <i>Toxicology and Applied Pharmacology</i> , 1989, 98, 49-57.	1.3	57
647	Effect of a change in the luminal perfusion rate on intestinal drug absorption studied by a simple unified organ clearance approach. <i>Pharmaceutical Research</i> , 1989, 06, 1056-1059.	1.7	7
648	Two-compartment dispersion model for analysis of organ perfusion system of drugs by fast inverse laplace transform (FILT). <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1989, 17, 179-202.	0.6	69
649	Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1989, 14, 269-278.	0.6	5
650	Atracurium, pharmacokinetics and metabolites. <i>Canadian Journal of Anaesthesia</i> , 1989, 36, 257-261.	0.7	2
651	Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery. <i>Pharmaceutical Research</i> , 1989, 06, 105-118.	1.7	68
652	Effect of Plasma Protein Binding on Kinetics of PN 200â€110 in the Isolated Perfused Rat Heart. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1989, 65, 258-264.	0.0	4
653	Aging and determinants of hepatic drug clearance. <i>Hepatology</i> , 1989, 9, 331-334.	3.6	52
654	Hepatic Drug Clearance in Children: Studies with Indocyanine Green as a Model Substrate. <i>Journal of Pharmaceutical Sciences</i> , 1989, 78, 452-456.	1.6	35
655	Enantiomeric Interaction of Flurbiprofen in the Rat. <i>Journal of Pharmaceutical Sciences</i> , 1989, 78, 632-634.	1.6	39
656	Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls. <i>Journal of Pharmaceutical Sciences</i> , 1989, 78, 695-715.	1.6	376
657	Simultaneous Determinations of Tolbutamide and its Hydroxy and Carboxy Metabolites in Serum and Urine: Application to Pharmacokinetic Studies of Tolbutamide in the Rat. <i>Journal of Pharmaceutical Sciences</i> , 1989, 78, 863-866.	1.6	13
658	Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. <i>Biopharmaceutics and Drug Disposition</i> , 1989, 10, 187-203.	1.1	20
659	Lack of effect of co-trimoxazole on the pharmacokinetics of orally administered theophylline. <i>Biopharmaceutics and Drug Disposition</i> , 1989, 10, 573-580.	1.1	2
660	Stereoselective determination of plasma pindolol in endotoxin-pretreated rats by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1989, 494, 381-388.	1.7	22
661	Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients. <i>European Journal of Clinical Pharmacology</i> , 1989, 36, 175-180.	0.8	7
662	Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 1989, 37, 257-260.	0.8	21
663	In vitro protein binding of propafenone in normal and uraemic human sera. <i>European Journal of Clinical Pharmacology</i> , 1989, 36, 495-499.	0.8	17

#	ARTICLE	IF	CITATIONS
664	Hepatic extraction of morphine is impaired in cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 1989, 36, 501-506.	0.8	86
665	Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope. <i>European Journal of Clinical Pharmacology</i> , 1989, 37, 381-385.	0.8	15
666	Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. <i>British Journal of Cancer</i> , 1989, 60, 107-111.	2.9	55
667	Short-term effects of calcium antagonists on hemodynamics and cyclosporine pharmacokinetics in heart-transplant and kidney-transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 657-667.	2.3	13
668	Effects of positive-pressure ventilatory frequency on hepatic blood flow and performance. <i>Journal of Critical Care</i> , 1989, 4, 153-165.	1.0	7
671	Liver blood flow measurement in the rat the electromagnetic versus the microsphere and the clearance methods. <i>Journal of Pharmacological Methods</i> , 1989, 21, 287-297.	0.7	44
672	Pharmacokinetics of hexobarbital in young and old rats. <i>Mechanisms of Ageing and Development</i> , 1989, 50, 289-298.	2.2	4
673	EFFECT OF TURPENTINE-INDUCED INFLAMMATION ON THE DISPOSITION KINETICS OF PROPRANOLOL, METOPROLOL, AND ANTIPYRINE IN THE RAT. <i>Fundamental and Clinical Pharmacology</i> , 1989, 3, 79-88.	1.0	50
674	The polymorphic oxidation of beta-adrenoceptor antagonists. , 1989, 41, 461-477.		23
675	Disposition of pentachlorophenol in rainbow trout (<i>Salmo gairdneri</i>): effect of inhibition of metabolism. <i>Aquatic Toxicology</i> , 1989, 14, 131-147.	1.9	27
676	Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 781-787.	1.1	51
677	Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure.. <i>British Journal of Clinical Pharmacology</i> , 1989, 28, 45-52.	1.1	15
678	The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.. <i>British Journal of Clinical Pharmacology</i> , 1989, 28, 61-69.	1.1	105
679	Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study.. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 179-189.	1.1	18
680	Lack of effect of treatment with human recombinant tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP).. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 257-261.	1.1	3
681	The effect of roxatidine acetate and cimetidine on hepatic drug clearance assessed by simultaneous administration of three model substrates.. <i>British Journal of Clinical Pharmacology</i> , 1989, 28, 171-174.	1.1	5
682	Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy.. <i>British Journal of Clinical Pharmacology</i> , 1989, 28, 357-361.	1.1	3
683	Pharmacokinetics and dromotropic activity of ajmaline in rats with hyperthyroidism. <i>British Journal of Pharmacology</i> , 1989, 96, 163-169.	2.7	2

#	ARTICLE	IF	CITATIONS
684	Clinical Pharmacology of the Perinatal Period and Early Infancy. <i>Clinical Pharmacokinetics</i> , 1989, 17, 13-28.	1.6	96
685	The Effects of Encainide versus Diltiazem on the Oxidative Metabolic Pathways of Antipyrine. <i>Pharmacotherapy</i> , 1989, 9, 315-321.	1.2	5
686	The Toxicokinetics of (1 <i>R</i> , <i>cis</i>)- and (1 <i>R</i> , <i>trans</i>)-Tetramethrin in the Isolated Perfused Rat Liver. <i>Xenobiotica</i> , 1989, 19, 509-519.	0.5	5
687	Saturable First-Pass Kinetics of Propranolol. <i>Journal of Clinical Pharmacology</i> , 1989, 29, 240-245.	1.0	9
688	The Pharmacokinetics of the Enantiomers of Mexiletine in Humans. <i>Xenobiotica</i> , 1989, 19, 677-682.	0.5	38
689	Physiologic Implications of Mechanical Ventilation on Pharmacokinetics. <i>DICP: the Annals of Pharmacotherapy</i> , 1989, 23, 316-323.	0.2	26
691	Comparison of disposition parameters of quinidine and quinine in the rat. <i>Journal of Pharmacobio-dynamics</i> , 1989, 12, 608-615.	0.5	12
692	Interspecies differences in pharmacokinetics of an antiallergic agent, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1,4-diazepin-1-yl)benzimidazole difumarate (KG-2413) after intravenous administration to rats, guinea pigs and dogs. <i>Chemical and Pharmaceutical Bulletin</i> , 1989, 37, 753-756.	0.6	7
694	Toxic Carbamazepine Concentrations following Cardiothoracic Surgery and Myocardial Infarction. <i>DICP: the Annals of Pharmacotherapy</i> , 1990, 24, 822-826.	0.2	1
695	Age-Related Cognitive Recovery After General Anesthesia. <i>Anesthesia and Analgesia</i> , 1990, 71, 217-224.	1.1	52
696	Effects of Single-Dose and Short-Term Oral Nifedipine on Indocyanine Green Clearance as Assessed by Spectrophotometry and High Performance Liquid Chromatography. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 693-698.	1.0	15
697	Effect of iodopyracet on renal excretion of sulfamethizole in rabbits. <i>Journal of Pharmacobio-dynamics</i> , 1990, 13, 179-185.	0.5	1
698	Effect of pregnancy on the disposition of valproate in rats. <i>Journal of Pharmacobio-dynamics</i> , 1990, 13, 533-542.	0.5	6
699	Kinetic studies on drug disposition in rabbits. I. Renal excretion of iodopyracet and sulfamethizole. <i>Journal of Pharmacobio-dynamics</i> , 1990, 13, 97-107.	0.5	8
700	Kinetic studies on drug disposition in rabbits. II. Dose dependent pharmacokinetics of sulfamethizole. <i>Journal of Pharmacobio-dynamics</i> , 1990, 13, 108-119.	0.5	5
701	Proposals for Improving Risk Assessment in Reproductive Toxicology. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1990, 66, 10-17.	0.0	7
702	The Rhesus Monkey as a Model for Studies of Pregnancy Induced Changes in Metoprolol Metabolism. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1990, 66, 32-36.	0.0	6
703	Pharmacokinetics of Terodiline and a Major Metabolite in Dogs with a Correlation to a Pharmacodynamic Effect. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1990, 66, 373-381.	0.0	3

#	ARTICLE	IF	CITATIONS
704	Effect of experimentally-induced hepatic cirrhosis on the pharmacokinetics of orally administered praziquantel in the rat. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1990, 15, 199-202.	0.6	6
705	Physiological modeling of drug and metabolite: Disposition of oxazepam and oxazepam glucuronides in the recirculating perfused mouse liver preparation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1990, 18, 423-448.	0.6	12
706	Kinetic assessment of apparent facilitation by albumin of cellular uptake of unbound ligands. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1990, 18, 121-135.	0.6	4
707	First-pass metabolism of inspired ethyl acetate in the upper respiratory tracts of the F344 rat and Syrian hamster. <i>Toxicology and Applied Pharmacology</i> , 1990, 102, 331-345.	1.3	62
708	Pharmacokinetics of methylethergometrine in the rat: evidence for enterohepatic recirculation by a linked-rat model. <i>Pharmaceutical Research</i> , 1990, 07, 14-20.	1.7	7
709	Pharmacokinetics of intravenous 2-mercaptopyronylglycine in man. <i>European Journal of Clinical Pharmacology</i> , 1990, 38, 499-503.	0.8	15
710	Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. <i>Cardiovascular Drugs and Therapy</i> , 1990, 4, 487-491.	1.3	8
711	Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 27, 101-105.	1.1	21
712	Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 1990, 38, 289-291.	0.8	30
713	Effect of nifedipine on antipyrine and theophylline disposition. <i>Biopharmaceutics and Drug Disposition</i> , 1990, 11, 157-164.	1.1	7
714	Multiple-dose propranolol administration does not influence the single dose pharmacokinetics of quinapril and its active metabolite (quinaprilat). <i>Biopharmaceutics and Drug Disposition</i> , 1990, 11, 191-196.	1.1	9
715	The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. <i>Biopharmaceutics and Drug Disposition</i> , 1990, 11, 507-518.	1.1	48
716	Renal sodium retention complicating alcoholic liver disease: Relation to portosystemic shunting and liver function. <i>Hepatology</i> , 1990, 12, 455-459.	3.6	17
717	Effect of exercise on disposition and pharmacokinetics of drugs. <i>Drug Development Research</i> , 1990, 20, 251-275.	1.4	28
718	Effects of Truncal Vagotomy and Partial Gastrectomy on the Pharmacokinetics of Propranolol Enantiomers in Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1990, 79, 292-294.	1.6	1
719	Pharmacokinetics of the Trichothecene Mycotoxin Verrucarol in Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1990, 79, 548-551.	1.6	14
720	Marked Heterogeneity in the Intrahepatic Distribution of Quinidine in Rats: Implications in Pharmacokinetics. <i>Journal of Pharmaceutical Sciences</i> , 1990, 79, 778-781.	1.6	4
721	Altered Pharmacokinetics in the Elderly. <i>Clinics in Geriatric Medicine</i> , 1990, 6, 257-267.	1.0	84

#	ARTICLE	IF	CITATIONS
722	Chirality: Pharmacological Action and Drug Development. , 1990, , 1-28.		11
723	Interspecies Metabolism and Pharmacokinetic Scaling of Theophylline Disposition. Drug Metabolism Reviews, 1990, 22, 179-207.	1.5	31
724	Pharmacokinetic Drug Interactions with Phenytoin (Part II). Clinical Pharmacokinetics, 1990, 18, 131-150.	1.6	46
725	Clinical Pharmacokinetics of Imipramine and Desipramine. Clinical Pharmacokinetics, 1990, 18, 346-364.	1.6	104
726	Disease-Induced Variations in Plasma Protein Levels. Clinical Pharmacokinetics, 1990, 19, 147-159.	1.6	80
727	Disease-Induced Variations in Plasma Protein Levels. Clinical Pharmacokinetics, 1990, 19, 218-229.	1.6	37
728	Pharmacokinetic Drug Interactions with Cyclosporin (Part I)1. Clinical Pharmacokinetics, 1990, 19, 319-332.	1.6	144
729	Hepatic Drug Metabolism and Aging. Clinical Pharmacokinetics, 1990, 19, 359-389.	1.6	166
730	Pharmacokinetic Drug Interactions with Cyclosporin (Part II). Clinical Pharmacokinetics, 1990, 19, 400-415.	1.6	59
731	Influence of Age on the Pharmacokinetics of Alfentanil. Clinical Pharmacokinetics, 1990, 19, 416-422.	1.6	74
732	Formation of Active Metabolites of Psychotropic Drugs. Clinical Pharmacokinetics, 1990, 18, 434-459.	1.6	57
733	Review Physiological pharmacokinetic modelling. Xenobiotica, 1990, 20, 1241-1257.	0.5	30
735	Pyridoxal Isonicotinoyl Hydrazone.. Annals of the New York Academy of Sciences, 1990, 612, 315-326.	1.8	42
736	Free and total lidocaine levels in cardiac surgical patients. Journal of Cardiothoracic and Vascular Anesthesia, 1990, 4, 340-347.	0.2	14
737	Clinical Significance of Pharmacokinetic Models of Hepatic Elimination. Clinical Pharmacokinetics, 1990, 18, 61-76.	1.6	37
738	Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer. The Journal of Steroid Biochemistry, 1990, 35, 355-366.	1.3	93
739	The effect of age on serum concentrations of albumin and alpha 1â€ acid glycoprotein.. British Journal of Clinical Pharmacology, 1990, 29, 201-206.	1.1	96
740	The metabolism and bioavailability of morphine in patients with severe liver cirrhosis.. British Journal of Clinical Pharmacology, 1990, 29, 289-297.	1.1	167

#	ARTICLE	IF	CITATIONS
741	The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man.. British Journal of Clinical Pharmacology, 1990, 29, 381-389.	1.1	21
742	Changes in indocyanine green kinetics after the administration of enalapril to healthy subjects.. British Journal of Clinical Pharmacology, 1990, 30, 297-300.	1.1	9
743	Enantiomer specific pharmacokinetics. , 1990, 45, 309-329.		195
744	Action by the lungs on circulating xenobiotic agents, with a case study of physiologically based pharmacokinetic modeling of benzo(a)pyrene disposition. , 1990, 48, 143-155.		21
745	Pharmacokinetic modeling in aquatic animals I. Models and concepts. Aquatic Toxicology, 1990, 18, 61-85.	1.9	100
746	Pharmacokinetic modeling in aquatic animals I. Models and concepts. Aquatic Toxicology, 1990, 17, 187-212.	1.9	48
747	Age does not influence the serum protein binding of bupivacaine.. British Journal of Clinical Pharmacology, 1991, 32, 501-503.	1.1	22
748	Influence of menstrual cycle phase on serum concentrations of alpha 1-acid glycoprotein.. British Journal of Clinical Pharmacology, 1991, 31, 197-199.	1.1	14
749	Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.. British Journal of Clinical Pharmacology, 1991, 31, 323-332.	1.1	14
750	Effect of zinc supplementation on oxidative drug metabolism in patients with hepatic cirrhosis.. British Journal of Clinical Pharmacology, 1991, 31, 488-491.	1.1	5
752	Receptor-mediated endocytosis of A14-125I-insulin by the nonfiltering perfused rat kidney. Biochimica Et Biophysica Acta - General Subjects, 1991, 1073, 442-450.	1.1	16
753	Cholyl-lysylfluorescein: synthesis, biliary excretion in vivo and during single-pass perfusion of isolated perfused rat liver. Biochimica Et Biophysica Acta - General Subjects, 1991, 1115, 151-156.	1.1	40
754	Pharmacokinetic Interactions with Calcium Channel Antagonists (Part II). Clinical Pharmacokinetics, 1991, 21, 448-460.	1.6	33
755	Effect of electroconvulsive therapy on serum concentration of alpha-1-acid glycoprotein. Biological Psychiatry, 1991, 30, 116-120.	0.7	4
756	Tissue Binding versus Plasma Binding of Drugs: General Principles and Pharmacokinetic Consequences. Advances in Drug Research, 1991, 20, 117-166.	0.8	65
757	Effect of traditional Chinese herbal medicines on the pharmacokinetics of western drugs in SD rats of different ages. I. Aminophylline-Tin Chuan Tang and aminophylline-Hsiao Ching Long Tang.. Journal of Pharmacobio-dynamics, 1991, 14, 201-206.	0.5	6
758	Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers. Pharmaceutical Research, 1991, 08, 162-167.	1.7	10
759	Effect of receptor up-regulation on insulin pharmacokinetics in streptozotocin-treated diabetic rats. Pharmaceutical Research, 1991, 08, 563-569.	1.7	33

#	ARTICLE	IF	CITATIONS
760	Toxicity and kinetics of [3H]microcystin-LR in isolated perfused rat livers. <i>Toxicology and Applied Pharmacology</i> , 1991, 107, 391-401.	1.3	35
761	Pharmacokinetic considerations in local drug delivery. <i>Advanced Drug Delivery Reviews</i> , 1991, 6, 1-18.	6.6	2
762	Drug interactions and adverse reactions. <i>Bailliere's Clinical Anaesthesiology</i> , 1991, 5, 703-733.	0.2	4
763	Glucuronidation of Morphine and some Drug Oxidation Reactions in Liver Microsomes from Pregnant and Non-Pregnant Rhesus Monkeys. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1991, 69, 78-80.	0.0	2
764	Quantitation of intrinsic drug-metabolizing capacity in human liver biopsy specimens: Support for the intact-hepatocyte theory. <i>Hepatology</i> , 1991, 13, 475-481.	3.6	31
765	Prediction of the Disposition of Propafenone in Humans and Dogs from Pharmacokinetic Parameters in Other Animal Species. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 1106-1109.	1.6	14
766	Plasma protein binding of ketoprofen enantiomers in man: Method development and its application. <i>Chirality</i> , 1991, 3, 460-466.	1.3	38
767	The functioning liver mass. <i>Research in Clinic and Laboratory</i> , 1991, 21, 9-40.	0.3	4
768	Receptor-recycling model of clearance and distribution of insulin in the perfused mouse liver. <i>Diabetologia</i> , 1991, 34, 613-621.	2.9	42
769	RESISTANCE TO ATRACURIUM IN A PATIENT WITH AN INCREASE IN PLASMA ALPHA1 GLOBULINS. <i>British Journal of Anaesthesia</i> , 1991, 67, 623-625.	1.5	17
770	Does regional norepinephrine spillover represent local sympathetic activity?. <i>Hypertension</i> , 1991, 18, 56-66.	1.3	45
771	Disorders of the liver, gallbladder and pancreas. <i>Reviews in Clinical Gerontology</i> , 1991, 1, 43-53.	0.5	1
772	Chronic ethanol consumption causes increased glucuronidation of morphine in rabbits. <i>Xenobiotica</i> , 1991, 21, 515-524.	0.5	9
773	Liver Blood Flow: Non-Invasive Estimation Using a Gamma Camera. <i>Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine</i> , 1992, 206, 99-103.	1.0	2
774	Principles of altered drug handling in the elderly. <i>Reviews in Clinical Gerontology</i> , 1992, 2, 11-19.	0.5	2
775	Absolute bioavailability of clarithromycin after oral administration in humans. <i>Antimicrobial Agents and Chemotherapy</i> , 1992, 36, 1147-1150.	1.4	87
776	Pharmacokinetics of Systemically Administered Antibiotics in Patients with Thermal Injury. <i>Clinical Infectious Diseases</i> , 1992, 14, 458-463.	2.9	81
777	Distribution of Quinidine in Rats with Carbon Tetrachloride-Intoxicated Hepatic Disease.. <i>Journal of Pharmacobio-dynamics</i> , 1992, 15, 167-174.	0.5	10

#	ARTICLE	IF	CITATIONS
778	Mechanisms of Pharmacokinetic Interaction between Propranolol and Quinidine in Rats.. Chemical and Pharmaceutical Bulletin, 1992, 40, 1876-1879.	0.6	2
779	Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis. Gastroenterology, 1992, 102, 1351-1355.	0.6	60
781	Liquid Chromatographic Determination of the Potential Memory Enhancing Agent CL 275,838 Using a Post-Column Photolysis and Fluorimetric Detection. Journal of Liquid Chromatography and Related Technologies, 1992, 15, 1463-1472.	0.9	5
782	Elucidating the Relationship Between Acetazolamide Plasma Protein Binding and Renal Clearance Using an Albumin Infusion. Journal of Clinical Pharmacology, 1992, 32, 1028-1032.	1.0	13
783	Comparison of Pentoxifylline Pharmacokinetics Between Smokers and Nonsmokers. Journal of Clinical Pharmacology, 1992, 32, 1054-1058.	1.0	19
784	Clinical Therapeutic Conference: Pharmacokinetic Principles in Clinical Medicine. Journal of Clinical Pharmacology, 1992, 32, 118-123.	1.0	2
785	Aromatase Inhibitors in Malignant Diseases of Aging. Drugs and Aging, 1992, 2, 530-545.	1.3	14
786	Evaluation of Hepatic Function Using the Pharmacokinetics of a Therapeutically Administered Drug. Clinical Pharmacokinetics, 1992, 23, 69-83.	1.6	3
787	Perturbation of paracetamol urinary metabolic ratios by urine flow rate.. British Journal of Clinical Pharmacology, 1992, 34, 359-362.	1.1	10
788	Effects of vaso-active agents on hepatic function and blood gases in patients with cirrhosis: A study of vasopressin and nitroglycerin. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 148-153.	1.4	8
789	Patient-controlled analgesic infusions: alfentanil versus morphine. Pain, 1992, 49, 301-310.	2.0	34
790	Clinical Pharmacokinetics of Calcium Antagonists. Clinical Pharmacokinetics, 1992, 22, 416-433.	1.6	102
791	Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active Oâ€œDesmethyl Metabolite. Journal of Clinical Pharmacology, 1992, 32, 716-724.	1.0	175
792	Effect of traditional Chinese herbal medicines on the pharmacokinetics of western drugs in Spragueâ€œDawley rats of different ages (II): Aminophylline-huan Shao Tan and aminophylline-pu Chung Yi Chi Tang. Mechanisms of Ageing and Development, 1992, 66, 93-106.	2.2	1
793	Pharmacokinetics in the elderly. Geriatric Nephrology and Urology, 1992, 2, 155-167.	0.4	1
794	Disposition of antipyrine in patients with extensive metastatic liver disease. European Journal of Clinical Pharmacology, 1992, 42, 465-469.	0.8	8
795	A comparative investigation of hepatic clearance models: Predictions of metabolite formation and elimination. Journal of Pharmacokinetics and Pharmacodynamics, 1992, 20, 105-145.	0.6	18
796	Axial tissue diffusion can account for the disparity between current models of hepatic elimination for lipophilic drugs. Journal of Pharmacokinetics and Pharmacodynamics, 1992, 20, 19-61.	0.6	13

#	ARTICLE	IF	CITATIONS
797	Toxicokinetics in aquatic systems: Model comparisons and use in hazard assessment. <i>Environmental Toxicology and Chemistry</i> , 1992, 11, 1709-1725.	2.2	316
798	Evaluation of the accuracy of a pharmacokinetically-based patient-controlled analgesia system. <i>European Journal of Clinical Pharmacology</i> , 1992, 43, 67-75.	0.8	15
799	Influence of co-medication on the metabolism of valproate. <i>Pharmaceutisch Weekblad Scientific Edition</i> , 1992, 14, 108-113.	0.9	21
800	Anaesthetic management of patients with alcoholic liver disease. <i>Bailliere's Clinical Anaesthesiology</i> , 1992, 6, 847-861.	0.2	1
801	Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. <i>Chirality</i> , 1992, 4, 148-154.	1.3	26
802	Linear pharmacokinetics of haloperidol in the rat. <i>Biopharmaceutics and Drug Disposition</i> , 1992, 13, 69-76.	1.1	48
803	Prediction of the volume of distribution of 7-hydroxycoumarin in man from in vitro and ex vivo data obtained in rat. <i>Biopharmaceutics and Drug Disposition</i> , 1992, 13, 389-402.	1.1	3
804	Human Pharmacokinetics of Ibuprofen Enantiomers following Different Doses and Formulations: Intestinal Chiral Inversion. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 221-225.	1.6	67
805	Propranolol Disposition in the Rat: Variation in Hepatic Extraction with Unbound Drug Fraction. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 255-258.	1.6	16
806	Pharmacokinetics of D-propranolol following oral, intra-arterial and intraportal administration: Contrasting effects of oral glucose pretreatment. <i>Biopharmaceutics and Drug Disposition</i> , 1993, 14, 217-231.	1.1	3
807	Nonlinear elimination and hepatic concentration of conjugation- metabolite of valproate in guinea-pigs. <i>Biopharmaceutics and Drug Disposition</i> , 1993, 14, 297-312.	1.1	3
808	Effect of infusion duration on valproate pharmacokinetics. <i>Biopharmaceutics and Drug Disposition</i> , 1993, 14, 389-399.	1.1	19
809	Relative bioavailability of two disopyramide capsules in humans based on total, unbound, and unbound enantiomer concentrations. <i>Biopharmaceutics and Drug Disposition</i> , 1993, 14, 409-418.	1.1	3
810	Clearance by the liver in cirrhosis. I. Relationship between propranolol metabolism in vitro and its extraction by the perfused liver in the rat. <i>Hepatology</i> , 1993, 17, 301-306.	3.6	25
811	Hepatic enzyme activity is the major factor determining elimination rate of high-clearance drugs in cirrhosis. <i>Hepatology</i> , 1993, 18, 54-60.	3.6	19
812	Intrahepatic Distribution of Hydrochlorothiazide and Quinidine in Rats: Implications in Pharmacokinetics. <i>Journal of Pharmaceutical Sciences</i> , 1993, 82, 992-996.	1.6	11
813	Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. <i>European Journal of Clinical Pharmacology</i> , 1993, 45, 247-253.	0.8	9
814	Pharmacokinetics of fenoterol in pregnant and nonpregnant women. <i>European Journal of Clinical Pharmacology</i> , 1993, 45, 275-277.	0.8	10

#	ARTICLE	IF	CITATIONS
815	Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans. <i>Acta Anaesthesiologica Scandinavica</i> , 1993, 37, 258-261.	0.7	14
816	Racemates and enantiomers in drug development. <i>International Journal of Pharmaceutics</i> , 1993, 92, 1-14.	2.6	42
817	Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. <i>Pharmaceutical Research</i> , 1993, 10, 434-440.	1.7	48
818	Effect of plasma protein binding on kinetics of capillary uptake and efflux. <i>Pharmaceutical Research</i> , 1993, 10, 300-304.	1.7	17
819	Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: Studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1993, 21, 395-422.	0.6	36
820	Nonlinear protein binding and enzyme heterogeneity: Effects on hepatic drug removal. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1993, 21, 43-74.	0.6	16
821	Metabolism and Pharmacokinetics of T-2 Toxin and Related Trichothecenes. <i>Drug Metabolism Reviews</i> , 1993, 25, 281-323.	1.5	41
822	Clinical pharmacology of nicardipine in liver transplant patients. <i>Fundamental and Clinical Pharmacology</i> , 1993, 7, 531-536.	1.0	5
823	Influence of human recombinant interleukin-1 β on the enantioselective disposition of propranolol in rats. <i>Biochemical Pharmacology</i> , 1993, 45, 1-6.	2.0	9
824	The influence of renal function on the enantioselective pharmacokinetics and pharmacodynamics of ketoprofen in patients with rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 1993, 36, 185-193.	1.1	30
825	In Vitro Methods for Assessing Human Hepatic Drug Metabolism: Their use in Drug Development. <i>Drug Metabolism Reviews</i> , 1993, 25, 453-484.	1.5	169
826	MEGX test in hepatology: The long-sought ultimate quantitative liver function test?. <i>Journal of Hepatology</i> , 1993, 19, 4-7.	1.8	38
827	Hypoxia, Arterial pH and Theophylline Disposition. <i>Clinical Pharmacokinetics</i> , 1993, 25, 283-299.	1.6	14
828	Presystemic Extraction: Mechanisms and Consequences. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 650-656.	1.0	16
829	Methodological Approach in the Study of Anticancer Drug Metabolism: Qualitative Considerations. <i>Drug Metabolism Reviews</i> , 1993, 25, 153-172.	1.5	1
830	Dose-Dependent Hepatic Handling of l-Propranolol Determined by Multiple Indicator Dilution Method: Influence of Tissue Binding of l-Propranolol on Its Hepatic Elimination. <i>Biological and Pharmaceutical Bulletin</i> , 1993, 16, 1019-1024.	0.6	17
831	Influence of Dietary Lipids on Glucuronidation and Sulfation of Phenol and Its para Substituent in the Rat. <i>Biological and Pharmaceutical Bulletin</i> , 1993, 16, 518-520.	0.6	4
832	The Influence of Increased Plasma Protein Binding on the Disposition of Quinidine in Turpentine-Treated Rats. <i>Biological and Pharmaceutical Bulletin</i> , 1993, 16, 63-67.	0.6	11

#	ARTICLE	IF	CITATIONS
833	Carbamazepine-Valnoctamide Interaction in Epileptic Patients: In Vitro/In Vivo Correlation. <i>Epilepsia</i> , 1993, 34, 954-959.	2.6	33
834	Metabolic Fate of Zolpidem. (I). Pharmacokinetics of Zolpidem in Rats after Single Dosing. <i>Drug Metabolism and Pharmacokinetics</i> , 1993, 8, 413-425.	0.0	0
835	Use of the [14C]aminopyrine breath test to assess the hepatic response of dietary obese rats to a very-low-energy diet. <i>American Journal of Clinical Nutrition</i> , 1993, 57, 863-867.	2.2	3
836	THE PHARMACOLOGY OF THE PHENOTHIAZINES, BUTYROPHENONES, THIOXANTHINES AND DIPHENYLBUTYLPIPERIDINES. , 1993, , 3-26.		5
837	Metabolic disposition of tacrine in primary suspensions of rat hepatocyte and in single-pass perfused liver: <i>in vitro/in vivo</i> comparisons. <i>Xenobiotica</i> , 1994, 24, 1107-1117.	0.5	10
838	Pharmacokinetic/Pharmacodynamic Consequences of Space Flight. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 684-691.	1.0	16
839	Disposition of Lorazepam in Gilbert's Syndrome: Effects of Fasting, Feeding, and Enterohepatic Circulation. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 978-984.	1.0	25
840	Pharmacokinetic and pharmacodynamic studies following single and multiple doses of rolafagrel, a novel inhibitor of thromboxane synthase, in normal volunteers. <i>European Journal of Clinical Pharmacology</i> , 1994, 47, 275-280.	0.8	3
841	Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. <i>European Journal of Clinical Pharmacology</i> , 1994, 47, 61-5.	0.8	19
842	Dose-Dependency of Flurbiprofen Enantiomer Pharmacokinetics in the Rat. <i>Journal of Pharmaceutical Sciences</i> , 1994, 83, 1077-1080.	1.6	8
843	Enantioselective disposition of oral amlodipine in healthy volunteers. <i>Chirality</i> , 1994, 6, 531-536.	1.3	19
844	Marked enantioselective protein binding in humans of ketorolac <i>in vitro</i> : Elucidation of enantiomer unbound fractions following facile synthesis and direct chiral hplc resolution of tritium-labelled ketorolac. <i>Chirality</i> , 1994, 6, 642-648.	1.3	16
845	Importance of cytochrome P-450III _A activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. <i>Hepatology</i> , 1994, 20, 309-316.	3.6	56
846	Dose-dependent pharmacokinetics: Experimental observations and theoretical considerations. <i>Biopharmaceutics and Drug Disposition</i> , 1994, 15, 1-31.	1.1	64
847	Disposition ofazole antifungal agents. III. Binding of fluconazole and other azoles in rat liver. <i>Pharmaceutical Research</i> , 1994, 11, 961-965.	1.7	14
848	Enantioselective kinetics of verapamil and norverapamil in isolated perfused rat livers. <i>Pharmaceutical Research</i> , 1994, 11, 1815-1819.	1.7	17
849	Pharmacokinetics of muscle relaxants. <i>Bailliere's Clinical Anaesthesiology</i> , 1994, 8, 349-367.	0.2	1
850	Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 35, 101-108.	1.1	11

#	ARTICLE	IF	CITATIONS
851	Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. <i>Biochemical Pharmacology</i> , 1994, 47, 1469-1479.	2.0	769
852	The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 75-78.	1.1	36
853	Plasma protein binding displacement interactions“why are they still regarded as clinically important?. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 125-128.	1.1	262
854	Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 375-381.	1.1	11
855	Mixed linear and non-linear disposition of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 545-551.	1.1	6
856	Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. <i>British Journal of Pharmacology</i> , 1994, 113, 317-323.	2.7	7
857	Methyphenidate-induced hepatotoxicity in mice and its potentiation by β^2 -adrenergic agonist drugs. <i>Life Sciences</i> , 1994, 55, 269-281.	2.0	12
858	Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics. <i>Toxicology in Vitro</i> , 1994, 8, 507-512.	1.1	31
859	Application of Physiologically Based Pharmacokinetic Models for Assessing Drug Disposition in Space. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 692-698.	1.0	16
860	Effect of dietary obesity on naloxone disposition in sheep. <i>Canadian Journal of Physiology and Pharmacology</i> , 1994, 72, 471-475.	0.7	7
861	Assessment of Liver Metabolic Function. <i>Clinical Pharmacokinetics</i> , 1994, 27, 216-248.	1.6	126
862	Local Disposition of a New Xanthine Oxidase/Xanthine Dehydrogenase Inhibitor, BOF-4272, in Rat Liver.. <i>Biological and Pharmaceutical Bulletin</i> , 1994, 17, 1301-1304.	0.6	14
863	Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism.. <i>Journal of Clinical Investigation</i> , 1994, 94, 2209-2214.	3.9	194
864	Hepatic metabolism in severe falciparum malaria: caffeine clearance study. <i>Annals of Tropical Medicine and Parasitology</i> , 1994, 88, 13-19.	1.6	9
865	In Vitro Prediction of the Terfenadine“Ketoconazole Pharmacokinetic Interaction. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 1222-1227.	1.0	99
866	Mild Hypothermia Alters Propofol Pharmacokinetics and Increases the Duration of Action of Atracurium. <i>Anesthesia and Analgesia</i> , 1995, 80, 1007-1014.	1.1	185
867	Pharmacokinetics of Ropivacaine and Bupivacaine During 21 Hours of Continuous Epidural Infusion in Healthy Male Volunteers. <i>Anesthesia and Analgesia</i> , 1995, 81, 1163-1168.	1.1	2
868	General integration and regulation of metabolism at the organ level. <i>Proceedings of the Nutrition Society</i> , 1995, 54, 213-232.	0.4	16

#	ARTICLE	IF	CITATIONS
869	Protein Binding of Chlorpromazine in Vivo and in Vitro: Effect of Chlorpromazine Metabolite on Chlorpromazine Protein Binding in Rat.. Biological and Pharmaceutical Bulletin, 1995, 18, 586-592.	0.6	11
871	Anti-infective agents and hepatic disease. Medical Clinics of North America, 1995, 79, 895-917.	1.1	10
872	Mild Hypothermia Alters Propofol Pharmacokinetics and Increases the Duration of Action of Atracurium. Anesthesia and Analgesia, 1995, 80, 1007-1014.	1.1	336
873	Pharmacokinetics of Ropivacaine and Bupivacaine During 21 Hours of Continuous Epidural Infusion in Healthy Male Volunteers. Anesthesia and Analgesia, 1995, 81, 1163-1168.	1.1	47
874	The Pharmacokinetics and Neuromuscular Effects of Rocuronium Bromide in Patients with Liver Disease. Anesthesia and Analgesia, 1995, 80, 754-759.	1.1	5
875	The influence of cimetidine on the pharmacokinetics of the enantiomers of verapamil in the dog during multiple oral dosing. Journal of Veterinary Pharmacology and Therapeutics, 1995, 18, 117-123.	0.6	14
876	The pharmacokinetics of oral and intravenous allopurinol and intravenous oxypurinol in the horse. Journal of Veterinary Pharmacology and Therapeutics, 1995, 18, 451-456.	0.6	5
877	Inactivation of kupffer cells after prolonged donor fasting improves viability of transplanted hepatic allografts. Hepatology, 1995, 22, 1236-1242.	3.6	35
878	Disposition of lorazepam in diabetes: differences between patients treated with beef/pork and human insulins. European Journal of Clinical Pharmacology, 1995, 48-48, 253-8.	0.8	3
879	Mechanisms of action of endocrine treatment in breast cancer. Critical Reviews in Oncology/Hematology, 1995, 21, 158-193.	2.0	45
880	Stereoselective pharmacokinetics of dihydropyridine calcium antagonists. Journal of Chromatography A, 1995, 694, 181-193.	1.8	54
881	Animal models for studying transport across the blood-brain barrier. Journal of Neuroscience Methods, 1995, 56, 1-15.	1.3	42
882	Lack of presystemic metabolism of nifedipine in the rabbit. Journal of Pharmacokinetics and Pharmacodynamics, 1995, 23, 567-580.	0.6	2
883	New hepatocellular diffusion model for analysis of hepatobiliary transport processes of drugs. Journal of Pharmacokinetics and Pharmacodynamics, 1995, 23, 183-203.	0.6	7
884	2 Liver function tests. Bailliere's Clinical Gastroenterology, 1995, 9, 661-677.	0.9	9
885	The Pharmacokinetics and Neuromuscular Effects of Rocuronium Bromide in Patients with Liver Disease. Anesthesia and Analgesia, 1995, 80, 754-759.	1.1	113
886	Propofol pharmacokinetics in children with biliary atresia. British Journal of Anaesthesia, 1995, 74, 46-49.	1.5	34
887	Basic Principles of Pharmacokinetics. Toxicologic Pathology, 1995, 23, 115-123.	0.9	122

#	ARTICLE	IF	CITATIONS
888	Kinetics of copper and nitrite in rainbow trout (<i>Oncorhynchus mykiss</i>): The isolated perfused head preparation as alternative to in vivo assays. <i>Toxicology in Vitro</i> , 1995, 9, 505-508.	1.1	2
889	Disposition and urinary excretion of phenylbutazone in normal and febrile greyhounds. <i>Research in Veterinary Science</i> , 1995, 59, 261-266.	0.9	7
890	Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function. <i>Gastroenterology</i> , 1995, 109, 1257-1265.	0.6	130
891	Liver transplantation and pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 1995, 50, 199-200.	1.0	10
892	Effect of Alosetron (a New 5-HT ₃ Receptor Antagonist) on the Pharmacokinetics of Haloperidol in Schizophrenic Patients. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 202-207.	1.0	11
893	Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide*. <i>Clinical Pharmacokinetics</i> , 1995, 29, 292-332.	1.6	51
894	Applications and prospects for physiologically based pharmacokinetic (PB-PK) models involving pharmaceutical agents. <i>Toxicology Letters</i> , 1995, 82-83, 349-355.	0.4	10
895	Chapter 33. Plasma Protein Binding of Drugs. <i>Annual Reports in Medicinal Chemistry</i> , 1996, , 327-336.	0.5	228
896	Antiepileptic drug therapy: Clinical laboratory significance. <i>Journal of Emergency Medicine</i> , 1996, 14, 473-481.	0.3	2
897	Depression Associated with Medical Illness. <i>CNS Drugs</i> , 1996, 5, 175-189.	2.7	43
898	Pharmacokinetics of Ondansetron in Patients with Hepatic Insufficiency. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 206-215.	1.0	42
900	Consideration on Moments of Outflow Profile in Liver Perfusion System with Change in Perfusate Flow Rate Using Oxacillin as Model Drug.. <i>Biological and Pharmaceutical Bulletin</i> , 1996, 19, 83-87.	0.6	4
901	Modeling of drug elimination by the liver. 1. Main concepts and physiologically justified clearance models (a review). <i>Pharmaceutical Chemistry Journal</i> , 1996, 30, 285-292.	0.3	3
902	Volumes of distribution and mean residence time of drugs with linear tissue distribution and binding and nonlinear protein binding. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1996, 24, 389-402.	0.6	8
903	Species differences in hepatic bile acid uptake: Comparative evaluation of taurocholate and tauroursodeoxycholate extraction in rat and rabbit. <i>Comparative Biochemistry and Physiology A, Comparative Physiology</i> , 1996, 113, 157-164.	0.7	7
904	Design principles for orally bioavailable drugs. <i>Drug Discovery Today</i> , 1996, 1, 179-189.	3.2	193
905	Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. <i>Pharmaceutical Research</i> , 1996, 13, 1559-1564.	1.7	57
906	Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. <i>Pharmaceutical Research</i> , 1996, 13, 497-513.	1.7	175

#	ARTICLE	IF	CITATIONS
907	Intravenous nicardipine does not alter hepatic blood flow after orthotopic liver transplant. <i>Intensive Care Medicine</i> , 1996, 22, 420-425.	3.9	1
908	Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 1996, 51, 309-313.	0.8	13
909	The effect of inflammation on the disposition of phenylbutazone in Thoroughbred horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 1996, 19, 475-481.	0.6	10
910	Indocyanine green elimination test in orthotopic liver recipients. <i>Hepatology</i> , 1996, 24, 1165-1171.	3.6	78
911	PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS. , 1996, 17, 273-310.		117
912	Myocardial uptake of thiopental enantiomers by the isolated perfused rat heart. , 1996, 8, 477-480.		2
913	The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 283-294.	2.3	13
914	Influence of Partial Hepatectomy on Theophylline Pharmacokinetics in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 1133-1135.	1.6	5
915	The Assessment of Flavin-Containing Monooxygenase Activity in Intact Animals. <i>Drug Metabolism and Drug Interactions</i> , 1996, 13, 1-28.	0.3	15
916	Phenytoin Protein Binding and Dosage Requirements during Acute and Convalescent Phases following Brain Injury. <i>Annals of Pharmacotherapy</i> , 1996, 30, 443-448.	0.9	21
917	Effects of Temperature and Propofol on Hepatic Blood Flow. <i>Anesthesia and Analgesia</i> , 1996, 82, 426.	1.1	0
918	Effects of Temperature and Propofol on Hepatic Blood Flow. <i>Anesthesia and Analgesia</i> , 1996, 82, 426.	1.1	12
919	Effect of Starvation on Organ Blood Flow in the Senescent Rat. <i>Archives of Physiology and Biochemistry</i> , 1997, 105, 337-341.	1.0	4
920	Chapter 5 Pharmacology in Space: Pharmacokinetics. <i>Advances in Space Biology and Medicine</i> , 1997, 6, 107-121.	0.5	10
921	Prediction of the pharmacokinetic parameters of reduced- dolasetron in man using in vitro-in vivo and interspecies allometric scaling. <i>Xenobiotica</i> , 1997, 27, 189-201.	0.5	19
922	The Effect of Halothane on the Recirculatory Pharmacokinetics of Physiologic Markers. <i>Anesthesiology</i> , 1997, 87, 1381-1393.	1.3	32
923	Hepatic Disposition of Alfentanil and Sufentanil in Patients Undergoing Orthotopic Liver Transplantation. <i>Anesthesia and Analgesia</i> , 1997, 84, 1019-1024.	1.1	7
924	Hepatic Disposition of Alfentanil and Sufentanil in Patients Undergoing Orthotopic Liver Transplantation. <i>Anesthesia and Analgesia</i> , 1997, 84, 1019-1024.	1.1	9

#	ARTICLE	IF	CITATIONS
925	Pharmacokinetics and Efficacy of Long-Term Epidural Ropivacaine Infusion for Postoperative Analgesia. <i>Anesthesia and Analgesia</i> , 1997, 85, 1322-1330.	1.1	19
926	Pharmacokinetics and Efficacy of Long-Term Epidural Ropivacaine Infusion for Postoperative Analgesia. <i>Anesthesia and Analgesia</i> , 1997, 85, 1322-1330.	1.1	54
927	Systemic Absorption and Block after Epidural Injection of Ropivacaine in Healthy Volunteers. <i>Anesthesiology</i> , 1997, 87, 1309-1317.	1.3	70
928	Pharmacokinetics of Pentazocine and Its Occupancy of Opioid Receptors in Rat Brain. <i>Biological and Pharmaceutical Bulletin</i> , 1997, 20, 1193-1198.	0.6	5
929	PHYSIOLOGICALLY BASED ALGEBRAIC FOR PREDICTING STEADY-STATE TOXICOKINETICS OF INHALED VAPORS. <i>Journal of Pharmaceutical Sciences</i> , 1997, 7, 205-226.		27
930	Prediction of Hepatic Clearance from Microsomes, Hepatocytes, and Liver Slices. <i>Drug Metabolism Reviews</i> , 1997, 29, 891-922.	1.5	286
931	Pharmacokinetics of High-Dosage Thiopental Sodium in Patients with Cerebral Injuries. <i>Clinical Drug Investigation</i> , 1997, 13, 255-269.	1.1	7
932	Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997, 63, 53-58.	1.2	18
933	Non-stationary pharmacokinetics of bupivacaine during continuous interpleural infusion. <i>Acute Pain</i> , 1997, 1, 15-20.	0.1	2
934	Effect of liver cirrhosis on the systemic availability of naltrexone in humans. <i>Journal of Hepatology</i> , 1997, 27, 505-511.	1.8	40
935	Drug elimination in chronic liver diseases. <i>Journal of Hepatology</i> , 1997, 26, 63-72.	1.8	20
936	Prescribing in liver disease. <i>Journal of Hepatology</i> , 1997, 26, 36-40.	1.8	9
937	Meloxicam pharmacokinetics in renal impairment. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 35-40.	1.1	2
938	Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 99-103.	1.1	10
939	Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. <i>Journal of Pineal Research</i> , 1997, 22, 45-51.	3.4	144
940	4 Drug disposition and action in the burned patient. <i>Bailliere's Clinical Anaesthesiology</i> , 1997, 11, 427-440.	0.2	1
941	Extrapolation of in vitro enzyme induction data to humans in vivo. <i>Chemico-Biological Interactions</i> , 1997, 107, 109-121.	1.7	50
942	Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. <i>Journal of Pharmaceutical Sciences</i> , 1997, 73, 147-171.		401

#	ARTICLE	IF	CITATIONS
943	Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. <i>Advanced Drug Delivery Reviews</i> , 1997, 27, 99-127.	6.6	280
944	The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. <i>Advanced Drug Delivery Reviews</i> , 1997, 27, 129-159.	6.6	143
945	Organ clearance concepts: new perspectives on old principles. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1997, 25, 449-470.	0.6	72
946	The effect of the acute-phase response on in vitro drug metabolism and plasma protein binding in the horse. <i>Veterinary Research Communications</i> , 1997, 21, 361-368.	0.6	9
947	Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents. , 1997, 19, 13-34.		5
948	Time-dependent pharmacokinetics of high dose thiopental infusion in intensive care patients. <i>Pharmaceutical Research</i> , 1997, 14, 1583-1588.	1.7	8
949	Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. <i>Biomedical Applications</i> , 1997, 701, 71-80.	1.7	69
950	Drugs in liver disease. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 462-465.	2.3	33
951	Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 519-528.	2.3	175
952	Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 237-247.	2.3	120
953	Site-specific Drug Delivery in the Dog using Flexible Fiberoptic Endoscopy. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 1209-1212.	1.6	1
954	Effect of variability in hepatic clearance on the bioequivalence parameters of a drug and its metabolite: simulations using a pharmacostatistical model. <i>Pharmaceutica Acta Helvetica</i> , 1998, 73, 135-144.	1.2	13
955	Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. <i>European Journal of Pharmaceutical Sciences</i> , 1998, 6, 93-98.	1.9	11
956	6 Interactions between intravenous anaesthetic agents. <i>Bailliere's Clinical Anaesthesiology</i> , 1998, 12, 247-261.	0.2	5
957	Transport of fluorescent bile acids by the isolated perfused rat liver: Kinetics, sequestration, and mobilization. <i>Hepatology</i> , 1998, 28, 510-520.	3.6	25
958	The kinetics of propranolol elimination from blood plasma and its distribution in myocardium and liver of rats with experimental inflammation and on the background of phenobarbital and cimetidine. <i>Pharmaceutical Chemistry Journal</i> , 1998, 32, 122-126.	0.3	0
959	The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 657-665.	1.9	11
960	Clinical aspects of indocyanine green pharmacokinetics following portal vein administration. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 41-47.	1.1	3

#	ARTICLE	IF	CITATIONS
961	The Activity of Mixed Function Oxidases, Estimated by in vivo Antipyrine Clearance, Is Similar in Horses and Camels. <i>Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology</i> , 1998, 119, 139-142.	0.5	2
962	The pharmacokinetic change of lidocaine by catecholamines using isolated perfused rat liver (IPRL). <i>Life Sciences</i> , 1998, 62, 2399-2405.	2.0	5
963	Effect of Chronic Bile Duct Obstruction and LPS Upon Targeting of Naproxen to the Liver Using Naproxen-Albumin Conjugate. <i>Journal of Drug Targeting</i> , 1998, 6, 105-117.	2.1	8
964	QUANTITATIVE PREDICTION OF IN VIVO DRUG CLEARANCE AND DRUG INTERACTIONS FROM IN VITRO DATA ON METABOLISM, TOGETHER WITH BINDING AND TRANSPORT. <i>Annual Review of Pharmacology and Toxicology</i> , 1998, 38, 461-499.	4.2	263
965	Pharmacodynamics and Pharmacokinetics of Thiopental. <i>Clinical Pharmacokinetics</i> , 1998, 35, 95-134.	1.6	92
966	Pharmacokinetic Alterations After Severe Head Injury. <i>Clinical Pharmacokinetics</i> , 1998, 35, 209-221.	1.6	45
967	Inhibition and Induction of Cytochrome P450 and the Clinical Implications. <i>Clinical Pharmacokinetics</i> , 1998, 35, 361-390.	1.6	674
968	Clinical Pharmacokinetics of Mibefradil. <i>Clinical Pharmacokinetics</i> , 1998, 35, 405-423.	1.6	63
969	In Vitro Approaches to Predicting Drug Interactions In Vivo. <i>Biochemical Pharmacology</i> , 1998, 55, 113-122.	2.0	188
970	Determination of drug-metabolizing enzyme activity in vivo : pharmacokinetic and statistical issues. <i>Xenobiotica</i> , 1998, 28, 1255-1273.	0.5	36
971	Single-Dose Pharmacokinetic Study of Ciprofloxacin and Fleroxacin in Healthy Adult Nigerian Volunteers. <i>Chemotherapy</i> , 1998, 44, 369-376.	0.8	11
972	Pharmacokinetic Analysis Program Based on Tank-in-Series Model, MULTI(TIS), for Evaluation of Capacity-Limited Local Disposition.. <i>Biological and Pharmaceutical Bulletin</i> , 1998, 21, 1338-1343.	0.6	2
973	Exercise-training-induced alterations in hepatic function in mares. <i>Journal of Applied Physiology</i> , 1998, 85, 1442-1447.	1.2	7
974	CLEARANCE CONCEPTS APPLIED TO THE METABOLISM OF INHALED VAPORS IN TISSUES LINING THE NASAL CAVITY. <i>Inhalation Toxicology</i> , 1999, 11, 873-897.	0.8	14
975	Molecular Structure-Based Prediction of the Toxicokinetics of Inhaled Vapors in Humans. <i>International Journal of Toxicology</i> , 1999, 18, 7-18.	0.6	32
976	Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking. <i>Journal of Endocrinology</i> , 1999, 162, 265-270.	1.2	51
977	Analysis program based on finite element method, MULTI(FEM), for evaluation of dose-dependent local disposition of drug in liver. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 538-543.	1.6	10
978	Diphenhydramine disposition in the sheep, maternal-placental-fetal unit: Determinants of plasma drug concentrations in the mother and the fetus. Abbreviations: DPHM, diphenhydramine; [2H10]DPHM, deuteriumlabeled diphenhydramine; CLmm, maternal total body clearance; CLff, fetal total body clearance; CLmf, maternal to fetal placental clearance; CLfm, fetal to maternal placental clearance; CLmo, maternal nonplacental clearance; CLfo, fetal nonplacental clearance; Cm, maternal plasma steady-state DPHM concentrat. <i>Journal of Pharmaceutical Sciences</i> , 1999, 88, 1259-1265.	1.6	2

#	ARTICLE	IF	CITATIONS
979	Oxidative Injury Reproduces Age-Related Impairment of Oxygen-Dependent Drug Metabolism. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 85, 230-232.	0.0	8
980	Modeling of hepatic elimination and organ distribution kinetics with the extended convection-dispersion model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 343-382.	0.6	24
981	Potential of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 569-581.	2.3	41
982	Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 594-601.	2.3	137
983	Mechanisms underlying variability in response to drug therapy: implications for amiodarone use. <i>American Journal of Cardiology</i> , 1999, 84, 29-36.	0.7	15
984	Effects of hypolipemic therapy on the pharmacokinetics of propranolol. <i>Current Therapeutic Research</i> , 1999, 60, 20-30.	0.5	2
985	Pharmacokinetics of Haloperidol. <i>Clinical Pharmacokinetics</i> , 1999, 37, 435-456.	1.6	208
986	Studies on the Pharmacokinetics and Pharmacodynamics of Propranolol in Hyperlipidemia. <i>Journal of Clinical Pharmacology</i> , 1999, 39, 826-833.	1.0	24
987	Measurement of Disposition Half-Life, Clearance, and Residence Times. <i>Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al]</i> , 2000, 4, Unit5.3.	1.1	0
988	Effect of Metoprolol and Verapamil Administered Separately and Concurrently after Single Doses on Liver Blood Flow and Drug Disposition. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 533-543.	1.0	17
989	Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 908-917.	1.0	20
990	Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 373-388.	5.7	376
991	Effect of β -Acid Glycoprotein on the Pharmacokinetics of Tamsulosin in Rats Treated with Turpentine Oil. , 2000, 89, 490-498.		9
992	Dose-dependent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31378, in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2000, 21, 279-284.	1.1	8
993	Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2000, 21, 193-204.	1.1	8
994	Efavirenz therapy in drug users. <i>HIV Medicine</i> , 2000, 1, 15-17.	1.0	10
995	Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 453-459.	0.7	20
996	Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. <i>Pharmaceutical Research</i> , 2000, 17, 903-905.	1.7	38

#	ARTICLE	IF	CITATIONS
997	Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. <i>Pharmaceutical Research</i> , 2000, 17, 205-208.	1.7	30
998	The interaction of diltiazem with simvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 267-274.	2.3	114
999	Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 342-350.	2.3	31
1000	Effects of the Antifungal Agents on Oxidative Drug Metabolism. <i>Clinical Pharmacokinetics</i> , 2000, 38, 111-180.	1.6	471
1001	Pharmacogenetics of Warfarin Elimination and its Clinical Implications. <i>Clinical Pharmacokinetics</i> , 2001, 40, 587-603.	1.6	278
1002	Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1313-1333.	2.9	602
1003	The use of preclinical pharmacokinetic and pharmacodynamic data to predict clinical doses: current and future perspectives. <i>International Congress Series</i> , 2001, 1220, 1-12.	0.2	2
1004	Effect of liver disease on dose optimization. <i>International Congress Series</i> , 2001, 1220, 247-258.	0.2	2
1006	Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. <i>Xenobiotica</i> , 2001, 31, 591-598.	0.5	102
1007	Effect of Mild Therapeutic Hypothermia on Phenytoin Pharmacokinetics. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 192-197.	1.0	53
1008	INTRODUCING PHARMACOKINETIC AND PHARMACODYNAMIC CONCEPTS*. <i>Journal of Liposome Research</i> , 2001, 11, 395-422.	1.5	3
1009	The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 213-217.	1.1	137
1010	Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 722-731.	1.6	10
1011	Drug metabolism and drug interactions in the elderly. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2001, 15, 897-918.	1.0	95
1012	Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 292-298.	2.3	43
1013	Treatment of Perioperative Myocardial Ischemia. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2001, 5, 166-183.	0.4	0
1014	Fast-track cardiac anaesthesia in the elderly: effect of two different anaesthetic techniques on mental recovery. <i>British Journal of Anaesthesia</i> , 2001, 86, 68-76.	1.5	32
1015	MASS TRANSPORT ANALYSIS: Inhalation RfC Methods Framework for Interspecies Dosimetric Adjustment. <i>Inhalation Toxicology</i> , 2001, 13, 437-463.	0.8	10

#	ARTICLE	IF	CITATIONS
1016	Interrelationships among Lipoprotein Levels, Sex Hormones, Anthropometric Parameters, and Age in Hypogonadal Men Treated for 1 Year with a Permeation-Enhanced Testosterone Transdermal System ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1026-1033.	1.8	59
1017	Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1149-1179.	1.0	261
1018	Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. <i>Xenobiotica</i> , 2002, 32, 87-107.	0.5	23
1019	Carrier-Mediated Active Transport of a Novel Thromboxane A ₂ Receptor Antagonist [2-(4-Chlorophenylsulfonfylaminomethyl)indan-5-yl]acetate (Z-335) into Rat Liver. <i>Drug Metabolism and Disposition</i> , 2002, 30, 498-504.	1.7	2
1020	Revisiting the Significance of Warfarin Protein-Binding Displacement Interactions. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1642-1644.	0.9	21
1021	Model-based Analysis of the Pharmacokinetic Interactions Between Ritonavir, Nelfinavir, and Saquinavir after Simultaneous and Staggered Oral Administration. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1455-1461.	1.7	16
1022	Effects of exercise and thermal stress on caffeine pharmacokinetics in men and eumenorrhic women. <i>Journal of Applied Physiology</i> , 2002, 93, 1471-1478.	1.2	76
1023	ICG Pulse Spectrophotometry for Perioperative Liver Function in Hepatectomy. <i>Journal of Surgical Research</i> , 2002, 103, 109-113.	0.8	104
1024	Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants. <i>Clinical Pharmacokinetics</i> , 2002, 41, 1077-1094.	1.6	129
1025	Intra-arterial pharmacokinetics and pulmonary first-pass of levamisole in rabbits. <i>Pharmacological Research</i> , 2002, 45, 285-289.	3.1	0
1026	Protein binding predictions in infants. <i>AAPS PharmSci</i> , 2002, 4, 19-26.	1.3	153
1027	Carvedilol therapy in pediatric patients with congestive heart failure: A study investigating clinical and pharmacokinetic parameters. <i>American Heart Journal</i> , 2002, 143, 916-922.	1.2	128
1028	Theoretical Aspects of P-glycoprotein Mediated Drug Efflux on the Distribution Volume of Anaesthetic-related Drugs in the Brain. <i>Anaesthesia and Intensive Care</i> , 2002, 30, 183-191.	0.2	12
1029	Quantitative Structure-Pharmacokinetic/Pharmacodynamic Relationships of Corticosteroids in Man. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 2441-2451.	1.6	39
1030	Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. <i>Biopharmaceutics and Drug Disposition</i> , 2002, 23, 327-338.	1.1	382
1031	In vitro-in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 493-503.	1.1	106
1032	Central nervous system alterations in liver cirrhosis: the role of portal-systemic shunt and portal hypoperfusion. <i>Metabolic Brain Disease</i> , 2002, 17, 347-358.	1.4	16
1033	Evaluation of the splanchnic circulation with indocyanine green pharmacokinetics in liver transplant patients. <i>Liver Transplantation</i> , 2002, 8, 476-481.	1.3	18

#	ARTICLE	IF	CITATIONS
1034	Hepatic drug metabolism and transport in patients with kidney disease. American Journal of Kidney Diseases, 2003, 42, 906-925.	2.1	103
1035	Preclinical Pharmacokinetics and Metabolism of BMS-14778, a Novel Melatonin Receptor Agonist. Journal of Pharmaceutical Sciences, 2003, 92, 760-772.	1.6	44
1036	Effects of Glucose on the Pharmacokinetics of Intravenous Chlorzoxazone in Rats with Acute Renal Failure Induced by Uranyl Nitrate. Journal of Pharmaceutical Sciences, 2003, 92, 1604-1613.	1.6	23
1037	The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clinical Pharmacology and Therapeutics, 2003, 74, 275-287.	2.3	177
1038	The Effect of Chronic Renal Failure on Hepatic Drug Metabolism and Drug Disposition. Seminars in Dialysis, 2003, 16, 45-50.	0.7	98
1039	Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics Journal, 2003, 3, 202-214.	0.9	95
1040	Metabolic Stability for Drug Discovery and Development. Clinical Pharmacokinetics, 2003, 42, 515-528.	1.6	158
1041	A model to investigate hepatic extraction of oxygen during anaesthesia in the dog. Research in Veterinary Science, 2003, 75, 179-183.	0.9	7
1042	Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrobial Agents and Chemotherapy, 2003, 47, 130-137.	1.4	126
1043	COMPARATIVE STUDIES ON THE CYTOCHROME P450-ASSOCIATED METABOLISM AND INTERACTION POTENTIAL OF SELEGILINE BETWEEN HUMAN LIVER-DERIVED IN VITRO SYSTEMS. Drug Metabolism and Disposition, 2003, 31, 1093-1102.	1.7	77
1044	EFFECTS OF ACUTE RENAL FAILURE ON THE PHARMACOKINETICS OF CHLORZOXAZONE IN RATS. Drug Metabolism and Disposition, 2003, 31, 776-784.	1.7	61
1045	Pharmacokinetics and Pharmacodynamics of Intravenous Azosemide in Mutant Nagase Analbuminemic Rats. Drug Metabolism and Disposition, 2003, 31, 194-201.	1.7	18
1046	Separate Assessment of Intestinal and Hepatic First-pass Effects Using a Rat Model with Double Cannulation of the Portal and Jugular Veins. Drug Metabolism and Pharmacokinetics, 2003, 18, 252-260.	1.1	37
1047	PREDICTION OF CYTOCHROME P450 3A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES. Drug Metabolism and Disposition, 2004, 32, 259-266.	1.7	203
1048	THE CHIMPANZEE (PAN TROGLODYTES) AS A PHARMACOKINETIC MODEL FOR SELECTION OF DRUG CANDIDATES: MODEL CHARACTERIZATION AND APPLICATION. Drug Metabolism and Disposition, 2004, 32, 1359-1369.	1.7	29
1049	STEREOSELECTIVE PHARMACOKINETICS OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS IN PREGNANT SHEEP. Drug Metabolism and Disposition, 2004, 32, 212-221.	1.7	38
1050	Aging Biology and Geriatric Clinical Pharmacology. Pharmacological Reviews, 2004, 56, 163-184.	7.1	656
1051	METABOLISM OF OPIOIDS IS ALTERED IN LIVER MICROSOMES OF SICKLE CELL TRANSGENIC MICE. Drug Metabolism and Disposition, 2004, 32, 98-104.	1.7	28

#	ARTICLE	IF	CITATIONS
1052	Pharmacokinetics of orally administered pirfenidone in male and female beagles. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2004, 27, 361-367.	0.6	21
1053	The Role of Metabolites in Bioequivalence. <i>Pharmaceutical Research</i> , 2004, 21, 1331-1344.	1.7	38
1054	Dose-dependent pharmacokinetics of KR-31378, a new neuroprotective agent for ischaemia-reperfusion damage in dogs. <i>Biopharmaceutics and Drug Disposition</i> , 2004, 25, 143-148.	1.1	2
1055	Determination of Volume of Distribution at Steady State with Complete Consideration of the Kinetics of Protein and Tissue Binding in Linear Pharmacokinetics. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 364-374.	1.6	50
1056	Effects of acute renal failure on the pharmacokinetics of oltipraz in rats. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2353-2363.	1.6	9
1057	Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 2388-2398.	1.6	14
1058	Pharmacokinetic changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. <i>International Journal of Pharmaceutics</i> , 2004, 275, 227-238.	2.6	23
1059	Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 324-330.	2.3	86
1060	Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 64-72.	2.3	366
1061	PREDICTING HUMAN DRUG GLUCURONIDATION PARAMETERS: Application of In Vitro and In Silico Modeling Approaches. <i>Annual Review of Pharmacology and Toxicology</i> , 2004, 44, 1-25.	4.2	203
1062	Nonlinear Mixed Effects Model Analysis of the Pharmacokinetics of Metoprolol in Routinely Treated Japanese Patients. <i>Biological and Pharmaceutical Bulletin</i> , 2004, 27, 1642-1648.	0.6	29
1063	Effect of Hemodialysis on the Metabolic Clearance of 5-Fluorouracil in a Patient With End-Stage Renal Failure. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 816-818.	1.0	20
1064	Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh). <i>Therapeutics</i> , 2005, 77, 529-541.	2.3	56
1065	Pharmacokinetic Principles of Immunosuppressive Drugs. <i>American Journal of Transplantation</i> , 2005, 5, 207-217.	2.6	59
1066	Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. <i>Biopharmaceutics and Drug Disposition</i> , 2005, 26, 173-182.	1.1	15
1067	Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2005, 26, 233-241.	1.1	16
1068	Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2005, 12, 16-22.	2.0	310
1069	Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. <i>Xenobiotica</i> , 2005, 35, 455-465.	0.5	16

#	ARTICLE	IF	CITATIONS
1070	Binding of acellular, native and cross-linked human hemoglobins to haptoglobin: enhanced distribution and clearance in the rat. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, G1301-G1309.	1.6	13
1071	Hypoalbuminaemia and propofol pharmacokinetics. <i>British Journal of Anaesthesia</i> , 2005, 95, 559.	1.5	6
1072	Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus. <i>Clinical Chemistry</i> , 2005, 51, 1374-1381.	1.5	187
1073	Clinical Pathology Approaches to Hepatic Injury. <i>Toxicologic Pathology</i> , 2005, 33, 9-16.	0.9	46
1074	IN VITRO-IN VIVO EXTRAPOLATION OF CYP2D6 INACTIVATION BY PAROXETINE: PREDICTION OF NONSTATIONARY PHARMACOKINETICS AND DRUG INTERACTION MAGNITUDE. <i>Drug Metabolism and Disposition</i> , 2005, 33, 845-852.	1.7	120
1075	Multigenic Control of Drug Response and Regulatory Decision-Making in Pharmacogenomics: The Need for an Upper-Bound Estimate of Genetic Contributions. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2005, 3, 53-71.	0.3	26
1076	The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 987-1003.	1.0	153
1077	RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICE. <i>Drug Metabolism and Disposition</i> , 2005, 33, 175-181.	1.7	211
1078	Atypical Cytochrome P450 Kinetics. <i>Drugs in R and D</i> , 2006, 7, 349-363.	1.1	50
1079	Pharmacokinetic Changes in Critical Illness. <i>Critical Care Clinics</i> , 2006, 22, 255-271.	1.0	250
1081	Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. <i>Xenobiotica</i> , 2006, 36, 473-497.	0.5	209
1082	Distribution "in vitro Tests" Protein Binding. , 2006, , 473-486.		4
1083	In vitro "in vivo extrapolation of quantitative hepatic biotransformation data for fish. <i>Aquatic Toxicology</i> , 2006, 78, 74-90.	1.9	131
1084	Pharmacokinetics of oltipraz in rat models of diabetes mellitus induced by alloxan or streptozotocin. <i>Life Sciences</i> , 2006, 78, 2287-2294.	2.0	12
1085	Effects of glucose supplementation on the pharmacokinetics of intravenous chlorzoxazone in rats with water deprivation for 72 h. <i>Life Sciences</i> , 2006, 79, 2179-2186.	2.0	6
1086	Disposition and pharmacodynamics of propofol during isovolaemic haemorrhage followed by crystalloid resuscitation in humans. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 256-261.	1.1	16
1087	CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications. <i>Pharmaceutical Research</i> , 2006, 23, 1089-1116.	1.7	242
1088	An integrated approach to model hepatic drug clearance. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 29, 215-230.	1.9	76

#	ARTICLE	IF	CITATIONS
1089	Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: A case study with toluene. <i>Toxicology and Applied Pharmacology</i> , 2006, 214, 78-87.	1.3	59
1090	Effects of renal failure on drug transport and metabolism. , 2006, 109, 1-11.		248
1091	Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, 112, 71-105.		501
1092	Negligible pharmacokinetic interaction between oral DA-8159, a new erectogenic, and amlodipine in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2006, 27, 125-131.	1.1	2
1093	Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous omeprazole in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2006, 27, 209-218.	1.1	29
1094	Pharmacokinetics of omeprazole in rats with water deprivation for 72 hours. <i>Biopharmaceutics and Drug Disposition</i> , 2006, 27, 361-370.	1.1	7
1095	KICG value, a reliable real-time estimator of graft function, accurately predicts outcomes in adult living-donor liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 605-613.	1.3	63
1096	A Convenient Method for Estimating the Quantity of Drug Eliminated by the Routes Other than Hepatic Metabolism and Renal Excretion and the Fraction of Drug that Reaches the "First Pass" after Oral Administration. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 828-833.	1.6	2
1097	The influence of drug kinetics in blood on the calculation of oral bioavailability in linear pharmacokinetics: The traditional equation may considerably overestimate the true value. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 834-848.	1.6	9
1098	Pharmacokinetics and Therapeutic Effects of Oltipraz after Consecutive or Intermittent Oral Administration in Rats with Liver Cirrhosis Induced by Dimethylnitrosamine. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 985-997.	1.6	13
1099	Pharmacokinetics of Oltipraz in Mutant Nagase Analbuminemic Rats. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 998-1005.	1.6	5
1100	Pharmacokinetics of Chlorzoxazone in Rats with Diabetes: Induction of CYP2E1 on 6-Hydroxychlorzoxazone Formation. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 2452-2462.	1.6	31
1101	Dose-Independent Pharmacokinetics of Metformin in Rats: Hepatic and Gastrointestinal First-Pass Effects. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 2543-2552.	1.6	102
1102	Antidepressant-Drug Interactions are Potentially but Rarely Clinically Significant. <i>Neuropsychopharmacology</i> , 2006, 31, 1594-1604.	2.8	32
1103	Changes in the effect of propofol in response to altered plasma protein binding during normothermic cardiopulmonary bypass. <i>British Journal of Anaesthesia</i> , 2006, 96, 179-185.	1.5	43
1104	STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1208-1219.	1.7	73
1105	Kinetics of Valproic Acid Glucuronidation: Evidence for in Vivo Autoactivation. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1380-1386.	1.7	13
1106	Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007, 85, 502-506.	0.7	2

#	ARTICLE	IF	CITATIONS
1107	Effects of Cysteine on the Pharmacokinetic Parameters of Omeprazole in Rats With Proteinâ€Calorie Malnutrition: Partial Restoration of Some Parameters to Control Levels by Oral Cysteine Supplementation. <i>Journal of Parenteral and Enteral Nutrition</i> , 2007, 31, 37-46.	1.3	5
1108	Misuse of the Well-Stirred Model of Hepatic Drug Clearance: Fig. 1.. <i>Drug Metabolism and Disposition</i> , 2007, 35, 501-502.	1.7	153
1109	Nonlinear Mixed Effects Model Analysis of the Pharmacokinetics of Aripiprazole in Healthy Japanese Males. <i>Biological and Pharmaceutical Bulletin</i> , 2007, 30, 2154-2158.	0.6	13
1110	Replicate Study Design in Bioequivalency Assessment, Pros and Cons: Bioavailabilities of the Antidiabetic Drugs Pioglitazone and Glimepiride Present in a Fixed-Dose Combination Formulation. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 806-816.	1.0	13
1111	Physiologically based approaches towards the prediction of pharmacokinetics:in vitroâ€in vivoextrapolation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 865-878.	1.5	48
1113	Incorporating In Vitro Information on Drug Metabolism Into Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphism on Pharmacokinetics and Pharmacodynamics: Dextromethorphan as a Model Application. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 175-186.	1.0	39
1114	The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. <i>International Journal of Impotence Research</i> , 2007, 19, 253-264.	1.0	133
1115	Use of<i>In Vitro</i>Absorption, Distribution, Metabolism, and Excretion (ADME) Data in Bioaccumulation Assessments for Fish. <i>Human and Ecological Risk Assessment (HERA)</i> , 2007, 13, 1164-1191.	1.7	46
1116	In vitroâ€in vivoextrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects. <i>Xenobiotica</i> , 2007, 37, 1090-1109.	0.5	60
1117	Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: Faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2007, 10, 420.	0.9	23
1118	Effect of Liver Disease on Pharmacokinetics. , 2007, , 73-87.		4
1119	Effects of water deprivation on the pharmacokinetics of metformin in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2007, 28, 373-383.	1.1	5
1120	Effects of water deprivation on the pharmacokinetics of theophylline and one of its metabolites, 1,3â€dimethyluric acid, after intravenous and oral administration of aminophylline to rats. <i>Biopharmaceutics and Drug Disposition</i> , 2007, 28, 445-454.	1.1	5
1121	Drugs as Indicators of Hepatic Function. <i>Hepatology</i> , 2007, 2, 97S-105S.	3.6	109
1122	Noninvasive Measurement of Nutrient Portal Blood Shunting: An Experimental Study with [14C]Ursodeoxyeholie Acid. <i>Hepatology</i> , 1982, 2, 412S-419S.	3.6	15
1123	Differential Effects of Oral Contraceptive Steroids on the Metabolism of Benzodiazepines. <i>Hepatology</i> , 1983, 3, 248-253.	3.6	50
1124	Determinants of Drug Disposition in Patients with Cirrhosis. <i>Hepatology</i> , 2007, 3, 913-918.	3.6	122
1125	Clearly There is Intrinsic Value in Intrinsic Clearance. <i>Hepatology</i> , 2007, 3, 1036-1038.	3.6	4

#	ARTICLE	IF	CITATIONS
1126	Pharmacokinetics of omeprazole after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. <i>International Journal of Pharmaceutics</i> , 2007, 330, 37-44.	2.6	16
1127	Effects of bacterial lipopolysaccharide on the pharmacokinetics of metformin in rats. <i>International Journal of Pharmaceutics</i> , 2007, 337, 194-201.	2.6	6
1128	Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 140-148.	21.5	471
1129	Introduction of Quantitative Methods in Pharmacology and Clinical Pharmacology: A Historical Overview. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 3-6.	2.3	29
1130	Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats. <i>British Journal of Pharmacology</i> , 2007, 151, 24-34.	2.7	13
1131	The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies ? CYP2C9 and warfarin as an example. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 14-26.	1.1	41
1132	Review article: hypoxia and hepatic drug metabolism—clinical implications. <i>Alimentary Pharmacology and Therapeutics</i> , 1990, 4, 213-225.	1.9	25
1133	The pivotal role of hepatocytes in drug discovery. <i>Chemico-Biological Interactions</i> , 2007, 168, 2-15.	1.7	152
1134	Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. <i>European Journal of Pharmaceutical Sciences</i> , 2007, 31, 190-201.	1.9	29
1135	Pharmacokinetic interaction between oltipraz and omeprazole in rats: Competitive inhibition of metabolism of oltipraz by omeprazole via CYP1A1 and 3A2, and of omeprazole by oltipraz via CYP1A1/2, 2D1/2, and 3A1/2. <i>European Journal of Pharmaceutical Sciences</i> , 2007, 32, 328-339.	1.9	5
1136	In vitro— <i>in vivo</i> extrapolation of quantitative hepatic biotransformation data for fish. II. Modeled effects on chemical bioaccumulation. <i>Environmental Toxicology and Chemistry</i> , 2007, 26, 1304-1319.	2.2	76
1137	Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts. <i>AAPS Journal</i> , 2007, 9, E268-E283.	2.2	51
1138	Telithromycin Pharmacokinetics in Rat Model of Diabetes Mellitus Induced by Alloxan or Streptozotocin. <i>Pharmaceutical Research</i> , 2008, 25, 1915-1924.	1.7	34
1139	Effects of water deprivation on drug pharmacokinetics: Correlation between drug metabolism and hepatic CYP isozymes. <i>Archives of Pharmacal Research</i> , 2008, 31, 951-964.	2.7	6
1140	Effects of endotoxin derived from <i>Escherichia coli</i> lipopolysaccharide on the pharmacokinetics of drugs. <i>Archives of Pharmacal Research</i> , 2008, 31, 1073-1086.	2.7	36
1141	Effects of <i>E. Coli</i> lipopolysaccharide on the pharmacokinetics of ipriflavone and its metabolites, M1 and M5, after intravenous and oral administration of ipriflavone to rats: Decreased metabolism of ipriflavone due to decreased expression of hepatic CYP1A2 and 2C11. <i>Journal of Pharmaceutical Sciences</i> . 2008. 97. 5024-5036.	1.6	6
1142	Changes in metformin pharmacokinetics after intravenous and oral administration to rats with short-term and long-term diabetes induced by streptozotocin. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 5363-5375.	1.6	25
1143	New method for the simultaneous estimation of intrinsic hepatic clearance and protein binding by matrix inhibition. <i>Biopharmaceutics and Drug Disposition</i> , 2008, 29, 7-16.	1.1	10

#	ARTICLE	IF	CITATIONS
1144	Gender differences in ondansetron pharmacokinetics in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2008, 29, 406-413.	1.1	11
1145	Pharmacokinetic interaction between DA-8159, a new erectogenic, and metformin in rats: competitive inhibition of metabolism via hepatic CYP3A1/2. <i>British Journal of Pharmacology</i> , 2008, 153, 1568-1578.	2.7	12
1146	EFFECTS OF LIVER FIBROSIS ON VERAPAMIL PHARMACOKINETICS IN RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 287-294.	0.9	9
1147	FACTORS CONTRIBUTING TO VARIABILITY IN DRUG PHARMACOKINETICS. II. DRUG DISTRIBUTION*. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 10, 15-23.	0.7	3
1148	Time-dependent effects of <i>Klebsiella pneumoniae</i> endotoxin on the telithromycin pharmacokinetics in rats; restoration of the parameters in 96-hour KPLPS rats to the control levels. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 860-865.	1.1	0
1149	Effects of water deprivation for 72h on the pharmacokinetics of ipriflavone in rats. <i>Research in Veterinary Science</i> , 2008, 85, 149-155.	0.9	4
1150	Some features of the kinetics and equilibrium of drug binding to plasma proteins. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 1479-1498.	1.5	28
1151	Time-Dependent Effects of <i>Klebsiella Pneumoniae</i> Endotoxin (KPLPS) on the Pharmacokinetics of Theophylline in Rats: Return of the Parameters in 96-Hour KPLPS Rats to the Control Levels. <i>Drug Metabolism and Disposition</i> , 2008, 36, 811-815.	1.7	16
1152	Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1365-1374.	1.7	101
1153	Effects of <i>Escherichia coli</i> Lipopolysaccharide on Telithromycin Pharmacokinetics in Rats: Inhibition of Metabolism via CYP3A. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1046-1051.	1.4	7
1154	Applying Organ Clearance Concepts in a Clinical Setting. <i>American Journal of Pharmaceutical Education</i> , 2008, 72, 121.	0.7	5
1155	The effect of chronic renal failure on drug metabolism and transport. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 1065-1074.	1.5	200
1156	Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 909-922.	1.5	105
1157	Pharmacokinetics of a Five-day Oral Dihydroartemisinin Monotherapy Regimen in Patients with Uncomplicated Falciparum Malaria. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 158-164.	1.1	17
1158	Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 1932-1939.	0.8	129
1159	CYP2D6 is Primarily Responsible for the Metabolism of Clomiphene. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 101-105.	1.1	19
1160	Effects of the CYP2D6 Gene Duplication on the Pharmacokinetics and Pharmacodynamics of Tramadol. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 78-83.	0.7	150
1161	Physicochemical Properties, Pharmacokinetics, and Pharmacodynamics of a Reformulated Microemulsion Propofol in Rats. <i>Anesthesiology</i> , 2008, 109, 436-447.	1.3	38

#	ARTICLE	IF	CITATIONS
1162	Effects of Diabetes Mellitus Induced by Alloxan on the Pharmacokinetics of Metformin in Rats: Restoration of Pharmacokinetic Parameters to the Control State by Insulin Treatment. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2008, 11, 88.	0.9	22
1163	Introduction to Clinical Pharmacology. , 2009, , 321-338.		2
1164	Presentation of a modified dispersion model (MDM) for hepatic drug extraction and a new methodology for the prediction of the rate-limiting step in hepatic metabolic clearance. <i>Xenobiotica</i> , 2009, 39, 57-71.	0.5	9
1166	Automated Drug Screening for ADMET Properties. , 0, , 127-166.		2
1167	A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of "Bottom-Up" vs "Top-Down" Recognition of Covariates. <i>Drug Metabolism and Pharmacokinetics</i> , 2009, 24, 53-75.	1.1	311
1168	Therapeutic potential of dithiolethiones for hepatic diseases. , 2009, 124, 31-43.		23
1169	Pharmacokinetics of Nitrazepam in Saliva and Serum after a Single Oral Dose. <i>Acta Pharmacologica Et Toxicologica</i> , 1979, 45, 20-24.	0.0	29
1170	Pharmacokinetics of Terbutaline and Theophylline in Guinea Pigs when Administered Simultaneously. <i>Acta Pharmacologica Et Toxicologica</i> , 1981, 48, 13-20.	0.0	3
1171	Pharmacokinetics and First-Pass Metabolism of Levomepromazine in the Rat. <i>Acta Pharmacologica Et Toxicologica</i> , 1982, 50, 148-154.	0.0	2
1172	<i>In Vivo</i> Pharmacokinetics of Felodipine Predicted from <i>In Vitro</i> Studies in Rat, Dog and Man. <i>Acta Pharmacologica Et Toxicologica</i> , 1986, 59, 113-122.	0.0	76
1173	Safety testing of metabolites: Expectations and outcomes. <i>Chemico-Biological Interactions</i> , 2009, 179, 45-59.	1.7	35
1174	On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1922-1927.	1.6	17
1175	Prediction of the possibility of the secondary peaks of iv bolus drug plasma concentration time curve by the model that directly takes into account the transit time through the organ. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4376-4390.	1.6	5
1176	Faster clearance of omeprazole in mutant Nagase analbuminemic rats: possible roles of increased protein expression of hepatic CYP1A2 and lower plasma protein binding. <i>Biopharmaceutics and Drug Disposition</i> , 2009, 30, 107-116.	1.1	6
1177	Ipriflavone pharmacokinetics in mutant Nagase analbuminemic rats. <i>Biopharmaceutics and Drug Disposition</i> , 2009, 30, 294-304.	1.1	2
1178	Prediction of drug bioavailability in humans using immobilized artificial membrane phosphatidylcholine column chromatography and <i>in vitro</i> hepatic metabolic clearance. <i>Biomedical Chromatography</i> , 2009, 23, 764-769.	0.8	11
1179	Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 374-375.	1.1	5
1180	Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis. <i>British Journal of Pharmacology</i> , 2009, 156, 1019-1028.	2.7	21

#	ARTICLE	IF	CITATIONS
1181	Application of mechanism-based CYP inhibition for predicting drug-drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 579-605.	1.5	29
1182	Impact of Hepatic Uptake Transporters on Pharmacokinetics and Drug-Drug Interactions: Use of Assays and Models for Decision Making in the Pharmaceutical Industry. <i>Molecular Pharmaceutics</i> , 2009, 6, 1662-1677.	2.3	60
1183	Optimization of an isolated perfused rainbow trout liver model: Clearance studies with 7-ethoxycoumarin. <i>Aquatic Toxicology</i> , 2009, 95, 182-194.	1.9	17
1185	Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 463-476.	1.6	35
1186	Effects of <i>Escherichia coli</i> lipopolysaccharide on the metformin pharmacokinetics in rats. <i>Xenobiotica</i> , 2009, 39, 946-954.	0.5	3
1187	Interplay of Transporters and Enzymes in Drug and Metabolite Processing. <i>Molecular Pharmaceutics</i> , 2009, 6, 1734-1755.	2.3	88
1188	Interplay of Drug Metabolism and Transport: A Real Phenomenon or an Artifact of the Site of Measurement?. <i>Molecular Pharmaceutics</i> , 2009, 6, 1756-1765.	2.3	22
1189	Attenuating the effects of cardiac arrest on hepatic drug metabolism: Just chill out!*. <i>Critical Care Medicine</i> , 2009, 37, 369-370.	0.4	0
1191	Synergistic antifibrotic effect of verapamil and interferon- γ in rats: partially based on enhanced verapamil oral bioavailability. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 466-473.	0.8	1
1195	Effect of Acute Renal Failure on the Disposition of Cefoperazone. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 51, 361-366.	1.2	1
1196	Prediction of human pharmacokinetics—evaluation of methods for prediction of hepatic metabolic clearance. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 59, 803-828.	1.2	64
1197	Effects of cysteine on metformin pharmacokinetics in rats with protein-calorie malnutrition: partial restoration of some parameters to control levels. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 153-161.	1.2	5
1198	Faster clearance of omeprazole in rats with acute renal failure induced by uranyl nitrate: contribution of increased expression of hepatic cytochrome P450 (CYP) 3A1 and intestinal CYP1A and 3A subfamilies. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 843-851.	1.2	5
1199	Faster clearance of mirodenafil in rats with acute renal failure induced by uranyl nitrate: contribution of increased protein expression of hepatic CYP3A1 and intestinal CYP1A1 and 3A1/2. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 1325-1332.	1.2	8
1200	Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 1-23.	1.2	85
1201	Indocyanine green R15 ratio depends directly on liver perfusion flow rate. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 180-185.	1.4	19
1202	Clearance (n \ddot{a} e Rowland) concepts: a downgrade and an update. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010, 37, 529-539.	0.8	27
1203	Liquiritigenin pharmacokinetics in a rat model of diabetes mellitus induced by streptozotocin: greater formation of glucuronides in the liver, especially M2, due to increased hepatic uridine 5 \ddot{a} e ² -diphosphoglucuronic acid level. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1472-1480.	1.5	10

#	ARTICLE	IF	CITATIONS
1204	Slower clearance of intravenous metformin in rats with acute renal failure induced by uranyl nitrate: Contribution of slower renal and non-renal clearances. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 39, 1-7.	1.9	10
1205	Pharmacokinetic interaction between liquiritigenin (LQ) and DDB: Increased glucuronidation of LQ in the liver possibly due to increased hepatic blood flow rate by DDB. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 39, 181-189.	1.9	8
1206	Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 516-532.	1.1	32
1207	A Valid Equation for the Well-Stirred Perfusion Limited Physiologically Based Pharmacokinetic Model that Consistently Accounts for the Blood-Tissue Drug Distribution in the Organ and the Corresponding Valid Equation for the Steady State Volume of Distribution. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 475-485.	1.6	23
1208	Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 1107-1122.	1.6	267
1209	Lack of Appreciable Species Differences in Nonspecific Microsomal Binding. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 3620-3627.	1.6	22
1210	Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2. <i>British Journal of Pharmacology</i> , 2010, 161, 815-829.	2.7	37
1211	Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 465-474.	1.1	23
1212	The pharmacokinetics of nitazoxanide active metabolite (tizoxanide) in goats and its protein binding ability <i>in vitro</i> . <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2010, 33, 147-153.	0.6	20
1213	Pharmacology and the Elderly. <i>Dental Update</i> , 2010, 37, 666-672.	0.1	1
1214	Pharmacokinetics of liquiritigenin and its two glucuronides, M1 and M2, in rats with acute hepatitis induced by D-galactosamine/lipopolysaccharide or CCl ₄ . <i>Xenobiotica</i> , 2010, 40, 424-436.	0.5	7
1215	Pharmacokinetics of Itraconazole in Diabetic Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 931-933.	1.4	4
1216	In Vitro Characterization of Sarizotan Metabolism: Hepatic Clearance, Identification and Characterization of Metabolites, Drug-Metabolizing Enzyme Identification, and Evaluation of Cytochrome P450 Inhibition. <i>Drug Metabolism and Disposition</i> , 2010, 38, 905-916.	1.7	6
1217	Quantitative Investigation on the Metabolism of 1,3-Butadiene and of Its Oxidized Metabolites in Once-through Perfused Livers of Mice and Rats. <i>Toxicological Sciences</i> , 2010, 114, 25-37.	1.4	9
1218	Contribution of Intestinal Cytochrome P450-Mediated Metabolism to Drug-Drug Inhibition and Induction Interactions. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 28-47.	1.1	100
1219	Metabolite Profiling of Praziquantel and its Analogs During the Analysis of <i>in vitro</i> Metabolic Stability Using Information-Dependent Acquisition on a Hybrid Triple Quadrupole Linear Ion Trap Mass Spectrometer. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 487-499.	1.1	43
1222	The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1215-1230.	1.5	11
1223	Effect of experimental renal dysfunction on bioavailability of ajmaline in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 805-813.	1.2	11

#	ARTICLE	IF	CITATIONS
1224	Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling. <i>Clinical Pharmacokinetics</i> , 2010, 49, 239-258.	1.6	55
1225	A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance. <i>Clinical Pharmacokinetics</i> , 2010, 49, 189-206.	1.6	178
1226	In Vitro Techniques to Study Drug-Drug Interactions of Drug Metabolism: Cytochrome P450. , 2010, , 169-215.		6
1227	Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of liquiritigenin and its two glucuronides, M1 and M2, in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 63, 49-57.	1.2	8
1228	Rationalization and prediction of <i>in vivo</i> metabolite exposures: the role of metabolite kinetics, clearance predictions and <i>in vitro</i> parameters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1095-1109.	1.5	29
1229	Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous and oral administration of mirodenafil to streptozotocin-induced diabetes mellitus rats. <i>Xenobiotica</i> , 2010, 40, 129-137.	0.5	5
1230	Dose-dependent presystemic elimination of propranolol due to hepatic first-pass metabolism in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 37, 826-828.	1.2	25
1231	Protein and Lipid Binding Parameters in Rainbow Trout (<i>Oncorhynchus mykiss</i>) Blood and Liver Fractions to Extrapolate from an <i>In Vitro</i> Metabolic Degradation Assay to <i>In Vivo</i> Bioaccumulation Potential of Hydrophobic Organic Chemicals. <i>Chemical Research in Toxicology</i> , 2011, 24, 1134-1143.	1.7	71
1232	The $\tilde{\tau}$ -Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1233-1243.	1.5	3
1233	Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients. <i>Clinical Pharmacokinetics</i> , 2011, 50, 809-822.	1.6	70
1234	Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. <i>Xenobiotica</i> , 2011, 41, 623-638.	0.5	50
1235	Recent Developments in Physiologically Based Pharmacokinetic Modeling. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011, , 483-499.	0.2	1
1236	Mefloquine Effect on Disposition of Halofantrine in the Isolated Perfused Rat Liver. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 48, 723-728.	1.2	6
1237	Kinetic Interaction between Fluoxetine and Imipramine as a Function of Elevated Serum Alpha-1-acid Glycoprotein Levels. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 50, 419-424.	1.2	2
1238	Possibility of Partial Absorption of Nicardipine by Routes Other Than the Hepato-portal System After Oral Administration in Rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 50, 775-781.	1.2	1
1239	Principles of Drug Disposition in the Critically Ill Child. , 2011, , 1538-1552.		1
1240	Route- and dose-dependent pharmacokinetics of hexobarbitone in the rat: a re-evaluation of the use of sleeping times in metabolic studies. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 37, 550-554.	1.2	9
1241	Effect of saturable binding on the pharmacokinetics of drugs: a simulation. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 32, 471-477.	1.2	45

#	ARTICLE	IF	CITATIONS
1242	Effects of some hepatomegalic agents on liver DNA content: relationship to changes in liver blood flow. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 35, 191-194.	1.2	2
1243	Amidopyrine disposition in rat. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 31, 787-788.	1.2	26
1244	In-vitro biotransformation of antipyrine, lignocaine and propranolol in the liver of rats with turpentine-induced inflammation. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 39, 883-886.	1.2	12
1245	Plasma protein binding ^â lipophilicity relationships: interspecies comparison of some organic acids. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 39, 79-83.	1.2	19
1246	The Effect of Fever on Quinine and Quinidine Disposition in the Rat. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 43, 705-708.	1.2	12
1247	The effect of a nutritional model of chronic liver injury on the hepatic glucuronidation of morphine in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 45, 998-999.	1.2	0
1248	The stereoselectivity of the ^â single drug binding site ^â ™ of human ^â 1-acid glycoprotein (orosomucoïd). <i>Journal of Pharmacy and Pharmacology</i> , 2011, 39, 986-990.	1.2	32
1249	Sex-related Differences in Disposition and Response to Phenprocoumon in Rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 40, 403-407.	1.2	4
1250	Caffeine disposition and effects in young and one-year-old rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 32, 596-599.	1.2	31
1251	The Influence of ^â 1-Acid Glycoprotein on Quinine and Quinidine Disposition in the Rat Isolated Perfused Liver Preparation. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 43, 650-654.	1.2	9
1252	The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(^â)-acenocoumarol in the rat. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 38, 122-125.	1.2	26
1253	Influence of Lignocaine on Plasma Protein Binding and Pharmacokinetics of Verapamil in Dogs. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 42, 45-49.	1.2	5
1254	Differential Influence of Laboratory Anaesthetic Regimens upon Renal and Hepatosplanchnic Haemodynamics in the Rat. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 42, 693-697.	1.2	36
1255	The influence of oxygen tension on theophylline clearance in the rat isolated perfused liver. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 38, 236-238.	1.2	15
1256	Binding of [3H]mianserin to bovine serum albumin, human serum albumin and ^â 1-acid glycoprotein. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 36, 16-20.	1.2	8
1257	Hepatic and renal clearance of sodium cromoglycate. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 33, 744-745.	1.2	8
1258	High capacity for pulmonary first-pass elimination of propranolol in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 39, 1049-1051.	1.2	14
1259	The disposition of nifurtimox in the rat isolated perfused liver: effect of dose size. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 45, 72-74.	1.2	3

#	ARTICLE	IF	CITATIONS
1260	Plasma Protein Binding of Quinine: Binding to Human Serum Albumin, β 2-Microglobulin and Plasma from Patients with Malaria. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 44, 806-811.	1.2	40
1261	Absorption and metabolism of hexamethylmelamine and pentamethylmelamine in rat everted perfused gut segments: correlation with in-vivo data. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 37, 629-636.	1.2	13
1262	Effect of inflammation and proadifen on the disposition of antipyrine, lignocaine and propranolol in rat isolated perfused liver. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 39, 997-1002.	1.2	4
1263	In vitro hepatic oxidative metabolism of antipyrine, phenytoin and phenylbutazone in uraemic rabbits. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 32, 135-136.	1.2	4
1264	Pharmacokinetics: Absorption, Distribution, Metabolism, Excretion Overview Chapter. , 2012, , 21-26.		1
1265	Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (f _{up} /f _{mic}) for refined prediction of phase I mediated metabolic hepatic clearance. <i>Journal of Pharmacological and Toxicological Methods</i> , 2011, 63, 35-39.	0.3	12
1266	Risk assessment of accidental nortriptyline poisoning: The importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 265-272.	1.9	16
1268	Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 4965-4973.	1.6	17
1269	Pharmacokinetics of mirodenafil and Its two metabolites, SK3541 and SK3544, in spontaneously or DOCA-induced hypertensive rats. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 38-49.	1.1	4
1270	Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 303-318.	1.1	35
1271	Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 38, 177-181.	1.2	96
1272	Pharmacokinetics of sildenafil and its metabolite, <i>N</i> -desmethylsildenafil, in rats with liver cirrhosis and diabetes mellitus, alone and in combination. <i>Xenobiotica</i> , 2011, 41, 164-174.	0.5	8
1274	QSARs for PBPK modelling of environmental contaminants. SAR and QSAR in Environmental Research, 2011, 22, 129-169.	1.0	44
1275	Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats. <i>Xenobiotica</i> , 2011, 41, 797-804.	0.5	22
1276	Cysteine effects on the pharmacokinetics of etoposide in protein-calorie malnutrition rats: increased gastrointestinal absorption by cysteine. <i>Xenobiotica</i> , 2011, 41, 885-894.	0.5	7
1277	Effects of cysteine on the pharmacokinetics of docetaxel in rats with protein-calorie malnutrition. <i>Xenobiotica</i> , 2012, 42, 442-455.	0.5	6
1278	Pharmacokinetics of the Soluble Guanylate Cyclase Activator Cinaciguat in Individuals With Hepatic Impairment. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1714-1724.	1.0	5
1279	Influence of capsaicin on fluctuation of digoxin pharmacokinetics in lipopolysaccharide-treated rats. <i>Xenobiotica</i> , 2012, 42, 798-807.	0.5	6

#	ARTICLE	IF	CITATIONS
1280	Îµ-Acetamidocaproic acid pharmacokinetics in rats with gastric ulcer or small bowel inflammation. <i>Xenobiotica</i> , 2012, 42, 310-315.	0.5	3
1281	Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407. <i>Xenobiotica</i> , 2012, 42, 766-774.	0.5	11
1282	Pharmacokinetic interaction between metoprolol and SP-8203 in rats: competitive inhibition for the metabolism of metoprolol by SP-8203 via hepatic CYP2D subfamily. <i>Xenobiotica</i> , 2012, 42, 1017-1027.	0.5	6
1283	Integration of Dosimetry, Exposure, and High-Throughput Screening Data in Chemical Toxicity Assessment. <i>Toxicological Sciences</i> , 2012, 125, 157-174.	1.4	336
1287	Reduced clearance of Îµ-acetamidocaproic acid in rats with acute renal failure induced by uranyl nitrate. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 1452-1460.	1.2	1
1288	Effects of cysteine on the pharmacokinetics of tamoxifen in rats with protein-calorie malnutrition. <i>Xenobiotica</i> , 2012, 42, 1225-1234.	0.5	4
1289	Effect of Liver Disease on Pharmacokinetics. , 2012, , 81-96.		3
1290	Assessment of Intestinal Availability of Various Drugs in the Oral Absorption Process Using Portal Vein-Cannulated Rats. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2231-2238.	1.7	44
1291	Benet L Z and Galeazzi R L: Noncompartmental Determination of the Steady-State Volume of Distribution, <i>J Pharm Sci</i> 68, 1071â€“1074, 1979â€”the Backstory. <i>AAPS Journal</i> , 2012, 14, 164-167.	2.2	6
1292	Evaluation of the novel in vitro systems for hepatic drug clearance and assessment of their predictive utility. <i>Toxicology in Vitro</i> , 2012, 26, 1265-1271.	1.1	13
1293	Effect of Ketoconazole on the Pharmacokinetic Profile of Buprenorphine following Administration of a Once-Weekly Buprenorphine Transdermal System. <i>Clinical Drug Investigation</i> , 2012, 32, 583-592.	1.1	22
1294	Effects of poloxamer 407-induced hyperlipidemia on the pharmacokinetics of carbamazepine and its 10,11-epoxide metabolite in rats: Impact of decreased expression of both CYP3A1/2 and microsomal epoxide hydrolase. <i>European Neuropsychopharmacology</i> , 2012, 22, 431-440.	0.3	29
1295	Effect of decursinol angelate on the pharmacokinetics of theophylline and its metabolites in rats. <i>Food and Chemical Toxicology</i> , 2012, 50, 3666-3672.	1.8	4
1296	Pharmacokinetic and pharmacodynamic interaction between nifedipine and metformin in rats: competitive inhibition for metabolism of nifedipine and metformin by each other via CYP isozymes. <i>Xenobiotica</i> , 2012, 42, 483-495.	0.5	22
1297	Quantitative<i>in vitro</i> to<i>in vivo</i> extrapolation of cell-based toxicity assay results. <i>Critical Reviews in Toxicology</i> , 2012, 42, 633-652.	1.9	190
1298	Impact of the Pharmaceutical Sciences on Health Care: A Reflection over the Past 50 Years. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 4075-4099.	1.6	32
1299	From Mouse to Man: Predictions of Human Pharmacokinetics of Orally Administered Docetaxel From Preclinical Studies. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 370-380.	1.0	4
1300	Effects of Experimental Hyperlipidemia on the Pharmacokinetics of Tadalafil in Rats. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2012, 15, 528.	0.9	20

#	ARTICLE	IF	CITATIONS
1301	The blood concentration and organ distribution of haloperidol at therapeutic and toxic doses in severe fatty liver disease. <i>Legal Medicine</i> , 2012, 14, 147-153.	0.6	5
1302	Novel In Vitro-In Vivo Extrapolation (IVIVE) Method to Predict Hepatic Organ Clearance in Rat. <i>Pharmaceutical Research</i> , 2012, 29, 603-617.	1.7	57
1303	Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2013, 38, 139-148.	0.6	9
1304	Prediction of Warfarin Maintenance Dose in Han Chinese Patients Using a Mechanistic Model Based on Genetic and Non-Genetic Factors. <i>Clinical Pharmacokinetics</i> , 2013, 52, 567-581.	1.6	16
1305	A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1975-1993.	1.7	89
1306	Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1743-1755.	1.4	63
1307	Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance. <i>Molecular Pharmacology</i> , 2013, 84, 655-669.	1.0	180
1308	Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2013, 73, 1723-1732.	4.9	32
1309	A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. <i>Forensic Science International</i> , 2013, 226, e26-e31.	1.3	33
1310	Effects of 17 β -ethynylestradiol-induced cholestasis on the pharmacokinetics of doxorubicin in rats: reduced biliary excretion and hepatic metabolism of doxorubicin. <i>Xenobiotica</i> , 2013, 43, 901-907.	0.5	10
1311	Deriving an explicit hepatic clearance equation accounting for plasma protein binding and hepatocellular uptake. <i>Toxicology in Vitro</i> , 2013, 27, 11-15.	1.1	10
1312	Faster non-renal clearance of metoprolol in streptozotocin-induced diabetes mellitus rats. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 447-453.	1.9	4
1313	Pharmacokinetics of Pentoxifylline and Its Main Metabolites in Patients With Different Degrees of Heart Failure Following a Single Dose of a Modified-Release Formulation. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 51-57.	1.0	9
1314	Once-Weekly Transdermal Buprenorphine Application Results in Sustained and Consistent Steady-State Plasma Levels. <i>Journal of Pain and Symptom Management</i> , 2013, 46, 65-75.	0.6	31
1315	Effects of physiological and biochemical factors based on aging, pathological conditions and drug combinations on propranolol pharmacokinetics using physiologically-based pharmacokinetic model in humans. <i>Biomedicine and Aging Pathology</i> , 2013, 3, 107-114.	0.8	0
1316	Pharmacokinetics and Toxicokinetics. , 2013, , 31-68.		5
1318	Distribution - In Vitro Tests - Protein Binding. , 2013, , 897-913.		2
1320	Effects of Korean red ginseng extract on acute renal failure induced by gentamicin and pharmacokinetic changes by metformin in rats. <i>Food and Chemical Toxicology</i> , 2013, 59, 153-159.	1.8	24

#	ARTICLE	IF	CITATIONS
1321	Relative Impact of Incorporating Pharmacokinetics on Predicting In Vivo Hazard and Mode of Action from High-Throughput In Vitro Toxicity Assays. <i>Toxicological Sciences</i> , 2013, 132, 327-346.	1.4	104
1322	Hepatic Clearance of 6 Polycyclic Aromatic Hydrocarbons by Isolated Perfused Trout Livers: Prediction From In Vitro Clearance by Liver S9 Fractions. <i>Toxicological Sciences</i> , 2013, 136, 359-372.	1.4	47
1323	Toward improved models for predicting bioconcentration of wellâ€metabolized compounds by rainbow trout using measured rates of in vitro intrinsic clearance. <i>Environmental Toxicology and Chemistry</i> , 2013, 32, 1611-1622.	2.2	97
1324	Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 153-168.	1.5	85
1325	Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac. <i>Drug Metabolism and Disposition</i> , 2013, 41, 2024-2032.	1.7	123
1326	Pharmacokinetics of drugs in mutant Nagase analbuminemic rats and responses to select diuretics. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 66, 2-13.	1.2	1
1327	Renohepatic crosstalk: does acute kidney injury cause liver dysfunction?. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1634-1647.	0.4	75
1330	Pharmacokinetics and Toxicokinetics. , 2013, , 69-106.		3
1331	Effects of morin on the pharmacokinetics of etoposide in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in female Sprague-Dawley rats. <i>Oncology Reports</i> , 2013, 29, 1215-1223.	1.2	17
1332	Pharmacokinetics of a Cytochrome P450 2E1 Probe, Chlorzoxazone, and its 6-Hydroxy Metabolite in Poloxamer 407-Induced Hyperlipidemic Rats. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 648.	0.9	2
1333	Validity of the Lipid Sink as a Mechanism for the Reversal of Local Anesthetic Systemic Toxicity. <i>Anesthesiology</i> , 2013, 118, 1350-1361.	1.3	64
1334	Postoperative morphine concentration in infants with or without biliary atresia and its association with hepatic blood flow. <i>Anaesthesia</i> , 2014, 69, 583-590.	1.8	6
1335	Xenobiotic Metabolism: The Effect of Acute Kidney Injury on Non-Renal Drug Clearance and Hepatic Drug Metabolism. <i>International Journal of Molecular Sciences</i> , 2014, 15, 2538-2553.	1.8	43
1336	Pharmacokinetics of tolbutamide and its metabolite 4â€hydroxy tolbutamide in poloxamer 407â€induced hyperlipidemic rats. <i>Biopharmaceutics and Drug Disposition</i> , 2014, 35, 264-274.	1.1	12
1337	The pharmacokinetics of glycopyrrolate in Standardbred horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2014, 37, 260-268.	0.6	4
1338	Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 1-64.	0.2	8
1339	Influence of Gestational Age and Body Weight on the Pharmacokinetics of Labetalol in Pregnancy. <i>Clinical Pharmacokinetics</i> , 2014, 53, 373-383.	1.6	48
1340	Pharmacokinetics of drugs in spontaneously or secondary hypertensive rats. <i>Xenobiotica</i> , 2014, 44, 77-88.	0.5	1

#	ARTICLE	IF	CITATIONS
1341	Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach. <i>AAPS Journal</i> , 2014, 16, 379-391.	2.2	37
1342	Pharmacometrics in Pregnancy: An Unmet Need. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 53-69.	4.2	76
1343	The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 631-635.	1.5	19
1344	The effects of acute renal failure on drug metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 11-23.	1.5	40
1345	Prediction of Pharmacokinetics and Drug-Drug Interactions When Hepatic Transporters are Involved. <i>Clinical Pharmacokinetics</i> , 2014, 53, 659-678.	1.6	92
1346	Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 95-115.	1.1	26
1347	Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 411-418.	1.1	31
1348	Pharmacokinetic changes of drugs in a rat model of liver cirrhosis induced by dimethylnitrosamine, alone and in combination with diabetes mellitus induced by streptozotocin. <i>Biopharmaceutics and Drug Disposition</i> , 2015, 36, 1-14.	1.1	1
1349	A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 338-349.	1.3	29
1350	<i>In silico</i> ADME/T modelling for rational drug design. <i>Quarterly Reviews of Biophysics</i> , 2015, 48, 488-515.	2.4	250
1351	An Introduction to Basic Pharmacokinetics. <i>Transplantation</i> , 2015, 99, 903-907.	0.5	5
1352	Study of the <i>in vitro</i> metabolism of TJ0711 using ultra high performance liquid chromatography with quadrupole time-of-flight and ultra fast liquid chromatography with quadrupole linear ion trap mass spectrometry. <i>Journal of Separation Science</i> , 2015, 38, 1837-1849.	1.3	7
1353	Drug Distribution and Drug Elimination. , 2015, , .		17
1354	Gender differences in corydaline pharmacokinetics in rats. <i>Xenobiotica</i> , 2015, 45, 456-463.	0.5	10
1355	Drug-Drug Interactions Related to Altered Absorption and Plasma Protein Binding: Theoretical and Regulatory Considerations, and an Industry Perspective. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 916-929.	1.6	21
1356	A probabilistic method to report predictions from a human liver microsomes stability QSAR model: a practical tool for drug discovery. <i>Journal of Computer-Aided Molecular Design</i> , 2015, 29, 327-338.	1.3	20
1357	Short-Term Fasting Alters Cytochrome P450-Mediated Drug Metabolism in Humans. <i>Drug Metabolism and Disposition</i> , 2015, 43, 819-828.	1.7	26
1358	Toxicokinetic Triage for Environmental Chemicals. <i>Toxicological Sciences</i> , 2015, 147, 55-67.	1.4	117

#	ARTICLE	IF	CITATIONS
1359	A Physiologically Based Pharmacokinetic Drugâ€“Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows. <i>Clinical Pharmacokinetics</i> , 2015, 54, 943-962.	1.6	40
1360	Use of Transgenic Mouse Models to Understand the Oral Disposition and Drug-Drug Interaction Potential of Cobimetinib, a MEK Inhibitor. <i>Drug Metabolism and Disposition</i> , 2015, 43, 864-869.	1.7	19
1361	Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2â€“p53 interaction, in rats, dogs and monkeys: <i>in vitroâ€“in vivo</i> correlation. <i>Xenobiotica</i> , 2015, 45, 681-692.	0.5	11
1362	Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment. <i>Toxicology</i> , 2015, 332, 94-101.	2.0	127
1363	Effects of capsaicin on pharmacokinetics of pitavastatin in rats. <i>Xenobiotica</i> , 2015, 45, 171-176.	0.5	7
1364	Predictive Performance of the Winterâ€“Tozer and Derivative Equations for Estimating Free Phenytoin Concentration. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, 269-79.	0.1	12
1365	Effects of poloxamer 407â€“induced hyperlipidemia on hepatic multidrug resistance protein 2 (Mrp2/Abcc2) and the pharmacokinetics of mycophenolic acid in rats. <i>Biopharmaceutics and Drug Disposition</i> , 2016, 37, 352-365.	1.1	5
1366	Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1103-1115.	1.7	17
1367	A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly proteinâ€“bound drugs and the impact of errors in plasma protein binding. <i>Biopharmaceutics and Drug Disposition</i> , 2016, 37, 123-141.	1.1	32
1368	Foundations of Pharmacodynamic Systems Analysis. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 161-175.	0.2	4
1369	Rapid Infusion of Hydroxyethyl Starch 70/0.5 but not Acetate Ringerâ€“s Solution Decreases the Plasma Concentration of Propofol during Target-controlled Infusion. <i>Anesthesiology</i> , 2016, 125, 304-312.	1.3	12
1371	Pharmacologic Considerations for Solid Organ Transplant Recipients Who Become Pregnant. <i>Pharmacotherapy</i> , 2016, 36, 971-982.	1.2	12
1372	Principi di farmacocinetica applicati allâ€™anestesia. <i>EMC - Anestesia-Rianimazione</i> , 2016, 21, 1-14.	0.1	0
1373	2016 Remington Honor Medal Address: Science for the profession. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2016, 56, 365-368.	0.7	0
1374	Principios de farmacocinÃ©tica aplicados a la anestesia. <i>EMC - Anestesia-ReanimaciÃ³n</i> , 2016, 42, 1-15.	0.1	1
1375	Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance. <i>Anesthesiology</i> , 2016, 125, 1103-1112.	1.3	46
1376	Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2016, 39, 213-223.	0.6	28
1377	Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 403-412.	0.6	8

#	ARTICLE	IF	CITATIONS
1378	Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 82, 64-78.	1.9	26
1379	Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 276-284.	2.8	20
1380	Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 383-396.	0.6	27
1381	Korean red ginseng extract enhances paclitaxel distribution to mammary tumors and its oral bioavailability by P-glycoprotein inhibition. <i>Xenobiotica</i> , 2017, 47, 450-459.	0.5	13
1382	Pharmacokinetic Steady-States Highlight Interesting Target-Mediated Disposition Properties. <i>AAPS Journal</i> , 2017, 19, 772-786.	2.2	21
1383	Minipig and Human Metabolism of Aldehyde Oxidase Substrates: In Vitro vs In Vivo Comparisons. <i>AAPS Journal</i> , 2017, 19, 1163-1174.	2.2	15
1384	Integrated Lead Optimization: Translational Models as We Advance Toward the Clinic. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2017, , 165-230.	0.2	0
1385	Pharmacokinetic Changes in Liver Failure and Impact on Drug Therapy. <i>AACN Advanced Critical Care</i> , 2017, 28, 93-101.	0.6	13
1386	The ontogeny and population variability of human hepatic dihydronicotinamide riboside:quinone oxidoreductase (NQO2). <i>Journal of Biochemical and Molecular Toxicology</i> , 2017, 31, e21921.	1.4	4
1387	Piperine Decreases Binding of Drugs to Human Plasma and Increases Uptake by Brain Microvascular Endothelial Cells. <i>Phytotherapy Research</i> , 2017, 31, 1868-1874.	2.8	9
1388	In vitro to in vivo extrapolation of biotransformation rates for assessing bioaccumulation of hydrophobic organic chemicals in mammals. <i>Environmental Toxicology and Chemistry</i> , 2017, 36, 1934-1946.	2.2	17
1389	An Intuitive Approach for Predicting Potential Human Health Risk with the Tox21 10k Library. <i>Environmental Science & Technology</i> , 2017, 51, 10786-10796.	4.6	120
1390	Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability. <i>Environment International</i> , 2017, 106, 105-118.	4.8	80
1391	Comparison of trout hepatocytes and liver S9 fractions as in vitro models for predicting hepatic clearance in fish. <i>Environmental Toxicology and Chemistry</i> , 2017, 36, 463-471.	2.2	24
1392	Identifying clinically relevant sources of variability: The clopidogrel challenge. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 264-273.	2.3	14
1393	Introduction to Clinical Pharmacology. , 2017, , 365-388.		15
1394	Basic Pharmacologic Principles. , 2017, , 187-201.e3.		7
1395	Impact of clinical factors and UGT1A9 and CYP2B6 genotype on inter-individual differences in propofol pharmacokinetics. <i>Journal of Anesthesia</i> , 2018, 32, 236-243.	0.7	7

#	ARTICLE	IF	CITATIONS
1396	Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1346-1353.	1.1	20
1397	Predicting Pharmacokinetics/Pharmacodynamics in the Individual Patient: Separating Reality From Hype. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 979-989.	1.0	7
1398	The Phenomenon of Albumin-Mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates: Prediction of the In Vivo Uptake Clearance from the In Vitro Uptake by Isolated Hepatocytes Using a Facilitated-Dissociation Model. <i>Drug Metabolism and Disposition</i> , 2018, 46, 259-267.	1.7	67
1399	GABAA receptor activity modulating piperine analogs: In vitro metabolic stability, metabolite identification, CYP450 reaction phenotyping, and protein binding. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1072, 379-389.	1.2	9
1400	In vitro to in vivo extrapolation for high throughput prioritization and decision making. <i>Toxicology in Vitro</i> , 2018, 47, 213-227.	1.1	162
1401	The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 521-525.	2.3	32
1402	Drug Excretion. , 2018, , 81-96.		2
1403	The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses. <i>Pharmaceutical Research</i> , 2018, 35, 242.	1.7	19
1404	Allometric scaling of hepatic biotransformation in rainbow trout. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2018, 214, 52-60.	1.3	7
1405	In-vitro metabolism, CYP profiling and metabolite identification of E- and Z- guggulsterone, a potent hypolipidmic agent. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 160, 202-211.	1.4	14
1406	Reliability of In Vitro Methods Used to Measure Intrinsic Clearance of Hydrophobic Organic Chemicals by Rainbow Trout: Results of an International Ring Trial. <i>Toxicological Sciences</i> , 2018, 164, 563-575.	1.4	36
1408	An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 502-514.	1.9	63
1409	The impact of desorption kinetics from albumin on hepatic extraction efficiency and hepatic clearance: a model study. <i>Archives of Toxicology</i> , 2018, 92, 2175-2182.	1.9	9
1410	Concentration-dependent plasma protein binding: Expect the unexpected. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 122, 341-346.	1.9	23
1411	Discussions on the hepatic well-stirred model: Re-derivation from the dispersion model and re-analysis of the lidocaine data. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 124, 46-60.	1.9	12
1412	<i>In vivo</i> hepatic clearance of lipophilic drugs predicted by <i>in vitro</i> uptake data into cryopreserved hepatocytes suspended in sera of rats, guinea pigs, monkeys and humans. <i>Xenobiotica</i> , 2019, 49, 887-894.	0.5	6
1413	Hepatic clearance concepts and misconceptions: Why the well-stirred model is still used even though it is not physiologic reality?. <i>Biochemical Pharmacology</i> , 2019, 169, 113596.	2.0	43
1414	Model qualification of the PK-SimÂ® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2019, 82, 789-814.	1.1	15

#	ARTICLE	IF	CITATIONS
1415	Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1511-1515.	1.6	3
1416	Assessing Toxicokinetic Uncertainty and Variability in Risk Prioritization. <i>Toxicological Sciences</i> , 2019, 172, 235-251.	1.4	40
1417	Challenges in working towards an internal threshold of toxicological concern (iTTC) for use in the safety assessment of cosmetics: Discussions from the Cosmetics Europe iTTC Working Group workshop. <i>Regulatory Toxicology and Pharmacology</i> , 2019, 103, 63-72.	1.3	30
1418	Concentration dependence of in vitro biotransformation rates of hydrophobic organic sunscreen agents in rainbow trout S9 fractions: Implications for bioaccumulation assessment. <i>Environmental Toxicology and Chemistry</i> , 2019, 38, 548-560.	2.2	29
1419	Methods to Predict Volume of Distribution. <i>Current Pharmacology Reports</i> , 2019, 5, 391-399.	1.5	7
1420	Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 136, 104938.	1.9	15
1421	LC478, a Novel Di-Substituted Adamantyl Derivative, Enhances the Oral Bioavailability of Docetaxel in Rats. <i>Pharmaceutics</i> , 2019, 11, 135.	2.0	2
1422	Special Populations: Protein Binding Aspects. , 2019, , 1-8.		0
1423	Relevance of In Vitro Metabolism Models to PET Radiotracer Development: Prediction of In Vivo Clearance in Rats from Microsomal Stability Data. <i>Pharmaceutics</i> , 2019, 12, 57.	1.7	10
1424	Scaling in vitro activity of CYP3A7 suggests human fetal livers do not clear retinoic acid entering from maternal circulation. <i>Scientific Reports</i> , 2019, 9, 4620.	1.6	11
1425	Effects of Orotic Acid-Induced Non-Alcoholic Fatty Liver on the Pharmacokinetics of Metoprolol and its Metabolites in Rats. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2019, 22, 98-111.	0.9	8
1426	Building in-house PBPK modelling tools for oral drug administration from literature information. <i>ADMET and DMPK</i> , 2019, 7, 4-21.	1.1	8
1428	Evaluation of the bioaccumulation potential of selected alternative brominated flame retardants in marine fish using in vitro metabolic transformation rates. <i>Science of the Total Environment</i> , 2019, 653, 1333-1342.	3.9	16
1429	Liver and Gastrointestinal Pharmacology. , 2019, , 645-656.		0
1430	An in vivo evaluation of the ontogeny of stereoselective fluoxetine metabolism and disposition in lambs from birth to one year of age. <i>Xenobiotica</i> , 2019, 49, 1360-1372.	0.5	0
1431	Efficient brain uptake and distribution of an expanded CAG RNA inhibitor DB213 via intranasal administration. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 127, 240-251.	1.9	6
1432	Clearance in Drug Design. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2245-2255.	2.9	99
1433	Pharmacokinetic alterations in poloxamer 407-induced hyperlipidemic rats. <i>Xenobiotica</i> , 2019, 49, 611-625.	0.5	7

#	ARTICLE	IF	CITATIONS
1434	Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 214-223.	0.8	19
1435	Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study Analysis. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 391-399.	1.0	4
1436	The pharmacokinetics of mycophenolic acid in rats with orotic acid induced nonalcoholic fatty liver disease. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 169-176.	0.7	2
1437	Scaffold-hopping as a strategy to address metabolic liabilities of aromatic compounds. <i>RSC Medicinal Chemistry</i> , 2020, 11, 18-29.	1.7	34
1438	Toxicity testing in the 21st century: progress in the past decade and future perspectives. <i>Archives of Toxicology</i> , 2020, 94, 1-58.	1.9	209
1439	Effect of treatment period with LC478, a disubstituted adamantyl derivative, on P-glycoprotein inhibition: its application to increase docetaxel absorption in rats. <i>Xenobiotica</i> , 2020, 50, 863-874.	0.5	1
1440	Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. <i>Veterinary Anaesthesia and Analgesia</i> , 2020, 47, 210-218.	0.3	11
1441	Differences in teratogenicity of some vitamin K antagonist substances used as human therapeutic or rodenticide are due to major differences in their fate after an oral administration. <i>Toxicology Letters</i> , 2020, 333, 71-79.	0.4	12
1442	Hepatic Clearance Binding Terms of Hydrophobic Organic Chemicals in Rainbow Trout: Application of a Streamlined Sorbent-Phase Dosing Method. <i>Environmental Science and Technology Letters</i> , 2020, 7, 672-676.	3.9	10
1443	<p>LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 4439-4449.	2.0	4
1444	Slower Elimination of Tofacitinib in Acute Renal Failure Rat Models: Contribution of Hepatic Metabolism and Renal Excretion. <i>Pharmaceutics</i> , 2020, 12, 714.	2.0	7
1445	The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1493-1500.	1.6	31
1446	Investigating the Theoretical Basis for In Vitro-In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways. <i>AAPS Journal</i> , 2020, 22, 120.	2.2	21
1447	In vitro-in vivo extrapolation of hepatic and gastrointestinal biotransformation rates of hydrophobic chemicals in rainbow trout. <i>Aquatic Toxicology</i> , 2020, 228, 105629.	1.9	11
1448	Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 373, 488-501.	1.3	14
1449	Pharmacokinetic Interaction between Metformin and Verapamil in Rats: Inhibition of the OCT2-Mediated Renal Excretion of Metformin by Verapamil. <i>Pharmaceutics</i> , 2020, 12, 468.	2.0	8
1450	Direct Comparison of Total Clearance Prediction: Computational Machine Learning Model versus Bottom-Up Approach Using In Vitro Assay. <i>Molecular Pharmaceutics</i> , 2020, 17, 2299-2309.	2.3	33
1451	Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. <i>CNS Drugs</i> , 2020, 34, 795-800.	2.7	81

#	ARTICLE	IF	CITATIONS
1452	Critical Analysis of Hepatic Clearance Based on an Advection Mass Transfer Model and Mass Balance. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2059-2069.	1.6	8
1453	Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 783-793.	2.0	38
1454	Discovery of a First-in-Class Potent Small Molecule Antagonist against the Adrenomedullin-2 Receptor. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 706-719.	2.5	9
1455	High-throughput screening tools facilitate calculation of a combined exposure-bioactivity index for chemicals with endocrine activity. <i>Environment International</i> , 2020, 137, 105470.	4.8	10
1456	Art of Making Artificial Liver: Depicting Human Liver Biology and Diseases in Mice. <i>Seminars in Liver Disease</i> , 2020, 40, 189-212.	1.8	24
1457	Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 111-119.	2.0	4
1458	Pharmacokinetic studies in pregnancy. <i>Seminars in Perinatology</i> , 2020, 44, 151227.	1.1	9
1459	Auto-Induction of Intestinal First-Pass Effect Related Time-Dependent Pharmacokinetics of Artemisinin Rather than Dihydroartemisinin. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 458-466.	1.6	5
1460	Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid. <i>Xenobiotica</i> , 2021, 51, 324-334.	0.5	8
1461	Pharmacokinetics modeling in drug delivery. , 2021, , 279-334.		1
1463	Principles of pharmacokinetics and pharmacodynamics. , 2021, , 219-242.		0
1464	Human Fetal Liver Metabolism of Oxycodone Is Mediated by CYP3A7. <i>AAPS Journal</i> , 2021, 23, 24.	2.2	7
1465	Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions. <i>Methods in Molecular Biology</i> , 2021, 2342, 51-88.	0.4	3
1466	Mathematical Aspects of Clinical Pharmacokinetics. , 2021, ,		0
1468	Assessment of Cytochrome P450 Metabolic Clearance Using Hepatocyte Suspension. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 243-259.	0.1	0
1469	Differential Effect of a Continental Breakfast on Tacrolimus Formulations With Different Release Characteristics. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 899-907.	0.8	3
1470	Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy. <i>European Journal of Medicinal Chemistry</i> , 2021, 211, 113060.	2.6	7
1471	Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1195-1211.	2.0	16

#	ARTICLE	IF	CITATIONS
1472	Measurement of total liver blood flow in intact anesthetized rats using ultrasound imaging. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00731.	1.1	7
1473	Comparative Assessment of Extrapolation Methods Based on the Conventional Free Drug Hypothesis and Plasma Protein-Mediated Hepatic Uptake Theory for the Hepatic Clearance Predictions of Two Drugs Extensively Bound to Both the Albumin And Alpha-1-Acid Glycoprotein. <i>Journal of Pharmaceutical Sciences</i> . 2021, 110, 1385-1391.	1.6	8
1474	Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3546-3559.	2.9	29
1475	Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1369-1379.	0.8	2
1476	Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 321-338.	0.8	47
1477	The role of aldehyde oxidase in the metabolic clearance of substituted benzothiazoles. <i>Drug Metabolism Letters</i> , 2021, 14, 126-136.	0.5	1
1478	Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats. <i>Pharmaceutics</i> , 2021, 13, 740.	2.0	4
1479	Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug-drug interaction in healthy adults and its extrapolation to virtual chronic heart failure patients for dose optimization. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 717-724.	1.5	4
1480	Recent developments in <i>in vitro</i> and <i>in vivo</i> models for improved translation of preclinical pharmacokinetics and pharmacodynamics data. <i>Drug Metabolism Reviews</i> , 2021, 53, 207-233.	1.5	15
1481	A Validated LC-MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation. <i>Molecules</i> , 2021, 26, 2717.	1.7	7
1482	There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions. <i>AAPS Journal</i> , 2021, 23, 67.	2.2	19
1483	Quantitative <i>In Vitro</i> to <i>In Vivo</i> Extrapolation for Mixtures: A Case Study of Superfund Priority List Pesticides. <i>Toxicological Sciences</i> , 2021, 183, 60-69.	1.4	8
1484	Evaluation and comparison of <i>in vitro</i> intrinsic clearance rates measured using cryopreserved hepatocytes from humans, rats, and rainbow trout. <i>Toxicology</i> , 2021, 457, 152819.	2.0	12
1485	Re-Examining the Impact of Minimal Scans in Liquid Chromatography-Mass Spectrometry Analysis. <i>Journal of the American Society for Mass Spectrometry</i> , 2021, 32, 2110-2122.	1.2	10
1486	Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between <i>in vitro</i> and <i>in vivo</i> . , 2022, 229, 107938.		10
1487	High-throughput PBTK models for <i>in vitro</i> to <i>in vivo</i> extrapolation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 903-921.	1.5	42
1488	LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1179, 122806.	1.2	10
1489	Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12286-12303.	2.9	9

#	ARTICLE	IF	CITATIONS
1490	Age-Related Change in Hepatic Clearance Inferred from Multiple Population Pharmacokinetic Studies: Comparison with Renal Clearance and Their Associations with Organ Weight and Blood Flow. <i>Clinical Pharmacokinetics</i> , 2021, , 1.	1.6	8
1491	LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3915-3925.	2.0	2
1492	Drug metabolic stability in early drug discovery to develop potential lead compounds. <i>Drug Metabolism Reviews</i> , 2021, 53, 459-477.	1.5	26
1493	Prediction of Oral Pharmacokinetics Using a Combination of In Silico Descriptors and In Vitro ADME Properties. <i>Molecular Pharmaceutics</i> , 2021, 18, 1071-1079.	2.3	30
1495	Methods for the Study of Lung Metabolism. <i>Novartis Foundation Symposium</i> , 1980, 78, 61-83.	1.2	1
1498	The effects of ageing on the disposition of benzodiazepines in man. , 1979, , 103-116.		4
1499	Pharmacokinetics of lignocaine and chlormethiazole in the elderly; with some preliminary observations on other drugs. , 1979, , 117-132.		3
1501	Impact of Physiological Determinants: Flow, Binding, Transporters and Enzymes on Organ and Total Body Clearances. , 2010, , 107-147.		2
1502	Physiologic Response to Anesthesia in the Elderly. , 2011, , 291-303.		5
1503	Animal Models in the Study of Hepatobiliary Radiotracers. , 1983, , 179-209.		3
1504	Update on Bile Formation and on Mechanism of Bile Acid-Induced Cholestasis. , 1989, , 41-67.		5
1505	Integral Procedures in Pharmacokinetics and their Application to the Parameter Determination of Appearing Metabolites. , 1984, , 253-279.		3
1506	Clinical Pharmacokinetics in Congestive Heart Failure. , 1994, , 323-340.		2
1507	Interspecies Scaling in Pharmacokinetics. , 1991, , 203-226.		14
1508	The Role of Pharmacokinetics in the Drug Development Process. , 1993, , 115-123.		4
1509	Pharmacokinetics and the clinical relevance of drug metabolism. , 1986, , 199-238.		1
1510	Mechanistic Animal-Replacement Approaches for Predicting Pharmacokinetics of Organic Chemicals. , 1999, , 115-139.		12
1511	Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions. <i>Methods in Molecular Biology</i> , 2014, 1113, 57-91.	0.4	18

#	ARTICLE	IF	CITATIONS
1512	Drug Metabolism in Man: in vivo and in vitro Correlations. Archives of Toxicology Supplement, 1978, , 339-342.	0.7	2
1513	Metabolism and Kinetics. Handbook of Experimental Pharmacology, 1980, , 287-304.	0.9	4
1514	Kinetics and Biotransformation of Adrenergic Inhibitors. Handbook of Experimental Pharmacology, 1981, , 417-504.	0.9	7
1515	Hepatic Drug Disposition in Liver Disease: Consequences for Dosage Adjustments. , 1983, , 45-51.		3
1516	The Diseased Lung and Drugs. Archives of Toxicology Supplement, 1984, 7, 66-87.	0.7	3
1517	Hepatic Disposition and Elimination of Biliary Contrast Media. Handbook of Experimental Pharmacology, 1984, , 367-418.	0.9	6
1518	Risikoerfassung und optimierende Therapie bei intrahepatisehen Erkrankungen der Leber. , 1988, , 79-83.		1
1520	Steady-State Pharmacokinetics of Nisoldipine in Patients with Liver Disease. , 1987, , 80-84.		5
1521	Pharmacokinetic Aspects of Antifungal Therapy. Handbook of Experimental Pharmacology, 1990, , 183-204.	0.9	4
1522	Transport of Drugs. Handbook of Experimental Pharmacology, 1992, , 279-300.	0.9	2
1523	Biologically Based Modeling in Toxicology Research. Archives of Toxicology Supplement, 1992, 15, 217-227.	0.7	11
1524	Metabolism: Scaling-up from In Vitro to Organ and Whole Body. Handbook of Experimental Pharmacology, 1994, , 101-187.	0.9	9
1525	Rhythms in Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion. Handbook of Experimental Pharmacology, 1997, , 177-204.	0.9	36
1526	Clinical utility and limitations of pharmacokinetics. , 1983, , 397-414.		5
1527	Antiarrhythmic Agents. Developments in Cardiovascular Medicine, 1980, , 1-45.	0.1	2
1528	Pharmacokinetics In Geriatric Psychopharmacology. , 1980, , 169-212.		2
1529	Effect of age and sex on the plasma binding of acidic and basic drugs. European Journal of Clinical Pharmacology, 1984, 27, 91-97.	0.8	38
1530	Fate of Xenobiotics: Physiologic and Kinetic Considerations. , 1983, , 213-250.		4

#	ARTICLE	IF	CITATIONS
1531	Kinetic Aspects of Metabolism and Elimination of Foreign Compounds in Animals. , 1980, , 9-24.		2
1532	Presystemic drug metabolism in the liver. , 1982, , 69-77.		2
1533	Physiological factors affecting hepatic first-pass metabolism. , 1982, , 78-95.		1
1534	Presystemic hepatic drug elimination in cirrhosis. , 1982, , 96-107.		1
1535	Presystemic drug metabolism of exogenous compounds by the lung. , 1982, , 173-185.		1
1536	Hepatic Physiology and Pathophysiology. , 2010, , 411-440.		6
1537	Basic Principles of Pharmacology. , 2010, , 479-513.		5
1538	Principles of Drug Disposition in the Critically Ill Child. , 2006, , 1639-1658.		1
1539	Determinants of drug disposition in infants. , 1996, , 59-66.		1
1540	The Influence of Liver Diseases on Drug Disposition. Clinics in Gastroenterology, 1979, 8, 105-121.	0.6	18
1541	Hepatic Circulation in Cirrhosis. Clinics in Gastroenterology, 1985, 14, 155-168.	0.6	29
1542	The Importance of Presystemic Extraction in Clinical Psychopharmacology. Journal of Clinical Psychopharmacology, 1996, 16, 417-419.	0.7	7
1543	DECREASED PATIENT ANALGESIC REQUIREMENTS AFTER LIVER TRANSPLANTATION AND ASSOCIATED NEUROPEPTIDE LEVELS. Transplantation, 1997, 63, 1423-1429.	0.5	31
1544	Meloxicam pharmacokinetics in renal impairment. British Journal of Clinical Pharmacology, 1997, 43, 35-40.	1.1	14
1545	Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. British Journal of Clinical Pharmacology, 1997, 43, 99-103.	1.1	28
1546	Albumin helps mediate removal of taurocholate by rat liver.. Journal of Clinical Investigation, 1981, 67, 1517-1522.	3.9	188
1547	Uptake of oleate from albumin solutions by rat liver. Failure to detect catalysis of the dissociation of oleate from albumin by an albumin receptor.. Journal of Clinical Investigation, 1987, 79, 1070-1077.	3.9	91
1548	The Isolated Perfused Liver as a Tool in Drug Metabolism Studies. , 1999, , 425-442.		7

#	ARTICLE	IF	CITATIONS
1549	Apparent Volume of Distribution. <i>Drugs and the Pharmaceutical Sciences</i> , 1982, , 199-219.	0.1	4
1550	R Package for High-Throughput Toxicokinetics . <i>Journal of Statistical Software</i> , 2017, 79, 1-26.	1.8	256
1551	Effect of Ketoconazole on the Pharmacokinetic Profile of Buprenorphine following Administration of a Once-Weekly Buprenorphine Transdermal System. <i>Clinical Drug Investigation</i> , 2012, 32, 583-592.	1.1	18
1552	CYP enzyme system and its relevance to the pharmacology of sleep. , 2008, , 153-159.		7
1553	Medical applications of stereolithography: An overview. <i>International Journal of Academic Medicine</i> , 2018, 4, 252.	0.2	11
1554	Pharmacokinetics, Metabolism and Excretion of Hypolipidemic DRUG: 16-Dehydropregnenolone. <i>Journal of Drug Metabolism & Toxicology</i> , 2013, 04, .	0.1	1
1555	Increased Clearance of Propranolol in Thyrotoxicosis. <i>Annals of Internal Medicine</i> , 1981, 94, 472.	2.0	21
1556	Mechanism-based Pharmacokinetics and Pharmacodynamics. <i>Future Perspectives.. Drug Metabolism and Pharmacokinetics</i> , 2000, 15, 478-483.	0.0	0
1557	Japanese Journal of Thrombosis and Hemostasis.		
1558	Introducing Pharmacokinetic and Pharmacodynamic Concepts. <i>Drugs and the Pharmaceutical Sciences</i> , 2001, , 1-31.	0.1	0
1559	Effects of the Beta-Adrenoceptor Blocker Carvedilol in Children with Myocardial Failure. <i>Progress in Experimental Cardiology</i> , 2003, , 123-133.	0.0	0
1560	The Impact of Chirality in Pharmacokinetics and Therapeutic Drug Monitoring. , 2003, , .		0
1561	Pharmakokinetische Prinzipien der Arzneimitteltherapie. , 2004, , 801-815.		0
1562	Pharmacokinetic Evaluation of Anticonvulsants in a Patient with Porphyria. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2004, 35, 291-296.	0.1	0
1563	Basic Pharmacologic Principles. , 2004, , 179-190.		1
1565	Pharmacokinetic principles. , 2006, , 101-117.		0
1566	Application of Pharmacokinetics and Pharmacodynamics in Antimicrobial Global Drug Development. , 2007, , 445-460.		0
1567	Principles of Pharmacokinetics. <i>Novartis Foundation Symposium</i> , 1980, , 13-33.	1.2	1

#	ARTICLE	IF	CITATIONS
1572	Clinical Pharmacologic Principles and Immunosuppression. , 2011, , 87-109.		0
1573	Basic Pharmacologic Principles. , 2011, , 211-223.		0
1574	Cardiovascular Pharmacology. , 2011, , 235-295.		2
1576	Toxicokinetics and Drug Disposition. , 2013, , 55-76.		0
1577	The Interaction of Anesthetic Agents with Hepatic Microsomal Enzymes. , 1978, , 169-222.		0
1578	Pharmacokinetic Aspects of the Formation and Inactivation of Chemically Reactive Metabolites. , 1978, , 375-397.		0
1579	Interindividual Differences in Plasma Concentrations and Effect of the Adrenergic Beta-receptor Blocking Drug Alprenolol and its Metabolite 4-hydroxy-alprenolol in Man. , 1979, , 13-22.		0
1580	Methods of the Assessment of the Effect of Drugs on Liver Blood Flow in Man. , 1980, , 79-85.		0
1581	Leber: Anaesthesie und Intensivtherapie. , 1980, , 232-241.		0
1582	Evaluation of altered pharmacokinetics in intensive-care patients. , 1980, , 229-241.		0
1583	Methods for the measurement of drug binding to plasma proteins. , 1980, , 267-273.		0
1584	PULMONARY METABOLISM AND EXCRETION OF ARENE OXIDES. , 1980, , 683-686.		1
1585	Drug Metabolism at Various Ages â€” Young. , 1980, , 98-107.		0
1586	Die medikamentÃ¶se Belastbarkeit der pathologisch verÃ¤nderten Leber. , 1980, , 252-255.		0
1587	Evaluation of the clinical significance of the first-pass effect of verapamil in patients. , 1980, , 218-228.		1
1588	Liver function tests and elimination of drugs in man. , 1980, , 169-175.		0
1589	Clinically Significant Drug Interactions with Beta Adrenoceptors. , 1981, , 23-32.		0
1590	Drugs and the Kidney. , 1981, , 657-694.		3

#	ARTICLE	IF	CITATIONS
1591	Basics of Biotransformation. , 1982, , 1-10.		0
1592	Basics of Biotransformation. , 1982, , 1-10.		0
1593	Grundlagen der Biotransformation. , 1982, , 1-10.		0
1594	First-pass metabolism by the lung: introduction. , 1982, , 111-116.		0
1595	Interaktionen von Ulcusterapeutica. Interdisziplinäre Gastroenterologie, 1982, , 325-344.	0.0	0
1596	Metabolism and Pharmacokinetics of Cephalothin in Liver Dis-eases. Japanese Journal of Clinical Pharmacology and Therapeutics, 1982, 13, 273-283.	0.1	0
1597	Schock, Wandel der Perspektiven. Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin, 1982, , 205-244.	0.0	0
1598	Vorbereitung und DurchfÅ¼hrung der AnÃsthesie bei FunktionsstÃ¶rungen der metabolischen Organe. Klinische Anesthesiologie Und Intensivtherapie, 1984, , 266-278.	0.1	0
1599	Clearance â€” Models, Validation and Implications. , 1984, , 133-146.		0
1600	Pharmacokinetics and Drug Concentrations Measurement: Relevance to Treatment of Anxiety Disorders. , 1984, , 329-339.		0
1601	Klinische Pharmakologie. Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin, 1984, , 1835-1911.	0.0	0
1602	Pharmakokinetische Aspekte der Therapie im Alter. , 1984, , 18-31.		0
1604	Clinical Pharmacokinetics of Antidepressants. , 1984, , 119-137.		0
1605	Anticoagulants in the treatment of cardiovascular disease. , 1985, , 199-222.		0
1606	Title is missing!. Japanese Journal of Clinical Pharmacology and Therapeutics, 1985, 16, 137-138.	0.1	0
1607	Pharmacokinetic Properties of Cardiovascular Drugs. Treatment in Clinical Medicine, 1985, , 1-14.	0.0	0
1608	Methodological Concerns for Clinical Trials in Geriatrics. , 1986, , 189-205.		0
1609	The Effects of Age on Hepatic Drug Metabolism. , 1986, , 101-121.		0

#	ARTICLE	IF	CITATIONS
1610	Pharmacokinetics and Patient Care. , 1986, , 131-160.		0
1611	Pharmacokinetic Drug Interactions. Progress in Clinical Biochemistry and Medicine, 1987, , 101-131.	0.5	0
1612	Definition der gest�rten Leberfunktion. Zusammenarbeit Von Klinik Und Klinischer Chemie, 1987, , 43-52.	0.2	0
1613	New methods of administering old drugs: IV infusion of mercaptopurine. , 1987, , 115-123.		0
1615	Urinary metabolites of nilvadipine in man.. Drug Metabolism and Pharmacokinetics, 1987, 2, 649-655.	0.0	2
1617	Variability in Toxicokinetics in Exposure to Solvents. International Archives of Occupational and Environmental Health Supplement, 1988, Suppl, 31-38.	0.0	0
1618	Hepatic Spaces and Transport in the Perfused Liver. Proceedings in Life Sciences, 1989, , 45-57.	0.5	1
1619	Pharmakokinetische Prinzipien der Arzneimitteltherapie. , 1989, , 704-717.		0
1620	Der alkoholranke Patient auf der Intensivstation. , 1991, , 1-12.		1
1621	Stereoselective Pharmacokinetics. , 1991, , 227-255.		0
1622	ACTION BY THE LUNGS ON CIRCULATING XENOBIOTIC AGENTS, WITH A CASE STUDY OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF BENZO(a)PYRENE DISPOSITION. , 1993, , 89-105.		0
1623	Significance of Cyclosporine Pharmacokinetics in Liver Transplantation. Medical Science Symposia Series, 1993, , 25-30.	0.0	0
1624	Pharmacokinetics and Pharmacodynamics During Cardiac Surgery and Cardiopulmonary Bypass. , 1995, , 55-87.		1
1625	Kinetics and .ALPHA.1 in blood plasma of new calcium antagonist.Acid glucoprotein concentration.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1995, 26, 181-182.	0.1	0
1626	Pharmakokinetische Prinzipien der Arzneimitteltherapie. , 1996, , 1139-1156.		0
1627	Pharmacokinetics and the clinical relevance of drug metabolism. , 1996, , 180-216.		0
1628	A Quantitative Structure-toxicokinetic Relationship Model for Highly Metabolised Chemicals. ATLA Alternatives To Laboratory Animals, 1998, 26, 45-55.	0.7	5
1629	Basis for Selection of the Dosage Form. Drugs and the Pharmaceutical Sciences, 1998, , 7-143.	0.1	2

#	ARTICLE	IF	CITATIONS
1630	Clinical pharmacology in cardiac insufficiency.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1999, 30, 629-632.	0.1	0
1631	Drug-Drug Interactions: Regulatory and Theoretical Considerations, and an Industry Perspective. RSC Drug Discovery Series, 2015, , 263-282.	0.2	0
1632	Chapter 7. Pharmacokinetics, Drug Metabolism, and Drug Disposition. , 2015, , .		0
1633	VOLUME OF DISTRIBUTION OF ATRACURIUM IN DIFFERENT COHORTS : A COMPARITIVE STUDY. Journal of Evidence Based Medicine and Healthcare, 2015, 2, 6001-6009.	0.0	0
1635	Influence of Menstrual Cycle on Pharmacokinetics of Ciprofloxacin. IOSR Journal of Pharmacy and Biological Sciences, 2016, 11, 30-35.	0.1	0
1636	Physiologic Responses to Anesthesia in the Elderly. , 2017, , 1-21.		1
1637	In Silico Approaches for the Prediction of In Vivo Biotransformation Rates. Challenges and Advances in Computational Chemistry and Physics, 2017, , 425-451.	0.6	1
1638	Bridging the gap between in silico and in vivo by modeling opioid disposition in a kidney proximal tubule microphysiological system. Scientific Reports, 2021, 11, 21356.	1.6	16
1640	Cardiovascular Pharmacology. , 1983, , 261-308.		1
1641	Functional Dissection of the Diseased Liver. , 1983, , 29-44.		2
1642	Humanalbumin: Depot- und/oder Transportprotein für Pharmaka. , 1983, , 89-96.		0
1643	Pharmacological Challenges in Neurocritical Care. Current Clinical Neurology, 2020, , 73-85.	0.1	0
1645	Sex Disparity Among Faculty of Physiology in North American Academia: Differences in Scholarly Productivity and Academic Rank. Cureus, 2020, 12, e11850.	0.2	0
1646	Effect of liver disease on pharmacokinetics. , 2022, , 91-112.		0
1647	Physiologic Responses to Anesthesia in the Elderly. , 2020, , 339-359.		0
1648	Decreased analgesic requirement in recipient of liver transplantation from monozygotic twin - A case report -. Anesthesia and Pain Medicine, 2020, 15, 83-87.	0.5	0
1649	Special Populations: Protein Binding Aspects. , 2020, , 765-772.		0
1650	Chapter 2: Pharmacogenomics: Drug Exposure and Response. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
1651	In Defense of Current Concepts and Applications of Clearance in Drug Development and Therapeutics. Drug Metabolism and Disposition, 2022, 50, 187-190.	1.7	9
1652	Can <i>In Vitro</i> – <i>In Vivo</i> Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions. Clinical Pharmacology and Therapeutics, 2022, 111, 1022-1035.	2.3	16
1653	Opportunities and Considerations in the Application of Artificial Intelligence to Pharmacokinetic Prediction. Methods in Molecular Biology, 2022, 2390, 461-482.	0.4	4
1654	Management of Regional Anesthesia. , 2008, , 278-292.		1
1655	Physiological Pharmacokinetic Models. Drugs and the Pharmaceutical Sciences, 1982, , 355-384.	0.1	0
1656	Adverse Drug Effects in the Elderly Patient. Otolaryngologic Clinics of North America, 1982, 15, 451-463.	0.5	1
1657	The Fate of Drugs in Pregnancy. Clinics in Obstetrics and Gynaecology, 1986, 13, 161-175.	0.5	16
1658	Alcoholic Cirrhosis. Clinics in Gastroenterology, 1981, 10, 443-455.	0.6	7
1659	Interethnic differences in drug glucuronidation: a comparison of paracetamol metabolism in Caucasians and Chinese. British Journal of Clinical Pharmacology, 1991, 32, 765-7.	1.1	12
1660	Evaluation of aggregated IgG in mice as an Fc receptor specific probe of the hepatic mononuclear phagocyte system. Clinical and Experimental Immunology, 1982, 49, 200-8.	1.1	17
1661	Drug administration and food. The BMJ, 1979, 1, 289.	0.0	0
1665	Drug interactions. Journal of the Royal College of Physicians of London, 1980, 14, 190-6.	0.2	1
1666	Assessment of the Kochak-Benet Equation for Hepatic Clearance for the Parallel-Tube Model: Relevance of Classic Clearance Concepts in PK and PBPK. AAPS Journal, 2022, 24, 5.	2.2	16
1667	Drug-Drug Interactions With a Pharmacokinetic Basis. , 2021, , .		0
1668	A weight of evidence approach for bioaccumulation assessment. Integrated Environmental Assessment and Management, 2023, 19, 1235-1253.	1.6	15
1669	Estimation of zorifertinib metabolic stability in human liver microsomes using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2022, 211, 114626.	1.4	7
1670	Will the Pharmacologically Meaningful Half-Life Please Stand Up?. Journal of Clinical Pharmacology, 2022, 62, 829-832.	1.0	1
1671	Effect of age and sex on the plasma binding of acidic and basic drugs. European Journal of Clinical Pharmacology, 1984, 27, 91-7.	0.8	37

#	ARTICLE	IF	CITATIONS
1672	Consideration of Fractional Distribution Parameter f_d in the Chen and Gross Method for Tissue-to-Plasma Partition Coefficients: Comparison of Several Methods. <i>Pharmaceutical Research</i> , 2022, 39, 463-479.	1.7	9
1673	Integration of toxicodynamic and toxicokinetic new approach methods into a weight-of-evidence analysis for pesticide developmental neurotoxicity assessment: A case-study with DL- and L-glufosinate. <i>Regulatory Toxicology and Pharmacology</i> , 2022, 131, 105167.	1.3	12
1674	Chapter 7: Clinical Pharmacokinetics. , 2022, , .		0
1675	Integration of Engineered Delivery with the Pharmacokinetics of Medical Candidates via Physiology-Based Pharmacokinetics. <i>Methods in Molecular Biology</i> , 2022, 2486, 57-69.	0.4	0
1678	Pharmacokinetic Principles. , 0, , 1-25.		0
1680	Interpretation of pharmacokinetic data in preclinical studies of new drugs. Single intravenous administration. <i>Pharmacokinetics and Pharmacodynamics</i> , 2022, , 55-60.	0.1	0
1681	PHARMACOLOGIC CONSIDERATIONS IN GERIATRIC DENTISTRY. <i>Dental Clinics of North America</i> , 1994, 38, 755-767.	0.8	2
1682	Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1039-1055.	1.6	11
1683	Using Partition Analysis as a Facile Method to Derive Net Clearances. <i>Clinical and Translational Science</i> , 2022, , .	1.5	2
1684	Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics. <i>Pharmaceutics</i> , 2022, 14, 1157.	2.0	0
1685	Pharmacokinetic and pharmacodynamic considerations of antibiotics and antifungals in liver transplantation recipients. <i>Liver Transplantation</i> , 2023, 29, 91-102.	1.3	2
1686	Assessment of the Kochak-Benet Equation for Hepatic Clearance for the Parallel-Tube Model: A Response to Jusko and Li. <i>Journal of Pharmaceutical Sciences</i> , 2022, , .	1.6	1
1689	Total Clearance and Organ Clearance. , 2022, , 1128-1137.		0
1690	Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein. <i>Drug Research</i> , 2022, 72, 319-326.	0.7	0
1691	A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes. <i>RSC Advances</i> , 2022, 12, 20387-20394.	1.7	8
1693	Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 0, , .	1.1	0
1694	Caffeine and Methylxanthine: A Human Pharmacokinetic Interaction Study. <i>Journal of Exercise and Nutrition</i> , 2022, 5, .	0.1	2
1695	Compartmental model describing the physiological basis for the HepQuant SHUNT test. <i>Translational Research</i> , 2023, 252, 53-63.	2.2	1

#	ARTICLE	IF	CITATIONS
1696	Review of the application of Kirchhoff's Laws of series and parallel flows to pharmacology: Defining organ clearance. , 2022, 239, 108278.		6
1697	Review of the First Recognized Application of Kirchhoff's Laws to Pharmacology: Defining Organ Clearance. SSRN Electronic Journal, 0, , .	0.4	0
1698	Chapter 2: Pharmacogenomics: Drug Exposure and Response. , 2022, , .		0
1699	Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs. Clinical Pharmacokinetics, 0, , .	1.6	6
1701	Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach. Epilepsia, 2022, 63, 2937-2948.	2.6	3
1703	Assessing Liver-to-Plasma Partition Coefficients and In Silico Calculation Methods: When Does the Hepatic Model Matter in PBPK?. Drug Metabolism and Disposition, 2022, 50, 1501-1512.	1.7	7
1704	Time matters – <i>in vitro</i> cellular disposition kinetics help rationalizing cellular potency disconnects. Xenobiotica, 2022, 52, 878-889.	0.5	3
1705	An HPLC-LUV validated bioanalytical method for measurement of <i>in vitro</i> phase 1 kinetics of β -synuclein binding bifunctional compounds. Xenobiotica, 2022, 52, 916-927.	0.5	0
1706	Models Used to Predict Chemical Bioaccumulation in Fish from <i>In Vitro</i> Biotransformation Rates Require Accurate Estimates of Blood-Water Partitioning and Chemical Volume of Distribution. Environmental Toxicology and Chemistry, 2023, 42, 33-45.	2.2	3
1707	Predicting Hepatic Clearance of Psychotropic Drugs in Isolated Perfused Fish Livers Using a Combination of Two <i>In Vitro</i> Assays. Environmental Science & Technology, 2022, 56, 15839-15847.	4.6	3
1709	Impact of chemical structure on the <i>in vitro</i> hydrolysis of fatty esters of 2-ethylhexanoic acid or 2-ethylhexanol and extrapolation to the <i>in vivo</i> situation. Regulatory Toxicology and Pharmacology, 2023, 137, 105315.	1.3	2
1710	Process and System Clearances in Pharmacokinetic Models: Our Basic Clearance Concepts Are Correct. Drug Metabolism and Disposition, 2023, 51, 532-542.	1.7	4
1711	Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice. Clinical Pharmacokinetics, 2023, 62, 55-66.	1.6	3
1712	Pharmacokinetics and Pharmacodynamics of Drugs in Liver Disease. , 2023, , 63-74.		0
1713	The Future of ADME in Drug Design and Development. , 2017, , 316-342.		1
1714	Pathophysiologic changes in chronic heart failure affecting drug pharmacokinetics. , 2023, , 17-30.		0
1715	Role of AI in ADME/Tox toward formulation optimization and delivery. , 2023, , 301-345.		0
1716	Methods for assessing the bioaccumulation of hydrocarbons and related substances in terrestrial organisms: A critical review. Integrated Environmental Assessment and Management, 2023, 19, 1433-1456.	1.6	1

#	ARTICLE	IF	CITATIONS
1717	An amended <i>in vitro</i> – <i>in vivo</i> extrapolation model that accounts for first pass clearance effects on chemical bioaccumulation in fish. <i>Environmental Sciences: Processes and Impacts</i> , 0, , .	1.7	0
1718	Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes. <i>Molecules</i> , 2023, 28, 2368.	1.7	5
1719	<i>In vitro</i> hepatic metabolism of the natural product quebecol. <i>Xenobiotica</i> , 2023, 53, 1-11.	0.5	0
1720	<i>In vitro</i> – <i>in vivo</i> extrapolation of hepatic biotransformation data for fish. III. An in-depth case study with pyrene. <i>Environmental Toxicology and Chemistry</i> , 0, , .	2.2	1
1721	The Uses and Advantages of Kirchhoff's Laws vs. Differential Equations in Pharmacology, Pharmacokinetics, and (Even) Chemistry. <i>AAPS Journal</i> , 2023, 25, .	2.2	5
1726	Predicting unpredictable human pharmacokinetics: case studies from the trenches of drug discovery. , 2023, , 317-349.		0
1730	<i>In vitro</i> to <i>in vivo</i> extrapolation methods in chemical hazard identification and risk assessment. , 2023, , 511-522.		0
1737	Notes on the Use of Kirchhoff's Laws in Pharmacokinetics. <i>AAPS Journal</i> , 2024, 26, .	2.2	1